db_id,participant_id,categories,drug_treatment,drugs,drug_combinations,line_of_treatment,treatment_regimen,start_date_dfd,stop_date_dfd,stop_reason,pre_status,post_status,notes,primary_cohort
15757,MGHCC0001,"Hormone/Endocrine Therapy, Other",TRUE,"Letrozole, Zoledronic Acid",,,letrozole/zometa,31,215,NA,,,,TRUE
15758,MGHCC0001,Hormone/Endocrine Therapy,TRUE,Letrozole,,,"LEE011/Letrozole, CDK4/6",264,318,NA,,,,TRUE
15759,MGHCC0001,Chemotherapy,TRUE,Capecitabine,,,capecitabine,312,490,NA,,,,TRUE
15760,MGHCC0001,Chemotherapy,TRUE,Eribulin Mesylate,,,eribulin,508,578,NA,,,,TRUE
15761,MGHCC0001,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,"LEE011/Exemestane/Everolimus, PIK3CA/mTOR",600,774,NA,,,,TRUE
15762,MGHCC0001,Chemotherapy,TRUE,Doxorubicin Hydrochloride Liposome,,,doxil,614,914,NA,,,admitted & dc'ed to hospice,TRUE
15763,MGHCC0001,Chemotherapy,TRUE,Vinorelbine Tartrate,,,navelbine,775,826,NA,,,,TRUE
15764,MGHCC0002,Chemotherapy,TRUE,"Cyclophosphamide, Fluorouracil, Methotrexate",,,cyclophosphamide/methotrexate/fluorouracil,18,170,NA,,,,TRUE
15765,MGHCC0002,Hormone/Endocrine Therapy,TRUE,Letrozole,,,letrozole,4744,5193,Progression and relapse,,,,TRUE
15766,MGHCC0002,,TRUE,Exemestane,,,exemestane,5193,5344,Progression and relapse,,,(worsening of liver mets & LNs),TRUE
15767,MGHCC0002,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,tamoxifen,5375,5648,Progression and relapse,,,,TRUE
15768,MGHCC0002,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,fulvestrant,5648,5832,NA,,,,TRUE
15769,MGHCC0002,Chemotherapy,TRUE,Capecitabine,,,capecitabine,5832,6320,Progression and relapse,,,,TRUE
15770,MGHCC0002,Chemotherapy,TRUE,Paclitaxel,,,paclitaxel,6377,6670,Progression and relapse,,,,TRUE
15771,MGHCC0002,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,exemestane/everolimus/LEE011,6694,7086,Progression and relapse,,,,TRUE
15772,MGHCC0002,Chemotherapy,TRUE,Doxorubicin,,,doxorubicin,7201,7995,NA,,,,TRUE
15773,MGHCC0002,Chemotherapy,TRUE,Vinorelbine Tartrate,,,vinorelbine,8024,8086,NA,,,,TRUE
15774,MGHCC0002,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,gemcitabine,8087,8449,NA,,,stopped for unrelated acute thrombotic microangiopathy,TRUE
15775,MGHCC0002,Chemotherapy,TRUE,Eribulin Mesylate,,,eribulin,8108,8128,Progression and relapse,,,,TRUE
15776,MGHCC0002,Precision/Targeted Therapy,TRUE,Abemaciclib,,,"abemaciclib, CDK 4/6",8150,8163,NA,,,,TRUE
15777,MGHCC0002,Chemotherapy,TRUE,Cyclophosphamide,,,cyclphosphamide,8253,8400,Progression and relapse,,,"progression, planned to start new chemo but never did",TRUE
15778,MGHCC0003,,TRUE,,CMF,,CMF,13,105,NA,,,,TRUE
15779,MGHCC0003,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin",,,cytoxan/adriamycin,154,291,NA,,,,TRUE
15780,MGHCC0003,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,tamoxifen,348,2174,NA,,,5 years of adjuvant endocrine therapy,TRUE
15781,MGHCC0003,Hormone/Endocrine Therapy,TRUE,Letrozole,,,letrozole,4886,5492,Progression and relapse,,,,TRUE
15782,MGHCC0003,Hormone/Endocrine Therapy,TRUE,"Exemestane, Fulvestrant",,,exemestane/faslodex,5523,5676,NA,,,,TRUE
15783,MGHCC0003,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,everolimus/exemestane,5676,5768,NA,,,,TRUE
15784,MGHCC0003,Chemotherapy,TRUE,Capecitabine,,,capecitabine,5768,5857,NA,,,"discontinued d/t toxicirty (severe nausea, vomiting and weight loss)",TRUE
15785,MGHCC0003,Chemotherapy,TRUE,Paclitaxel,,,paclitaxel,5888,6172,NA,,,clinical progression (rising tumor markers),TRUE
15786,MGHCC0003,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,exemestane/everolimus/LEE011,6401,6551,Progression and relapse,,,,TRUE
15787,MGHCC0003,Chemotherapy,TRUE,Eribulin Mesylate,,,eribulin,6577,6684,Progression and relapse,,,d/c'ed d/t neuropathy,TRUE
15788,MGHCC0003,"Chemotherapy, Precision/Targeted Therapy",TRUE,"Trastuzumab, Vinorelbine Tartrate",,,trastuzumab/navelbine,6738,6744,NA,,,transitioned to hospice,TRUE
15789,MGHCC0004,Hormone/Endocrine Therapy,TRUE,Letrozole,,,letrozole,8460,8825,NA,,,,TRUE
15790,MGHCC0004,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,fulvestrant,8825,8978,NA,,,break from therapy d/t weakness/possible rxn,TRUE
15791,MGHCC0004,Chemotherapy,TRUE,Capecitabine,,,capecitabine,9070,9168,Progression and relapse,,,CNS progression,TRUE
15792,MGHCC0004,Hormone/Endocrine Therapy,TRUE,Letrozole,,,"LEE011/Letrozole, CDK4/6",9221,9466,NA,,,"Screened for another trial after, did not enroll",TRUE
15793,MGHCC0005,Chemotherapy,TRUE,"Cyclophosphamide, Docetaxel, Doxorubicin",,,docetaxel/doxorubicin/cyclophosphamide,12,126,NA,,,,TRUE
15794,MGHCC0005,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,anastrozole,131,2019,NA,,,,TRUE
15795,MGHCC0005,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,tamoxifen,2019,2504,NA,,,,TRUE
15796,MGHCC0005,Chemotherapy,TRUE,Vinorelbine Tartrate,,,toremifene,2546,3474,NA,,,,TRUE
15797,MGHCC0005,Chemotherapy,TRUE,Capecitabine,,,capecitabine,3480,3786,Progression and relapse,,,,TRUE
15798,MGHCC0005,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,exemestane/everolimus,3788,3864,NA,,,,TRUE
15799,MGHCC0005,Chemotherapy,TRUE,Vinorelbine Tartrate,,,vinorelbine,3904,4143,NA,,,,TRUE
15800,MGHCC0005,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,exemestane/everolimus/LEE011,4166,4542,NA,,,,TRUE
15801,MGHCC0006,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,tamoxifen,1504,1637,NA,,,,TRUE
15802,MGHCC0006,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,arimidex,1637,1762,NA,,,,TRUE
15803,MGHCC0006,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,fulvestrant,1762,1823,NA,,,,TRUE
15804,MGHCC0006,Chemotherapy,TRUE,"Capecitabine, Exemestane",,,exemestane/xeloda,1839,2177,NA,,,,TRUE
15805,MGHCC0006,Chemotherapy,TRUE,Paclitaxel,,,taxol,2232,2517,Progression and relapse,,,,TRUE
15806,MGHCC0006,,TRUE,Exemestane,,,Exemestane/LEE011,2541,2597,Progression and relapse,,,,TRUE
15807,MGHCC0006,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,Exemestane/Everolimus/LEE011,2621,2665,Progression and relapse,,,,TRUE
15808,MGHCC0006,Chemotherapy,TRUE,Eribulin Mesylate,,,eribulin,2709,2803,NA,,,d/c'ed on hospice,TRUE
15809,MGHCC0007,,TRUE,Exemestane,,,exemestane,49,153,NA,,,d/c'ed for non-clinical reasons and switched to letrozole,TRUE
15810,MGHCC0007,Hormone/Endocrine Therapy,TRUE,Letrozole,,,letrozole,153,570,NA,,,,TRUE
15811,MGHCC0007,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,tamoxifen,573,644,Progression and relapse,,,,TRUE
15812,MGHCC0007,,TRUE,Exemestane,,,Exemestane + LEE011,716,884,NA,,,,TRUE
15813,MGHCC0007,Chemotherapy,TRUE,Capecitabine,,,capecitabine,922,1129,Progression and relapse,,,,TRUE
15814,MGHCC0007,Chemotherapy,TRUE,Vinorelbine Tartrate,,,navelbine,1176,1198,NA,,,,TRUE
15815,MGHCC1005,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin, Paclitaxel",,,adriamycin/cytoxan/taxol,20,118,Completion of standard course,,,completed course,TRUE
15816,MGHCC1005,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,tamoxifen,195,719,NA,,,,TRUE
15817,MGHCC1005,Hormone/Endocrine Therapy,TRUE,Letrozole,,,AI (letrozole),740,854,NA,,,progression,TRUE
15818,MGHCC1005,Hormone/Endocrine Therapy,TRUE,Letrozole,,,"LEE011/BYL719/letrozole, PIK3CA/mTOR",888,1252,Progression and relapse,,,,TRUE
15819,MGHCC1005,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,"LEE011/everolimus/exemestane, CDK 4/6",1336,1378,Progression and relapse,,,,TRUE
15820,MGHCC1005,Chemotherapy,TRUE,Capecitabine,,,capecitabine,1386,1526,Progression and relapse,,,,TRUE
15821,MGHCC1005,Chemotherapy,TRUE,Eribulin Mesylate,,,eribulin,1529,1619,NA,,,,TRUE
15822,MGHCC1006,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,anastrozole,9,2688,NA,,,,TRUE
15823,MGHCC1006,Hormone/Endocrine Therapy,TRUE,Letrozole,,,letrozole,4058,4117,NA,,,,TRUE
15824,MGHCC1006,Hormone/Endocrine Therapy,TRUE,Letrozole,,,"LEE011/Letrozole, CDK4/6",4117,4379,NA,,,,TRUE
15825,MGHCC1006,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Letrozole, Palbociclib",,,"palbociclib/letrozole, CDK4/6",4423,4620,NA,,,,TRUE
15826,MGHCC1006,Hormone/Endocrine Therapy,TRUE,"Alpelisib, Fulvestrant",,,"alpelisib/placebo + fulvestrant, PIK3CA/mTOR",4640,4747,NA,,,,TRUE
15827,MGHCC1006,Chemotherapy,TRUE,Capecitabine,,,capecitabine,4760,5653,Progression and relapse,,,progression (new hepatic mets),TRUE
15828,MGHCC1006,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Abemaciclib, Fulvestrant",,,"abemaciclib/fulvestrant, CDK4/6",5895,5929,NA,,,d/c'ed d/t LFT elevation,TRUE
15829,MGHCC1006,Chemotherapy,TRUE,Eribulin Mesylate,,,eribulin,5929,6010,Progression and relapse,,,"progression, enrolled in hospice",TRUE
15830,MGHCC1009,Chemotherapy,TRUE,"Gemcitabine Hydrochloride, Paclitaxel",,,taxol/gemcitabine,796,886,NA,,,,TRUE
15831,MGHCC1009,Hormone/Endocrine Therapy,TRUE,"Exemestane, Fulvestrant",,,fulvestrant/exemestane,886,900,NA,,,,TRUE
15832,MGHCC1009,Chemotherapy,TRUE,"Gemcitabine Hydrochloride, Paclitaxel",,,gemcitabine/paclitaxel,917,947,NA,,,,TRUE
15833,MGHCC1009,Hormone/Endocrine Therapy,TRUE,Letrozole,,,letrozole,978,1107,Progression and relapse,,,,TRUE
15834,MGHCC1009,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,exemestane/everolimus,1100,1330,NA,,,,TRUE
15835,MGHCC1009,Hormone/Endocrine Therapy,TRUE,Letrozole,,,"LEE011/BYL719/Letrozole, CDK4/6",1345,1596,NA,,,,TRUE
15836,MGHCC1009,Chemotherapy,TRUE,Capecitabine,,,capecitabine,1632,1931,Progression and relapse,,,,TRUE
15837,MGHCC1009,Chemotherapy,TRUE,"Carboplatin, Paclitaxel Albumin-stabilized Nanoparticle Formulation",,,carboplatin/abraxane,2009,2195,Progression and relapse,,,,TRUE
15838,MGHCC1009,Chemotherapy,TRUE,"Carboplatin, Gemcitabine Hydrochloride",,,carboplatin/gemcitabine,2200,,NA,,,,TRUE
15839,MGHCC1015,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin, Paclitaxel",,,Doxorubucin/cyclophosphamide/paclitaxel,41,192,NA,,,,TRUE
15840,MGHCC1015,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,254,2110,NA,,,,TRUE
15841,MGHCC1015,Hormone/Endocrine Therapy,TRUE,Letrozole,,,letrozole,3423,4362,NA,,,,TRUE
15842,MGHCC1015,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,Fulvestrant,4362,4598,NA,,,,TRUE
15843,MGHCC1015,Hormone/Endocrine Therapy,TRUE,Letrozole,,,"LEE011/Letrozole, CDK 4/6",5104,5270,NA,,,,TRUE
15844,MGHCC1015,Hormone/Endocrine Therapy,TRUE,Letrozole,,,"LEE011/Letrozole/BYL719, PIK3CA/mTOR",5293,5351,NA,,,,TRUE
15845,MGHCC1015,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,"LEE011/Exemestane/Everolimus, PIK3CA/mTOR",5433,5741,NA,,,,TRUE
15846,MGHCC1030,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin",,,doxorubicin/cyclophosphamide,63,155,Completion of standard course,,,,TRUE
15847,MGHCC1030,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,tamoxifen,186,807,NA,,,,TRUE
15848,MGHCC1030,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,anastrozole,927,4510,NA,,,,TRUE
15849,MGHCC1030,,TRUE,Raloxifene Hydrochloride,,,raloxifene,4510,5552,NA,,,,TRUE
15850,MGHCC1030,Hormone/Endocrine Therapy,TRUE,Letrozole,,,"LEE011/letrozole, CDK 4/6",5579,5831,Progression and relapse,,,,TRUE
15851,MGHCC1030,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,GDC0032/fulvestrant,5858,5894,Progression and relapse,,,,TRUE
15852,MGHCC1030,Chemotherapy,TRUE,Capecitabine,,,capecitabine,5907,5991,Progression and relapse,,,,TRUE
15853,MGHCC1030,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,"LEE011/everolimus/exemestane, PIK3CA/mTOR",6022,6049,Progression and relapse,,,,TRUE
15854,MGHCC1030,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,cisplatin/gemcitabine,6068,6124,NA,,,"gemzar d/c'ed, cisplatin held and never resumed",TRUE
15855,MGHCC1041,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin, Paclitaxel",,,doxorubicin/cyclophosphamide/paclitaxel,35,136,Completion of standard course,,,,TRUE
15856,MGHCC1041,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,tamoxifen,227,558,NA,,,stopped due to tinnitus/cramps in legs__,TRUE
15857,MGHCC1041,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,anastrozole,560,857,NA,,,d/c'ed d/t musculoskeletal symptoms & neuropathy,TRUE
15858,MGHCC1041,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,tamoxifen,885,1169,Progression and relapse,,,,TRUE
15859,MGHCC1041,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,"BKM120/fulvestrant, PIK3CA/mTOR",1239,1519,Progression and relapse,,,,TRUE
15860,MGHCC1041,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,LEE011/exemestane/everolimus,1532,1812,Progression and relapse,,,,TRUE
15861,MGHCC1041,Chemotherapy,TRUE,"Capecitabine, Exemestane",,,capecitabine/exemestane,1834,2061,Progression and relapse,,,,TRUE
15862,MGHCC1041,Chemotherapy,TRUE,Eribulin Mesylate,,,eribulin,2349,2415,Progression and relapse,,,,TRUE
15863,MGHCC1041,Chemotherapy,TRUE,Vinorelbine Tartrate,,,vinorelbine,2461,2479,Progression and relapse,,,progression (liver mets),TRUE
15864,MGHCC1041,Chemotherapy,TRUE,Doxorubicin,,,doxorubicin,2495,2526,NA,,,,TRUE
15865,MGHCC1041,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,fulvestrant,2546,2569,NA,,,d/c'ed on hospice,TRUE
15866,MGHCC1099,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin, Paclitaxel",,,doxorubicin/cyclophosphamide/paclitaxel,124,284,Completion of standard course,,,,TRUE
15867,MGHCC1099,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,tamoxifen,326,1371,NA,,,,TRUE
15868,MGHCC1099,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,fulvestrant,1418,1649,NA,,,d/c'ed d/t rising tumor markers,TRUE
15869,MGHCC1099,Chemotherapy,TRUE,Capecitabine,,,capecitabine,1652,1793,NA,,,,TRUE
15870,MGHCC1099,Hormone/Endocrine Therapy,TRUE,Letrozole,,,"BYL719/LEE011/letrozole, PIK3CA/mTOR",1818,2337,Progression and relapse,,,,TRUE
15871,MGHCC1099,Chemotherapy,TRUE,Vinorelbine Tartrate,,,vinorelbine,2357,2462,Progression and relapse,,,progression (new liver mets),TRUE
15872,MGHCC1099,Chemotherapy,TRUE,Eribulin Mesylate,,,eribulin,2560,2560,NA,,,"single dose, later admitted prior to next one",TRUE
15873,MGHCC1101,Chemotherapy,TRUE,"Cyclophosphamide, Docetaxel, Doxorubicin",,,docetaxel/cyclophosphamide/doxorubicin,2418,2523,Completion of standard course,,,,TRUE
15874,MGHCC1101,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,tamoxifen,2549,3684,NA,,,,TRUE
15875,MGHCC1101,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,anastrozole,3711,3751,Progression and relapse,,,,TRUE
15876,MGHCC1101,Chemotherapy,TRUE,Capecitabine,,,capecitabine,3751,3816,Progression and relapse,,,,TRUE
15877,MGHCC1101,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,"LEE011/exemestane/everolimus, CDK 4/6",3840,4005,Progression and relapse,,,,TRUE
15878,MGHCC1101,Chemotherapy,TRUE,Eribulin Mesylate,,,eribulin,4019,4186,NA,,,,TRUE
15879,MGHCC1101,Chemotherapy,TRUE,Methotrexate,,,high-dose methotrexate,4152,4194,NA,,,,TRUE
15880,MGHCC1101,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Everolimus, Fulvestrant",,,"fulvestrant/everolimus, PIK3CA/mTOR",4200,4285,Progression and relapse,,,,TRUE
15881,MGHCC1108,Chemotherapy,TRUE,"Cyclophosphamide, Docetaxel, Doxorubicin",,,docetaxel/doxorubicin/cyclophosphamide,61,168,NA,,,,TRUE
15882,MGHCC1108,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,anastrozole,191,1064,NA,,,,TRUE
15883,MGHCC1108,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,fulvestrant,1064,1723,Progression and relapse,,,,TRUE
15884,MGHCC1108,Hormone/Endocrine Therapy,TRUE,Letrozole,,,"BKM120/letrozole, PIK3CA/mTOR",1735,2015,NA,,,d/c'ed due to intolerable side effects,TRUE
15885,MGHCC1108,Chemotherapy,TRUE,Capecitabine,,,capecitabine,2157,2164,NA,,,"had one week, d/c'ed due to GI effects",TRUE
15886,MGHCC1108,Chemotherapy,TRUE,Vinorelbine Tartrate,,,vinorelbine,2171,2486,Progression and relapse,,,slight progression,TRUE
15887,MGHCC1108,Hormone/Endocrine Therapy,TRUE,Letrozole,,,"LEE011/letrozole, CDK 4/6",2521,2773,Progression and relapse,,,,TRUE
15888,MGHCC1108,Hormone/Endocrine Therapy,TRUE,Letrozole,,,"BYL719/LEE011/letrozole, PIK3CA/mTOR",2805,2843,NA,,,,TRUE
15889,MGHCC1108,Chemotherapy,TRUE,Eribulin Mesylate,,,eribulin,2843,2892,Progression and relapse,,,,TRUE
15890,MGHCC1108,Chemotherapy,TRUE,Capecitabine,,,capecitabine,2911,3564,Progression and relapse,,,slight progression,TRUE
15891,MGHCC1108,Chemotherapy,TRUE,Doxorubicin,,,doxorubicin,3564,3592,Progression and relapse,,,,TRUE
15892,MGHCC1112,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin, Paclitaxel",,,doxorubicin/cyclophosphamide/taxol,85,204,NA,,,,TRUE
15893,MGHCC1112,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,tamoxifen,277,730,NA,,,,TRUE
15894,MGHCC1112,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,anastrozole,758,1877,NA,,,,TRUE
15895,MGHCC1112,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,fulvestrant,1899,2045,Progression and relapse,,,,TRUE
15896,MGHCC1112,Chemotherapy,TRUE,Capecitabine,,,capecitabine,2073,2107,NA,,,,TRUE
15897,MGHCC1112,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,"LEE011/exemestane/everolimus, CDK 4/6",2130,2270,Progression and relapse,,,,TRUE
15898,MGHCC1112,Chemotherapy,TRUE,Eribulin Mesylate,,,eribulin,2307,2319,NA,,,d/c'ed d/t neutropenia & thrombocytopenia,TRUE
15899,MGHCC1112,Chemotherapy,TRUE,Paclitaxel Albumin-stabilized Nanoparticle Formulation,,,abraxane,2349,,NA,,,lost to follow-up,TRUE
15900,MGHCC1173,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,anastrozole,194,1156,NA,,,,TRUE
15901,MGHCC1173,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,"LEE011/everolimus/exemestane, CDK 4/6",1303,1583,Progression and relapse,,,,TRUE
15902,MGHCC1173,Chemotherapy,TRUE,Capecitabine,,,capecitabine,1594,1712,Progression and relapse,,,,TRUE
15903,MGHCC1173,Hormone/Endocrine Therapy,TRUE,"Cabozantinib-S-Malate, Fulvestrant",,,cabozantinib/fulvestrant,1742,1843,NA,,,"d/c'ed d/t rising markers, increased bone pain, and concern for progression (Scans w/ mixed response)",TRUE
15904,MGHCC1173,Chemotherapy,TRUE,Vinorelbine Tartrate,,,vinorelbine,1844,1948,NA,,,,TRUE
15905,MGHCC1173,Chemotherapy,TRUE,Doxorubicin,,,doxorubicin,1949,1956,NA,,,d/c'ed d/t infusion reactions,TRUE
15906,MGHCC1173,Chemotherapy,TRUE,Eribulin Mesylate,,,eribulin,1963,2160,NA,,,held and never restarted,TRUE
15907,MGHCC1328,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin",,,doxorubicin/cyclophosphamide,178,241,NA,,,,TRUE
15908,MGHCC1328,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,tamoxifen,365,1581,NA,,,,TRUE
15909,MGHCC1328,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,anastrozole,3499,3592,NA,,,,TRUE
15910,MGHCC1328,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Letrozole, Palbociclib",,,"palbociclib/letrozole, CDK4/6",6417,6613,Progression and relapse,,,,TRUE
15911,MGHCC1328,Hormone/Endocrine Therapy,TRUE,"Alpelisib, Fulvestrant",,,"alpelisib (or placebo)/fulvestrant, PIK3CA/mTOR",6628,6739,Progression and relapse,,,,TRUE
15912,MGHCC1328,Chemotherapy,TRUE,Capecitabine,,,capecitabine,6769,7273,Progression and relapse,,,,TRUE
15913,MGHCC1328,Chemotherapy,TRUE,Eribulin Mesylate,,,eribulin,7547,7574,NA,,,,TRUE
15914,MGHCC1328,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Abemaciclib, Fulvestrant",,,"abemaciclib/fulvestrant, CDK4/6",7615,7678,NA,,,d/c'ed d/t clical deterioration,TRUE
15915,MGHCC1328,Chemotherapy,TRUE,Doxorubicin,,,doxorubicin,7676,7767,Progression and relapse,,,transition to hospice,TRUE
15916,MGHCC1573,"Biological Therapy, Chemotherapy",TRUE,"Bevacizumab, Cyclophosphamide, Doxorubicin, Paclitaxel",,,dd Adriamycin/Cotoxan/Taxol + Avastin,13,146,NA,,,,TRUE
15917,MGHCC1573,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,tamoxifen,188,879,NA,,,,TRUE
15918,MGHCC1573,Hormone/Endocrine Therapy,TRUE,Letrozole,,,letrozole,861,951,NA,,,,TRUE
15919,MGHCC1573,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,"Lee011/Exemestane/Everolimus, CDK4/6",1526,1638,Progression and relapse,,,,TRUE
15920,MGHCC1573,Chemotherapy,TRUE,Vinorelbine Tartrate,,,vinorelbine,2071,2328,Progression and relapse,,,,TRUE
15921,MGHCC1573,Chemotherapy,TRUE,Eribulin Mesylate,,,eribulin,2442,2505,Progression and relapse,,,,TRUE
15922,MGHCC1573,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Fulvestrant, Palbociclib",,,"fulvestrant/palbociclib, CDK4/6",2505,2559,Progression and relapse,,,,TRUE
15923,MGHCC1573,Chemotherapy,TRUE,Doxorubicin,,,doxorubicin,2591,2912,Progression and relapse,,,,TRUE
15924,MGHCC1573,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Fulvestrant, Palbociclib",,,"fulvestrant/palbociclib, CDK4/6",2912,2953,NA,,,transitioned to hospice in setting of worsening respiratory symptoms,TRUE
15925,RA_1002,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin",,,adriamycin and Cytoxan (4 Cycles),0,0,NA,,,Regimen: adriamycin and Cytoxan (4 Cycles),TRUE
15926,RA_1002,,TRUE,,CMF,,CMF (6 Cycles),5478,5478,NA,,,Regimen: CMF (6 Cycles),TRUE
15927,RA_1002,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,5478,5844,NA,,,Regimen: Tamoxifen,TRUE
15928,RA_1002,Hormone/Endocrine Therapy,TRUE,Letrozole,,,Letrozole,5995,6574,NA,,,Regimen: Letrozole,TRUE
15929,RA_1002,,TRUE,Exemestane,,,Exemestane,6574,7670,NA,,,Regimen: Exemestane,TRUE
15930,RA_1002,Chemotherapy,TRUE,"Cyclophosphamide, Docetaxel",,,Taxotere + Cytoxan (X 4 Cycles),8825,8886,NA,,,Regimen: Taxotere + Cytoxan (X 4 Cycles),TRUE
15931,RA_1002,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,Anastrozole,9009,9243,NA,,,Regimen: Anastrozole,TRUE
15932,RA_1002,Chemotherapy,TRUE,"Carboplatin, Paclitaxel",,,Veliparib + Carbo/Paclitaxel (X17 Cycles),9255,9668,NA,Recurrence,,"Clinical Trial - Best Response = PR (-37.3% from BL) // PD = disease progression, increase in number of skin lesions (-13.9% from BL , +37.4% from Nadir) ~ Regimen: Veliparib + Carbo/Paclitaxel (X17 Cycles)",TRUE
15933,RA_1002,Hormone/Endocrine Therapy,TRUE,"Letrozole, Ribociclib",,,BYL719/LEE(Ribociclib)/letrozole (X 9 Cycles),9700,9951,NA,,,"Clinical Trial - Best Response = SD (-8.1% from BL) // PD = Interval increase in size of subcutaneous nodules in the left anterior chest wall and right lateral flank, concerning for worsening metastatic disease.Slight interval increase in size in soft tissue nodule within the musculature of the anterior chest wall ~ Regimen: BYL719/LEE(Ribociclib)/letrozole (X 9 Cycles)",TRUE
15934,RA_1002,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane, Ribociclib",,,LEE011(Ribociclib)/examestane/everolimus (X 2 Cycles),9990,10047,NA,,,"Clinical Trial  - Best Response =  SD (+17.5% from BL) = Taken off, interval increase  in thickening throughout anterior chest wall, extending into left anterior and lateral abdominal wall ~ Regimen: LEE011(Ribociclib)/examestane/everolimus (X 2 Cycles)",TRUE
15935,RA_1002,Chemotherapy,TRUE,Capecitabine,,,Xeloda,10062,10201,NA,,,Regimen: Xeloda,TRUE
15936,RA_1002,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Vinorelbine,10260,10316,NA,,,Regimen: Vinorelbine,TRUE
15937,RA_1002,Hormone/Endocrine Therapy,TRUE,Letrozole,,,GDC-0077 (PIK3CA Inhibitor) + letrozole (X3 Cycles),10351,10435,NA,,,Clinical Trial  - Best Response = // Progression =  PD in chest wall lesions ~ Regimen: GDC-0077 (PIK3CA Inhibitor) + letrozole (X3 Cycles),TRUE
15938,RA_1011,Precision/Targeted Therapy,TRUE,Everolimus,,,Everolimus,361,749,Progression and relapse,,,regression of chest wall lesions ~ Regimen: Everolimus,TRUE
15939,RA_1011,"Biological Therapy, Chemotherapy, Precision/Targeted Therapy",TRUE,"Bevacizumab, Doxorubicin Hydrochloride Liposome, Everolimus",,,Doxil/Everolimus/Bevacizumab (2 Cycles),780,826,Progression and relapse,,,Regimen: Doxil/Everolimus/Bevacizumab (2 Cycles),TRUE
15940,RA_1011,Chemotherapy,TRUE,"Carboplatin, Temsirolimus",,,Carboplatin + Temsirolimus (2 Cycles),827,915,Progression and relapse,,,progressive disease in the lungs ~ Regimen: Carboplatin + Temsirolimus (2 Cycles),TRUE
15941,RA_1011,Precision/Targeted Therapy,TRUE,Everolimus,,,Everolimus,959,1038,Other,,,D/C to pursue clinical trial ~ Regimen: Everolimus,TRUE
15942,RA_1011,Chemotherapy,TRUE,Paclitaxel Albumin-stabilized Nanoparticle Formulation,FEC,,FEC/Abraxane,,,Progression and relapse,,,Relapsed locally during adjuvant chemotherapy ~ Regimen: FEC/Abraxane,TRUE
15943,RA_1035,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin",,,Neoadjuvant ddAC (Adriamycin+ Cytoxan) - 4 Cycles,28,70,Completion of standard course,,,Regimen: Neoadjuvant ddAC (Adriamycin+ Cytoxan) - 4 Cycles,TRUE
15944,RA_1035,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin",,,Neoadjuvant ddAC (Adriamycin+ Cytoxan) - 4 Cycles,28,70,Completion of standard course,,,Regimen: Neoadjuvant ddAC (Adriamycin+ Cytoxan) - 4 Cycles,TRUE
15945,RA_1035,Chemotherapy,TRUE,Paclitaxel,,,Adjuvant Taxol - 4 Cycles,84,126,Completion of standard course,,,Regimen: Adjuvant Taxol - 4 Cycles,TRUE
15946,RA_1035,Chemotherapy,TRUE,Paclitaxel,,,Adjuvant Taxol - 4 Cycles,84,126,Completion of standard course,,,Regimen: Adjuvant Taxol - 4 Cycles,TRUE
15947,RA_1035,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,212,2069,Completion of standard course,,,Regimen: Tamoxifen,TRUE
15948,RA_1035,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,212,2069,Completion of standard course,,,Regimen: Tamoxifen,TRUE
15949,RA_1035,Hormone/Endocrine Therapy,TRUE,Letrozole,,,Femara,2082,2342,Other,,,"D/C due to ""Feeling Poorly"" ~ Regimen: Femara",TRUE
15950,RA_1035,Hormone/Endocrine Therapy,TRUE,Letrozole,,,Femara,2082,2342,Other,,,"D/C due to ""Feeling Poorly"" ~ Regimen: Femara",TRUE
15951,RA_1035,"Hormone/Endocrine Therapy, Other",TRUE,"Denosumab, Letrozole",,,Letrozole + Xgeva,2750,3224,Progression and relapse,,,"Progressing metastatic disease.  New scalp lesions, hepatic, gastric, rectal metastases. ~ Regimen: Letrozole + Xgeva",TRUE
15952,RA_1035,"Hormone/Endocrine Therapy, Other",TRUE,"Denosumab, Letrozole",,,Letrozole + Xgeva,2750,3224,Progression and relapse,,,"Progressing metastatic disease.  New scalp lesions, hepatic, gastric, rectal metastases. ~ Regimen: Letrozole + Xgeva",TRUE
15953,RA_1035,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Navelbine (X 4 Cycles),3226,3296,Toxicity,,,Neutropenia ~ Regimen: Navelbine (X 4 Cycles),TRUE
15954,RA_1035,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Navelbine (X 4 Cycles),3226,3296,Toxicity,,,Neutropenia ~ Regimen: Navelbine (X 4 Cycles),TRUE
15955,RA_1035,Hormone/Endocrine Therapy,TRUE,Letrozole,,,BYL-719 [PI3K? inhibitor]/Letrozole   (6 Cycles),3325,3490,Progression and relapse,,,Slight increase in bilateral pleural effusions. Significant increase in size of muliple liver lesions. New liver lesions are also seen ~ Regimen: BYL-719 [PI3K? inhibitor]/Letrozole   (6 Cycles),TRUE
15956,RA_1035,Hormone/Endocrine Therapy,TRUE,Letrozole,,,BYL-719 [PI3K? inhibitor]/Letrozole   (6 Cycles),3325,3490,Progression and relapse,,,Slight increase in bilateral pleural effusions. Significant increase in size of muliple liver lesions. New liver lesions are also seen ~ Regimen: BYL-719 [PI3K? inhibitor]/Letrozole   (6 Cycles),TRUE
15957,RA_1035,Chemotherapy,TRUE,Eribulin Mesylate,,,Eribulin (2 Cycles),3498,3542,Progression and relapse,,,"Diffuse osteoblastic metastases. Persistent lymphangitic carcinomatosis with bilateral pleural effusions. Scattered lung nodules, consistent with metastases. Prominent cervical lymph nodes ~ Regimen: Eribulin (2 Cycles)",TRUE
15958,RA_1035,Chemotherapy,TRUE,Eribulin Mesylate,,,Eribulin (2 Cycles),3498,3542,Progression and relapse,,,"Diffuse osteoblastic metastases. Persistent lymphangitic carcinomatosis with bilateral pleural effusions. Scattered lung nodules, consistent with metastases. Prominent cervical lymph nodes ~ Regimen: Eribulin (2 Cycles)",TRUE
15959,RA_1045,,TRUE,,AC-T,,Dose dense AC+T +AVASTIN (neoadjuvant),17,128,NA,,,Regimen: Dose dense AC+T +AVASTIN (neoadjuvant),TRUE
15960,RA_1045,"Chemotherapy, Precision/Targeted Therapy",TRUE,"Capecitabine, Trastuzumab",,,Herceptin (Trastuzumab) + Xeloda (Capecitabine),280,322,NA,,,Regimen: Herceptin (Trastuzumab) + Xeloda (Capecitabine),TRUE
15961,RA_1045,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Anastrozole, Trastuzumab",,,Herceptin (Trastuzumab) + Arimidex (Anastrazole),323,560,NA,,,Regimen: Herceptin (Trastuzumab) + Arimidex (Anastrazole),TRUE
15962,RA_1045,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,Arimidex (Anastrazole),561,1216,NA,,,Regimen: Arimidex (Anastrazole),TRUE
15963,RA_1045,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,BYL719/fulvestrant,1542,2998,NA,,,Clinic Trial: Best Response = Partial Response -79.2% // Progression new liver lesions multiple sites/ throughout all lobes (-78.84% from BL) ~ Regimen: BYL719/fulvestrant,TRUE
15964,RA_1045,Chemotherapy,TRUE,Capecitabine,,,Xeloda,3017,3075,NA,,,Regimen: Xeloda,TRUE
15965,RA_1045,Chemotherapy,TRUE,Eribulin Mesylate,,,Eribulin,3076,3083,NA,,,Regimen: Eribulin,TRUE
15966,RA_1078,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin, Paclitaxel",,,Doxorubicin + Taxol + Cytoxan,98,237,NA,,,Regimen: Doxorubicin + Taxol + Cytoxan,TRUE
15967,RA_1078,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,241,2063,NA,,,Regimen: Tamoxifen,TRUE
15968,RA_1078,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,Arimidex (Anastrozole),2063,2154,NA,,,Regimen: Arimidex (Anastrozole),TRUE
15969,RA_1078,Hormone/Endocrine Therapy,TRUE,"Letrozole, Pamidronate Disodium",,,Femara (Letrozole) + Aredia,4550,4620,NA,Recurrence,,Regimen: Femara (Letrozole) + Aredia,TRUE
15970,RA_1078,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,Faslodex (Fulvestrant),4641,4748,NA,,,Regimen: Faslodex (Fulvestrant),TRUE
15971,RA_1078,Chemotherapy,TRUE,Capecitabine,,,Xeloda (Capecitabine),4748,5221,NA,,,Regimen: Xeloda (Capecitabine),TRUE
15972,RA_1078,Other,TRUE,Denosumab,,,Denosumab,5260,5321,NA,,,Regimen: Denosumab,TRUE
15973,RA_1078,Chemotherapy,TRUE,Doxorubicin Hydrochloride Liposome,,,Doxil,5322,5389,NA,,,Regimen: Doxil,TRUE
15974,RA_1078,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,Everolimus/Exemestane,5390,5623,NA,,,Regimen: Everolimus/Exemestane,TRUE
15975,RA_1078,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,5625,5837,NA,,,Regimen: Tamoxifen,TRUE
15976,RA_1078,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Gemcitabine,5837,5957,NA,,,Regimen: Gemcitabine,TRUE
15977,RA_1078,Chemotherapy,TRUE,Eribulin Mesylate,,,Eribulin,5959,6203,NA,,,Regimen: Eribulin,TRUE
15978,RA_1078,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Vinorelbine,6358,6561,NA,,,Progression = new brain mets (cerbellar + occipital lobe) ~ Regimen: Vinorelbine,TRUE
15979,RA_1078,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Fulvestrant, Palbociclib",,,Fulvestrant/ Palbociclib,6565,6594,NA,,,Regimen: Fulvestrant/ Palbociclib,TRUE
15980,RA_1113,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin, Paclitaxel",,,Adjuvant ddAC (Cytoxan + Adriamycin) 4 Cycles + Taxol (4 Cycles),83,273,Completion of standard course,,,Regimen: Adjuvant ddAC (Cytoxan + Adriamycin) 4 Cycles + Taxol (4 Cycles),TRUE
15981,RA_1113,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin, Paclitaxel",,,Adjuvant ddAC (Cytoxan + Adriamycin) 4 Cycles + Taxol (4 Cycles),83,273,Completion of standard course,,,Regimen: Adjuvant ddAC (Cytoxan + Adriamycin) 4 Cycles + Taxol (4 Cycles),TRUE
15982,RA_1113,Precision/Targeted Therapy,TRUE,Trastuzumab,,,Herceptin,297,396,Toxicity,,,d/c for congestive heart failure ~ Regimen: Herceptin,TRUE
15983,RA_1113,Precision/Targeted Therapy,TRUE,Trastuzumab,,,Herceptin,297,396,Toxicity,,,d/c for congestive heart failure ~ Regimen: Herceptin,TRUE
15984,RA_1113,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,396,1924,Progression and relapse,,,Regimen: Tamoxifen,TRUE
15985,RA_1113,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,396,1924,Progression and relapse,,,Regimen: Tamoxifen,TRUE
15986,RA_1113,Chemotherapy,TRUE,"Exemestane, Vinorelbine Tartrate",,,Navelbine and Exemestane,1951,2175,Progression and relapse,,,Increased tumor markers ~ Regimen: Navelbine and Exemestane,TRUE
15987,RA_1113,Chemotherapy,TRUE,"Exemestane, Vinorelbine Tartrate",,,Navelbine and Exemestane,1951,2175,Progression and relapse,,,Increased tumor markers ~ Regimen: Navelbine and Exemestane,TRUE
15988,RA_1113,,TRUE,Exemestane,,,Exemestane,2175,2417,Progression and relapse,,,"new ill-defined low hypoattenuating lesions in the liver, suspicious for hepatic metastases; Rising tumor markers ~ Regimen: Exemestane",TRUE
15989,RA_1113,,TRUE,Exemestane,,,Exemestane,2175,2417,Progression and relapse,,,"new ill-defined low hypoattenuating lesions in the liver, suspicious for hepatic metastases; Rising tumor markers ~ Regimen: Exemestane",TRUE
15990,RA_1113,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,Faslodex,2417,2478,Progression and relapse,,,Rising tumor markers ~ Regimen: Faslodex,TRUE
15991,RA_1113,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,Faslodex,2417,2478,Progression and relapse,,,Rising tumor markers ~ Regimen: Faslodex,TRUE
15992,RA_1113,Chemotherapy,TRUE,Capecitabine,,,Capecitabine,2501,2718,Progression and relapse,,,progression of disease within the liver and increaing pleural metastases. ~ Regimen: Capecitabine,TRUE
15993,RA_1113,Chemotherapy,TRUE,Capecitabine,,,Capecitabine,2501,2718,Progression and relapse,,,progression of disease within the liver and increaing pleural metastases. ~ Regimen: Capecitabine,TRUE
15994,RA_1113,Chemotherapy,TRUE,Eribulin Mesylate,,,Eribulin,2725,2862,Progression and relapse,,,D/C for grade 4 peripheral neuropathy (minimal progression in the lung and liver) ~ Regimen: Eribulin,TRUE
15995,RA_1113,Chemotherapy,TRUE,Eribulin Mesylate,,,Eribulin,2725,2862,Progression and relapse,,,D/C for grade 4 peripheral neuropathy (minimal progression in the lung and liver) ~ Regimen: Eribulin,TRUE
15996,RA_1113,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Gemcitabine,2890,2937,Toxicity,,,"intercurrent pneumonia, tolerated poorly ~ Regimen: Gemcitabine",TRUE
15997,RA_1113,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Gemcitabine,2890,2937,Toxicity,,,"intercurrent pneumonia, tolerated poorly ~ Regimen: Gemcitabine",TRUE
15998,RA_1113,Chemotherapy,TRUE,Paclitaxel,,,Taxol,3001,3232,Progression and relapse,,,Regimen: Taxol,TRUE
15999,RA_1113,Chemotherapy,TRUE,Paclitaxel,,,Taxol,3001,3232,Progression and relapse,,,Regimen: Taxol,TRUE
16000,RA_1113,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,BYL-719 [PI3K inhibitor] + Fulvestrant (X 12 Cycles),3273,3608,Progression and relapse,,,Interval increase in size of multiple metastatic lesions in the liver. PD per RECIST. // Best Response = (-49.9%) ~ Regimen: BYL-719 [PI3K inhibitor] + Fulvestrant (X 12 Cycles),TRUE
16001,RA_1113,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,BYL-719 [PI3K inhibitor] + Fulvestrant (X 12 Cycles),3273,3608,Progression and relapse,,,Interval increase in size of multiple metastatic lesions in the liver. PD per RECIST. // Best Response = (-49.9%) ~ Regimen: BYL-719 [PI3K inhibitor] + Fulvestrant (X 12 Cycles),TRUE
16002,RA_1184,Chemotherapy,TRUE,"Carboplatin, Paclitaxel",,,carboplatin/paclitaxel (6 Cycles)  - Adjuvant,75,183,Completion of standard course,,,Regimen: carboplatin/paclitaxel (6 Cycles)  - Adjuvant,TRUE
16003,RA_1184,Chemotherapy,TRUE,"Carboplatin, Gemcitabine Hydrochloride",,,carboplatin/gemcitabine (5 cycles),479,618,Completion of standard course,,,Regimen: carboplatin/gemcitabine (5 cycles),TRUE
16004,RA_1184,Precision/Targeted Therapy,TRUE,"Golvatinib, Lenvatinib Mesylate",,,Golvatinib (E7050)/ lenvatinib (E7080) -[VEGFR Inhibitor] (16 Cycles),1518,1959,Progression and relapse,,,Best Response = SD per RECIST (-20.5%) // Final Response = PD (-8% from BL // +22.1% from nadir) ~ Regimen: Golvatinib (E7050)/ lenvatinib (E7080) -[VEGFR Inhibitor] (16 Cycles),TRUE
16005,RA_1187,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Gemcitabine,87,101,Toxicity,,,Neutropenia ~ Regimen: Gemcitabine,TRUE
16006,RA_1187,,TRUE,,FU-LV,,5-FU/LV deGramont [9 Cycles],143,275,Completion of standard course,,,Regimen: 5-FU/LV deGramont [9 Cycles],TRUE
16007,RA_1326,Hormone/Endocrine Therapy,TRUE,Letrozole,,,Letrozole,10,1063,NA,Recurrence,,progression of osteoblastic metastasis and LEFT breast soft tissue mass ~ Regimen: Letrozole,TRUE
16008,RA_1326,Hormone/Endocrine Therapy,TRUE,Letrozole,,,Letrozole + BYL719 +LEE011 (X 2 Cycles),1572,1602,NA,,,Clinical Trial:  Best Response = SD (-14.8%) D/C due to Nausea/Vomiting ~ Regimen: Letrozole + BYL719 +LEE011 (X 2 Cycles),TRUE
16009,RA_1326,Hormone/Endocrine Therapy,TRUE,"Cabozantinib-S-Malate, Fulvestrant",,,Cabozantinib + Faslodex (X 6 Cycles),1652,1818,NA,,,Clinical Trial: Best Response = SD (-11.7%) // progression = new liver lesions and (-17.4 %) change from BL ~ Regimen: Cabozantinib + Faslodex (X 6 Cycles),TRUE
16010,RA_1326,Chemotherapy,TRUE,Cyclophosphamide,,,cytoxan,2043,2065,NA,,,Regimen: cytoxan,TRUE
16011,RA_1373,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin",,,Adriamycin + Cytoxan (x 4 cycles),17,140,NA,,,Regimen: Adriamycin + Cytoxan (x 4 cycles),TRUE
16012,RA_1373,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,140,505,NA,,,Regimen: Tamoxifen,TRUE
16013,RA_1373,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,Faslodex,5527,5619,NA,Recurrence,,Regimen: Faslodex,TRUE
16014,RA_1373,Chemotherapy,TRUE,"Capecitabine, Doxorubicin Hydrochloride Liposome",,,Doxil + Xeloda,5649,5831,NA,,,Regimen: Doxil + Xeloda,TRUE
16015,RA_1373,"Chemotherapy, Precision/Targeted Therapy",TRUE,"Capecitabine, Trastuzumab",,,Herceptin  (Trastuzumab) + Xeloda,5892,6410,NA,,,Regimen: Herceptin  (Trastuzumab) + Xeloda,TRUE
16016,RA_1373,,TRUE,,CMF,,CMF,6410,6502,NA,,,Regimen: CMF,TRUE
16017,RA_1373,Chemotherapy,TRUE,Paclitaxel,,,Taxol,6502,6561,NA,,,Regimen: Taxol,TRUE
16018,RA_1373,Chemotherapy,TRUE,Eribulin Mesylate,,,Eribulin,6822,6843,NA,,,Regimen: Eribulin,TRUE
16019,RA_1373,Chemotherapy,TRUE,Eribulin Mesylate,,,Eribulin,6983,7046,NA,,,Regimen: Eribulin,TRUE
16020,RA_1373,Chemotherapy,TRUE,Cisplatin,,,Cisplatin,7053,7087,NA,,,Regimen: Cisplatin,TRUE
16021,RA_1511,Biological Therapy,TRUE,Bevacizumab,,,Carboplatin/Pemetrexed/Avastin,15,95,Progression and relapse,,,"Progression = New Liver Mets, increased size of liver mets, R. Adrenal Met, Mesenteric Nodule // decreased size right lower lobe lung nodules, right paratracheal and right hilar lymphadenopathy consistent with treatment response ~ Regimen: Carboplatin/Pemetrexed/Avastin",TRUE
16022,RA_1511,Immunotherapy,TRUE,Nivolumab,,,Nivolumab,186,186,Toxicity,,,nivolumab-related pneumonitis ~ Regimen: Nivolumab,TRUE
16023,RA_1526,Chemotherapy,TRUE,"Carboplatin, Paclitaxel",,,Taxol and carboplatin (Adjuvant),46,116,NA,,,Regimen: Taxol and carboplatin (Adjuvant),TRUE
16024,RA_1526,,TRUE,Megestrol Acetate,,,Megace,686,714,NA,Recurrence,,Regimen: Megace,TRUE
16025,RA_1526,,TRUE,Ziv-Aflibercept,,,Aflibercept (GOG-0229F) - VEGF-trap,715,795,NA,,,Clinical Trial: Discontinued for proteinuria ~ Regimen: Aflibercept (GOG-0229F) - VEGF-trap,TRUE
16026,RA_1526,Biological Therapy,TRUE,Bevacizumab,,,Avastin (Bevacizumab),820,1098,NA,,,Regimen: Avastin (Bevacizumab),TRUE
16027,RA_1526,Chemotherapy,TRUE,Paclitaxel,,,weekly Taxol,1099,1253,NA,,,Regimen: weekly Taxol,TRUE
16028,RA_1526,Biological Therapy,TRUE,Bevacizumab,,,Consolidation Avastin (Bevacizumab),1260,1736,NA,,,Regimen: Consolidation Avastin (Bevacizumab),TRUE
16029,RA_1526,Chemotherapy,TRUE,"Carboplatin, Doxorubicin Hydrochloride Liposome",,,Doxil + Carboplatin. Last platinum (#6)  then consolidation,1757,1918,NA,,,Regimen: Doxil + Carboplatin. Last platinum (#6)  then consolidation,TRUE
16030,RA_1526,Biological Therapy,TRUE,Bevacizumab,,,Consolidation Avastin (Bevacizumab)  15 mg/kg IV Q21D,1946,2009,NA,,,Regimen: Consolidation Avastin (Bevacizumab)  15 mg/kg IV Q21D,TRUE
16031,RA_1526,Chemotherapy,TRUE,Paclitaxel,,,MLN2480 + PACLITAXEL,2885,3036,NA,,,"Clinical Trial:  Best Response = SD (-19.2%) // Progression = +7% from BL, +32.4% from Nadir -- Increased size of pulmonary nodules ~ Regimen: MLN2480 + PACLITAXEL",TRUE
16032,RA_1526,Precision/Targeted Therapy,TRUE,"Navitoclax, Trametinib",,,TRAMETINIB + NAVITOCLAX,3074,3186,NA,,,"Clinical Trial:  Best Response = SD (-4.0%) // Progression = +7.3% from BL, +11.5% from Nadir -- PD of Lung mult sites/Pleura mult sites ~ Regimen: TRAMETINIB + NAVITOCLAX",TRUE
16033,RA_1526,Chemotherapy,TRUE,"Carboplatin, Doxorubicin Hydrochloride Liposome",,,Carboplatin + Doxil,3196,3374,NA,,,Regimen: Carboplatin + Doxil,TRUE
16034,RA_1526,Immunotherapy,TRUE,Avelumab,,,Avelumab (MSB0010718C) - anti PDL-1,3416,3461,NA,,,progression of mets in lung pleura and parenchyma with likely tumor in left lower lobe bronchus. ~ Regimen: Avelumab (MSB0010718C) - anti PDL-1,TRUE
16035,RA_1534,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,Anastrazole,6,495,NA,,,Metastatic at Diagnosis ~ Regimen: Anastrazole,TRUE
16036,RA_1534,Other,TRUE,"Exemestane, Zoledronic Acid",,,Exemestane + Zometa,496,555,NA,,,Regimen: Exemestane + Zometa,TRUE
16037,RA_1534,Chemotherapy,TRUE,Paclitaxel,,,Taxol,619,718,NA,,,Stable disease ~ Regimen: Taxol,TRUE
16038,RA_1534,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane, Ribociclib",,,LEE011(Ribociclib)/everolimus/exemestane X 10 Cycles,746,1026,NA,,,Clinical Trial: Best Response = Partial Response (-36.3%) ~ Regimen: LEE011(Ribociclib)/everolimus/exemestane X 10 Cycles,TRUE
16039,RA_1542,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Cisplatin/Gemcitabine (x 3 cycles),18,66,Progression and relapse,,,"Progression = Enlarged left and right diaphragmatic lymph nodes, concerning for metastasis; numerous bilobar liver metastases slightly enlarged ~ Regimen: Cisplatin/Gemcitabine (x 3 cycles)",TRUE
16040,RA_1542,,TRUE,,FOLFOX,,"FOLFOX, 5-FU",190,243,Progression and relapse,,,"Progression = Increase in metastatic burden throughout the liver; Mild increase in size of lung mets. ~ Regimen: FOLFOX, 5-FU",TRUE
16041,RA_1547,,TRUE,,TAC,,TAC (6 Cycles),56,161,NA,,,Regimen: TAC (6 Cycles),TRUE
16042,RA_1547,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,232,295,NA,,,Regimen: Tamoxifen,TRUE
16043,RA_1547,Hormone/Endocrine Therapy,TRUE,Toremifene,,,Toremifene,295,818,NA,,,Regimen: Toremifene,TRUE
16044,RA_1547,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,Anastrozole,818,1036,Progression and relapse,Recurrence,,Regimen: Anastrozole,TRUE
16045,RA_1547,"Hormone/Endocrine Therapy, Other",TRUE,"Fulvestrant, Zoledronic Acid",,,Fulvestrant + Zometa,1048,1268,Progression and relapse,,,Regimen: Fulvestrant + Zometa,TRUE
16046,RA_1547,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane, Ribociclib",,,LEE011 (Ribociclib) /exemestane/everolimus (X 17 Cycles),1309,1779,Progression and relapse,,,"Clinical Trial #: Best Response = SD (0.0%) - Bone only, eventual PD in Bone single site ~ Regimen: LEE011 (Ribociclib) /exemestane/everolimus (X 17 Cycles)",TRUE
16047,RA_1547,Chemotherapy,TRUE,Capecitabine,,,Xeloda (Capecitabine),1792,1958,Progression and relapse,,,Progression = new liver lesions ~ Regimen: Xeloda (Capecitabine),TRUE
16048,RA_1558,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin, Paclitaxel Albumin-stabilized Nanoparticle Formulation",,,Adriamycin/Cytoxan [4 Cycles] + Abraxane [4 Cycles],70,168,Completion of standard course,,,Regimen: Adriamycin/Cytoxan [4 Cycles] + Abraxane [4 Cycles],TRUE
16049,RA_1558,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,Arimidex (Adjuvant),239,2053,Completion of standard course,,,Regimen: Arimidex (Adjuvant),TRUE
16050,RA_1558,,TRUE,Exemestane,,,Exemestane,2334,2611,Progression and relapse,,,PD in internal mammary nodes ~ Regimen: Exemestane,TRUE
16051,RA_1558,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,BYL719/fulvestrant [2 Cycles],2642,2691,Toxicity,,,D/C for toxicity (Rash) - Overal RECIST Response = SD (-17.3%) ~ Regimen: BYL719/fulvestrant [2 Cycles],TRUE
16052,RA_1558,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,Fulvestrant (single agent),2696,3245,Progression and relapse,,,PD in left parasternal region ~ Regimen: Fulvestrant (single agent),TRUE
16053,RA_1558,Chemotherapy,TRUE,Capecitabine,,,Xeloda,3586,3894,Progression and relapse,,,Progression in Liver ~ Regimen: Xeloda,TRUE
16054,RA_1558,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Fulvestrant, Palbociclib",,,Fulvestrant/Palbociclib,3895,3977,Progression and relapse,,,Progression in Liver ~ Regimen: Fulvestrant/Palbociclib,TRUE
16055,RA_1558,Hormone/Endocrine Therapy,TRUE,Letrozole,,,GDC-0077 + Letrozole [2 Cycles],4120,4176,Progression and relapse,,,Final Response = PD (+14.78%) + New Liver Lesions ~ Regimen: GDC-0077 + Letrozole [2 Cycles],TRUE
16056,RA_1558,Chemotherapy,TRUE,Eribulin Mesylate,,,Eribulin [11 Cycles],4183,4405,Progression and relapse,,,Progression of Hepatic metastases ~ Regimen: Eribulin [11 Cycles],TRUE
16057,RA_1558,Chemotherapy,TRUE,Doxorubicin Hydrochloride Liposome,,,Doxil [2 Cycles],4708,4750,Progression and relapse,,,"liver, peritoneal, and bony progression ~ Regimen: Doxil [2 Cycles]",TRUE
16058,RA_1558,Precision/Targeted Therapy,TRUE,Abemaciclib,,,Abemaciclib,4763,4868,Progression and relapse,,,Patient passed away ~ Regimen: Abemaciclib,TRUE
16059,RA_1568,,TRUE,,AC,,neoadjuvant AC (4 Cycles),26,68,Completion of standard course,,,Regimen: neoadjuvant AC (4 Cycles),TRUE
16060,RA_1568,Chemotherapy,TRUE,Paclitaxel,,,Taxol,83,159,Completion of standard course,,,Regimen: Taxol,TRUE
16061,RA_1568,Chemotherapy,TRUE,Cisplatin,,,Cisplatin,224,238,Toxicity,,,Regimen: Cisplatin,TRUE
16062,RA_1598,Chemotherapy,TRUE,Paclitaxel,AC,,dose dense AC + taxol,64,166,NA,,,Regimen: dose dense AC + taxol,TRUE
16063,RA_1598,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,257,621,NA,,,Regimen: Tamoxifen,TRUE
16064,RA_1598,Hormone/Endocrine Therapy,TRUE,Leuprolide Acetate,,,Lupron,654,698,NA,Recurrence,,Regimen: Lupron,TRUE
16065,RA_1598,"Hormone/Endocrine Therapy, Other",TRUE,"Letrozole, Zoledronic Acid",,,Letrozole + Zometa,699,1652,NA,,,Regimen: Letrozole + Zometa,TRUE
16066,RA_1598,Hormone/Endocrine Therapy,TRUE,"Exemestane, Leuprolide Acetate",,,Lupron + Exemestane,1652,2136,NA,,,Regimen: Lupron + Exemestane,TRUE
16067,RA_1598,Chemotherapy,TRUE,Capecitabine,,,Xeloda,2136,2262,NA,,,Regimen: Xeloda,TRUE
16068,RA_1598,,TRUE,Cabozantinib-S-Malate,,,CABOZANITINIB (X 67 Cycles),2294,3724,NA,,,"Clinical Trial, Best Response = SD (0.0%) - Bone only disease // Progression = ""Interval increase in uptake intensity involving right precarinal and periportal lymph nodes, suspicious for disease progression. "" ~ Regimen: CABOZANITINIB (X 67 Cycles)",TRUE
16069,RA_1598,Hormone/Endocrine Therapy,TRUE,Letrozole,,,GDC-0032 + Letrozole (X 10 Cycles),3747,4012,NA,,,"Clinical Trial, Best Response = SD (0.0%) // Progression = New Liver Lesions (multiple sites) ~ Regimen: GDC-0032 + Letrozole (X 10 Cycles)",TRUE
16070,RA_1598,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Fulvestrant, Palbociclib",,,Fulvestrant/Palbociclib (X 2 Cycles),4040,4087,NA,,,Regimen: Fulvestrant/Palbociclib (X 2 Cycles),TRUE
16071,RA_1613,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Gemcitabine,11,211,NA,,,"Progression = ""interval progression of liver metastatic disease with new and enlarging metastases"" ~ Regimen: Gemcitabine",TRUE
16072,RA_1613,,TRUE,Neratinib  Maleate,,,Neratinib,224,247,NA,,,"Clinical Trial: Best Response = PD (""worsening metastatic disease particularly intrahepatic"") ~ Regimen: Neratinib",TRUE
16073,RA_1613,,TRUE,,FOLFOX,,FOLFOX,248,258,NA,,,Regimen: FOLFOX,TRUE
16074,RA_1644,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin",,,Doxorubicin(Adriamycin) + cyclophosphamide,69,152,NA,,,Regimen: Doxorubicin(Adriamycin) + cyclophosphamide,TRUE
16075,RA_1644,"Chemotherapy, Precision/Targeted Therapy",TRUE,"Paclitaxel, Trastuzumab",,,Taxol and Herceptin (Trastuzumab),153,230,NA,,,Regimen: Taxol and Herceptin (Trastuzumab),TRUE
16076,RA_1644,Precision/Targeted Therapy,TRUE,Trastuzumab,,,Herceptin (Trastuzumab),243,517,NA,,,Regimen: Herceptin (Trastuzumab),TRUE
16077,RA_1644,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,349,1011,NA,,,Regimen: Tamoxifen,TRUE
16078,RA_1644,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,Arimidex (Anastrazole),1012,1875,NA,,,Regimen: Arimidex (Anastrazole),TRUE
16079,RA_1644,"Chemotherapy, Precision/Targeted Therapy",TRUE,"Cyclophosphamide, Docetaxel, Pegfilgrastim, Trastuzumab",,,Taxotere/Cytoxan/Herceptin with neulasta,1889,1952,NA,,,Regimen: Taxotere/Cytoxan/Herceptin with neulasta,TRUE
16080,RA_1644,Precision/Targeted Therapy,TRUE,Trastuzumab,,,Herceptin (Trastuzumab),1973,2078,NA,,,Regimen: Herceptin (Trastuzumab),TRUE
16081,RA_1644,,TRUE,Exemestane,,,Exemestane,1985,2402,NA,,,Progression = enlarging mediastinal nodes ~ Regimen: Exemestane,TRUE
16082,RA_1644,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,GDC0032 + Faslodex (Fulvestrant) - (X 17 Cycles),2435,2903,NA,,,Clinical Trial: Best Response = PR (-35.1 %) // Progression = interval increase in size of bilateral lung nodules and left hilar nodes. (-16.2%) change from BL // (+29.2%) change from  Nadir ~ Regimen: GDC0032 + Faslodex (Fulvestrant) - (X 17 Cycles),TRUE
16083,RA_1644,Precision/Targeted Therapy,TRUE,"Everolimus, Exemestane",,,exemestane/everolimus/LEE011 - (X14 Cycles),2920,3312,NA,,,"Clinical Trial: Best Response = SD (+5.5%) // Progression =progression in lungs, overall (+23.67 %) Increase from BL ~ Regimen: exemestane/everolimus/LEE011 - (X14 Cycles)",TRUE
16084,RA_1644,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Letrozole, Palbociclib",,,GDC0077 + palbociclib + Letrozole (X 4 Cycles),3325,3410,NA,,,"Clinical Trial: Best Response = SD (-14.31%) // D/C d/t dysphagia, admission ~ Regimen: GDC0077 + palbociclib + Letrozole (X 4 Cycles)",TRUE
16085,RA_1657,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Gemcitabine/Cisplatin [7 Cycles],26,159,Progression and relapse,,,new lesion in segment V (Liver) ~ Regimen: Gemcitabine/Cisplatin [7 Cycles],TRUE
16086,RA_1657,,TRUE,,FOLFOX,,FOLFOX [3 Cycles],173,211,Progression and relapse,,,intrahepatic progression and likely extrahepatic spread to the retroperitoneal lymph nodes and possibly to the lungs ~ Regimen: FOLFOX [3 Cycles],TRUE
16087,RA_1657,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab [1 Cycles],215,229,Other,,,"Single Dose - Drug held for increased fluid retention, platelet increase ~ Regimen: Pembrolizumab [1 Cycles]",TRUE
16088,RA_1726,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Cisplatin/Gemcitabine,24,117,Progression and relapse,,,"Progression = Mixed response in bony and visceral sites, with new satellite lesions identified in liver ~ Regimen: Cisplatin/Gemcitabine",TRUE
16089,RA_1726,,TRUE,,FOLFOX,,FOLFOX,124,201,Progression and relapse,,,"Progression = Increase in lymphadenopathy in chest and abdomen, and increase in hepatic masses and peritoneal carcinomatosis, and increase in right liac bone lesion. ~ Regimen: FOLFOX",TRUE
16090,RA_1726,,TRUE,Dasatinib,,,Dasatinib,231,258,Progression and relapse,,,Clinical Progression ~ Regimen: Dasatinib,TRUE
16091,RA_1926,,TRUE,,FOLFOX,,FOLFOX (X 7 Cycles),15,103,Completion of standard course,,,Regimen: FOLFOX (X 7 Cycles),TRUE
16092,RA_1926,,TRUE,,FOLFOX,,FOLFOX (X 6 Cycles),1577,1644,Completion of standard course,,,"response of primary tumor, no new sites of metastatic disease ~ Regimen: FOLFOX (X 6 Cycles)",TRUE
16093,RA_1926,Chemotherapy,TRUE,"Carboplatin, Paclitaxel",,,Carbo (AUC 5) + Taxol,2282,2282,Other,,,"One dose, pursued Hospice ~ Regimen: Carbo (AUC 5) + Taxol",TRUE
16094,RA_1939,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Gemcitabine (X 7 Doses),117,200,Toxicity,,,Regimen: Gemcitabine (X 7 Doses),TRUE
16095,RA_1939,,TRUE,,FU-LV,,deGramont 5-fu (X 4 Cycles),207,258,Completion of standard course,,,Regimen: deGramont 5-fu (X 4 Cycles),TRUE
16096,RA_1939,,TRUE,,FOLFOX,,FOLFOX,488,712,Progression and relapse,Recurrence,,Progression of hepatic metastatic disease burden ~ Regimen: FOLFOX,TRUE
16097,RA_1939,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Gemcitabine + Cisplatin,1175,1278,Progression and relapse,,,Progression = new left ischial spine met ~ Regimen: Gemcitabine + Cisplatin,TRUE
16098,RA_2024,,TRUE,,FOLFOX,,FOLFOX,19,208,Completion of standard course,,,Regimen: FOLFOX,TRUE
16099,RA_2024,,TRUE,,FOLFOX,,FOLFOX,19,208,Completion of standard course,,,Regimen: FOLFOX,TRUE
16100,RA_2024,,TRUE,,FOLFIRI-BEVACIZUMAB,,FOLFIRI + bevacizumab,440,713,Progression and relapse,,,Regimen: FOLFIRI + bevacizumab,TRUE
16101,RA_2024,,TRUE,,FOLFIRI-BEVACIZUMAB,,FOLFIRI + bevacizumab,440,713,Progression and relapse,,,Regimen: FOLFIRI + bevacizumab,TRUE
16102,RA_2024,,TRUE,,FOLFIRI-CETUXIMAB,,FOLFIRI + cetuximab,727,797,Progression and relapse,,,"interval increase in size of paraesophageal lymph nodes, concerning for nodal metastasis. new retroperitoneal lymphadenopathy and abdominal  wall soft tissue nodularity, consistent with progressive metastatic disease with peritoneal carcinomatosis. ~ Regimen: FOLFIRI + cetuximab",TRUE
16103,RA_2024,,TRUE,,FOLFIRI-CETUXIMAB,,FOLFIRI + cetuximab,727,797,Progression and relapse,,,"interval increase in size of paraesophageal lymph nodes, concerning for nodal metastasis. new retroperitoneal lymphadenopathy and abdominal  wall soft tissue nodularity, consistent with progressive metastatic disease with peritoneal carcinomatosis. ~ Regimen: FOLFIRI + cetuximab",TRUE
16104,RA_2024,Precision/Targeted Therapy,TRUE,"Lapatinib Ditosylate, Trastuzumab",,,trastuzumab/lapatinib,825,901,Progression and relapse,,,"slight increase in size of mediastinal, pericardial, left supraclavicular, left subpectoral, left axillary lymphadenopathy, which remains concerning  for progressive disease. unchanged pulmonary nodules.  CT abdomen and pelvis: metastatic retroperitoneal adenopathy. Several lymph nodes have increased in size in the interim. Peritoneal carcinomatosis and ascites is unchanged. ~ Regimen: trastuzumab/lapatinib",TRUE
16105,RA_2024,Precision/Targeted Therapy,TRUE,"Lapatinib Ditosylate, Trastuzumab",,,trastuzumab/lapatinib,825,901,Progression and relapse,,,"slight increase in size of mediastinal, pericardial, left supraclavicular, left subpectoral, left axillary lymphadenopathy, which remains concerning  for progressive disease. unchanged pulmonary nodules.  CT abdomen and pelvis: metastatic retroperitoneal adenopathy. Several lymph nodes have increased in size in the interim. Peritoneal carcinomatosis and ascites is unchanged. ~ Regimen: trastuzumab/lapatinib",TRUE
16106,RA_2085,,TRUE,,FOLFOX,,FOLFOX [4 Cycles],22,64,Completion of standard course,,,partial response ~ Regimen: FOLFOX [4 Cycles],TRUE
16107,RA_2085,,TRUE,,FOLFOX,,FOLFOX,148,204,Completion of standard course,,,Regimen: FOLFOX,TRUE
16108,RA_2085,,TRUE,,FU-LV,,5FU + Radiation,231,269,Completion of standard course,,,Regimen: 5FU + Radiation,TRUE
16109,RA_2085,Biological Therapy,TRUE,Bevacizumab,FOLFOX,,FOLFOX with Avastin [8 Cycles],640,745,Completion of standard course,,,Regimen: FOLFOX with Avastin [8 Cycles],TRUE
16110,RA_2085,Biological Therapy,TRUE,Bevacizumab,FOLFIRI,,FOLFIRI plus Avastin [8 Cycles],983,1103,Completion of standard course,,,Regimen: FOLFIRI plus Avastin [8 Cycles],TRUE
16111,RA_2085,,TRUE,Cetuximab,,,Cetuximab,1341,1451,Progression and relapse,,,rising tmor markers/new disease ~ Regimen: Cetuximab,TRUE
16112,RA_2085,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,Ipilimumab/Nivolumab,1654,1752,Toxicity,,,checkpoint inhibitor colitis ~ Regimen: Ipilimumab/Nivolumab,TRUE
16113,RA_209,Immunotherapy,TRUE,"Atezolizumab, Cobimetinib, Vemurafenib",,,Vemurafenib + Cobimetinib+ Atezolizumab,4740,4754,Toxicity,,,"hypersensitivity reaction (Rash, pharyngitis, odynophagia) -  partial response to treatment ~ Regimen: Vemurafenib + Cobimetinib+ Atezolizumab",TRUE
16114,RA_209,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab,4803,4845,Progression and relapse,,,"New innumerable tiny centrilobular groundglass nodules throughout the lungs; 8 mm soft tissue nodule in the (L) posterior lateral mid chest SC fat; Growth of a peritoneal implant adjacent to the duodenal bulb, concerning for progression of a metastasis. ~ Regimen: Pembrolizumab",TRUE
16115,RA_209,Immunotherapy,TRUE,Ipilimumab,,,Ipilimumab,5342,5342,Toxicity,,,"Rash - Mixed response: decrease in FDG avidity of LUE, liver met, RUQ peritoneal nodule. New FDG avid nodule in L chest wall, enlargement of nodule in R pelvis.  New and increasing soft tissue nodules in L supraclav fossa, axilla, B breasts, chest wall. ~ Regimen: Ipilimumab",TRUE
16116,RA_209,Precision/Targeted Therapy,TRUE,"Dabrafenib Mesylate, Trametinib",,,Dabrafenib + Trametinib,5567,5793,Progression and relapse,,,"Marked increase in size of L breast masses, less pronounced increase in other truncal soft tissue/SC masses and R groin mass.  growing subq mets + new subq mets ~ Regimen: Dabrafenib + Trametinib",TRUE
16117,RA_209,Precision/Targeted Therapy,TRUE,"Binimetinib, Encorafenib",,,Encorafenib + Binimetinib,5801,5846,Progression and relapse,,,"Marked progression of diffuse metastatic disease; innumerable diffuse, enhancing and intensely FDG avid soft tissue nodules throughout all imaged subcutaneous space, all imaged peritoneal spaces, and also involving musculature and bowel.  interval development of innumerable diffuse enlarged, enhancing and intensely FDG avid subcutaneous nodules, axillary lymph nodes, supraclavicular lymph nodes, internal mammary lymph nodes, mediastinal and hilar lymph nodes. ~ Regimen: Encorafenib + Binimetinib",TRUE
16118,RA_2098,Chemotherapy,TRUE,"Carboplatin, Paclitaxel",,,Carboplatin/ Paclitaxel (x 6 cycles),44,181,Progression and relapse,,Recurrence,"Progression = Multiple new enhancing nodules along the anterior right and left upper abdomen, in the left anterior pelvis, and within and along the left rectus abdominus musculature ~ Regimen: Carboplatin/ Paclitaxel (x 6 cycles)",TRUE
16119,RA_2098,Immunotherapy,TRUE,"Pembrolizumab, Ziv-Aflibercept",,,Ziv-Aflibercept and Pembrolizumab (x 8 cycles),221,335,Progression and relapse,,,Progression = progression in L rectus muscle lesion and L pelvic side wall lymph node ~ Regimen: Ziv-Aflibercept and Pembrolizumab (x 8 cycles),TRUE
16120,RA_2098,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Gemcitabine  (x 2 cycles),366,398,Progression and relapse,,,"Progression = increased abdominal and pelvic adenopathy, pelvic masses and perihepatic lesions. ~ Regimen: Gemcitabine  (x 2 cycles)",TRUE
16121,RA_2098,"Biological Therapy, Precision/Targeted Therapy",TRUE,"Palbociclib, Ramucirumab",,,Palbociclib + Gedatolisib (PI3K/mTORi),471,513,Progression and relapse,,,"Progression = increasing intrathoracic LAD, peritoneal disease, abdominopelvic lymphadenopathy, and soft tissue masses ~ Regimen: Palbociclib + Gedatolisib (PI3K/mTORi)",TRUE
16122,RA_2098,Immunotherapy,TRUE,Nivolumab,,,TAK-659 + Nivolumab,590,674,Progression and relapse,,,Best Response = SD (+13.79% from BL) // Progression = PD (+22.7% from BL) Increased size of left peritoneal lesion ~ Regimen: TAK-659 + Nivolumab,TRUE
16123,RA_2113,Immunotherapy,TRUE,Ipilimumab,,,Nivolumab + Ipilimumab,56,69,Toxicity,,,stopped after a single dose of ipi/nivo due to increased dyspnea and likely autoimmune pneumonitis ~ Regimen: Nivolumab + Ipilimumab,TRUE
16124,RA_2168,,TRUE,,FOLFIRI,,FOLFIRI,32,228,Other,,,Regimen: FOLFIRI,TRUE
16125,RA_2177,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Gemcitabine + Cisplatin [6 Cycles],28,151,Progression and relapse,,,Regimen: Gemcitabine + Cisplatin [6 Cycles],TRUE
16126,RA_2177,Precision/Targeted Therapy,TRUE,Sorafenib,,,Sorafenib (2 Days),181,183,Toxicity,,,Rash ~ Regimen: Sorafenib (2 Days),TRUE
16127,RA_2185,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Gemcitabine/Cisplatin [12 Cycles],25,329,Progression and relapse,,,Marked worsening of hepatic disease. Growth of supraclavicular lymph nodes. ~ Regimen: Gemcitabine/Cisplatin [12 Cycles],TRUE
16128,RA_2185,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab [3 Cycles],371,420,Progression and relapse,,,Clinical Progression - Worsenning Ascites & Pain ~ Regimen: Pembrolizumab [3 Cycles],TRUE
16129,RA_2185,,TRUE,,FU-LV,,5FU + IVCI [7 Cycles],441,560,Progression and relapse,,,Regimen: 5FU + IVCI [7 Cycles],TRUE
16130,RA_2389,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,0,103,Other,,,"mixed response with decrease in liver lesions, stable bone disease, decrease in left axillary disease and increase in left breast disease. ~ Regimen: Tamoxifen",TRUE
16131,RA_2389,Hormone/Endocrine Therapy,TRUE,"Leuprolide Acetate, Tamoxifen Citrate",,,Tamoxifen/Lupron,103,284,Other,,,Regimen: Tamoxifen/Lupron,TRUE
16132,RA_2389,Hormone/Endocrine Therapy,TRUE,"Anastrozole, Leuprolide Acetate",,,Anastrozole/ Lupron,284,391,Toxicity,,,"previous left axillary and subpectoral region lymph nodes appeared to have regressed and no longer showed increased uptake, improvement in bony metastatic disease with diminished activity in all bony lesions and no evidence of liver metastases. ~ Regimen: Anastrozole/ Lupron",TRUE
16133,RA_2389,Hormone/Endocrine Therapy,TRUE,"Leuprolide Acetate, Tamoxifen Citrate",,,Tamoxifen/ Lupron,391,489,Progression and relapse,,,Regimen: Tamoxifen/ Lupron,TRUE
16134,RA_2389,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Fulvestrant, Leuprolide Acetate, Palbociclib",,,fulvestrant/palbociclib/Lupron,489,573,Progression and relapse,,,Regimen: fulvestrant/palbociclib/Lupron,TRUE
16135,RA_2389,Chemotherapy,TRUE,Capecitabine,,,Capecitabine,573,822,Progression and relapse,,,Bilateral hypermetabolic breasts lesions concerning for active tumor in both breasts. Multiple hypermetabolic and non hypermetabolic sclerotic foci within the skeleton. ~ Regimen: Capecitabine,TRUE
16136,RA_2389,Hormone/Endocrine Therapy,TRUE,"Fulvestrant, Goserelin Acetate, Neratinib  Maleate",,,Fulvestrant/Neratinib (TKI) with Goserelin (#13-615),877,891,Progression and relapse,,,rapid deterioration of her performance status ~ Regimen: Fulvestrant/Neratinib (TKI) with Goserelin (#13-615),TRUE
16137,RA_2402,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Letrozole, Palbociclib",,,Palbociclib/Letrozole [19 Cycles],116,647,Progression and relapse,,,progression in the liver ~ Regimen: Palbociclib/Letrozole [19 Cycles],TRUE
16138,RA_2402,Chemotherapy,TRUE,Capecitabine,,,Xeloda,919,1140,Progression and relapse,,,Initial Response of liver lesions // PD = New and enlarging hepatic metastases ~ Regimen: Xeloda,TRUE
16139,RA_2402,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Abemaciclib, Fulvestrant",,,Abemaciclib/Fulvestrant [1 Cycle],1224,1256,Progression and relapse,,,Rising Tumor Markers ~ Regimen: Abemaciclib/Fulvestrant [1 Cycle],TRUE
16140,RA_2402,Chemotherapy,TRUE,Doxorubicin Hydrochloride Liposome,,,Doxil [2 Cycles],1259,1287,Progression and relapse,,,Regimen: Doxil [2 Cycles],TRUE
16141,RA_2402,Chemotherapy,TRUE,Paclitaxel,,,Taxol [4 Cycles],1297,1406,Progression and relapse,,,Decrease in size of hepatic lesions ~ Regimen: Taxol [4 Cycles],TRUE
16142,RA_2402,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Vinorelbine,1406,1413,Progression and relapse,,,Regimen: Vinorelbine,TRUE
16143,RA_2408,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Gemcitabine/ Cisplatin (X 3 Cycles),105,177,Progression and relapse,,,Best Response = Progression in Liver ~ Regimen: Gemcitabine/ Cisplatin (X 3 Cycles),TRUE
16144,RA_2460,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Gemcitabine/Cisplatin/DKN-01,25,53,Progression and relapse,,,progression of disease with mild new biliary dilation ~ Regimen: Gemcitabine/Cisplatin/DKN-01,TRUE
16145,RA_2460,Precision/Targeted Therapy,TRUE,Olaparib,,,Olaparib + AZD5363,291,373,Progression and relapse,,,"Overall stable disease ""slightly increased size of right hepatic lesions, stable left hepatic lesions, and slightly decreased abdominal lymphadenopathy"" ~ Regimen: Olaparib + AZD5363",TRUE
16146,RA_2542,,TRUE,,CAF,,CAF (cyclophosphamide/ Adriamycin/ Fluorouracil) - 6 Cycles,29,182,Completion of standard course,,,Exact dates of treatment unknown ~ Regimen: CAF (cyclophosphamide/ Adriamycin/ Fluorouracil) - 6 Cycles,TRUE
16147,RA_2542,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen (Adjuvant),335,2161,Completion of standard course,,,Regimen: Tamoxifen (Adjuvant),TRUE
16148,RA_2542,Hormone/Endocrine Therapy,TRUE,Letrozole,,,Letrozole,2826,4656,Completion of standard course,,,Regimen: Letrozole,TRUE
16149,RA_2542,Hormone/Endocrine Therapy,TRUE,Letrozole,,,Letrozole,4912,6104,Progression and relapse,,,New Bone Lesions ~ Regimen: Letrozole,TRUE
16150,RA_2542,Chemotherapy,TRUE,Capecitabine,,,Capecitabine,6105,7746,Progression and relapse,,,Regimen: Capecitabine,TRUE
16151,RA_2542,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Fulvestrant, Palbociclib",,,Fulvestrant/Palbociclib,7749,7811,Progression and relapse,,,Regimen: Fulvestrant/Palbociclib,TRUE
16152,RA_2542,Chemotherapy,TRUE,Paclitaxel,,,Paclitaxel,8447,8610,Other,,,Patient pursued hospice care ~ Regimen: Paclitaxel,TRUE
16153,RA_2544,Chemotherapy,TRUE,"Carboplatin, Paclitaxel",,,Carboplatin AUC 5 + Taxol,41,253,Completion of standard course,,,Near complete interval resolution of the previously described bilateral pulmonary nodules.  Marked interval decrease in size of the right hepatic lobe and right retroperitoneal mass. Persistent right posterior retroperitoneal soft tissue infiltration of the intercostal spaces and infiltration of the posterior 11th rib with interval sclerosis. Interval decrease in size of the right renal posterior infiltrative mass in continuity with the large posterior retroperitoneal mass. Interval development of coarse calcifications within theretroperitoneal mass. ~ Regimen: Carboplatin AUC 5 + Taxol,TRUE
16154,RA_2544,Hormone/Endocrine Therapy,TRUE,Letrozole,,,Letrozole,259,793,Progression and relapse,,,Progression =  Enlargement of pulmonary nodules; progression of necrotic pulmonary metastasis; no change in R hepatic lobe lesion with adjacent soft tissue mass ~ Regimen: Letrozole,TRUE
16155,RA_255,Chemotherapy,TRUE,"Carboplatin, Paclitaxel",,,Carboplatin / Paclitaxel [2 Cycles],15,36,Completion of standard course,,,Previously identifiable 5 mm right anterior enhancing extrapleural lymph node is no longer identifiable. Biapical changes and complex calcifications in the left lower lobe are most consistent with chronic granulomatous changes. Complete disappearance of omental metastases and ascites. ~ Regimen: Carboplatin / Paclitaxel [2 Cycles],TRUE
16156,RA_255,Immunotherapy,TRUE,Ipilimumab,,,Ipilimumab [4 Cycles],65,127,Completion of standard course,,,no evidence of CNS disease and no evidence of other visceral metastases except for a number of new lytic lesions ~ Regimen: Ipilimumab [4 Cycles],TRUE
16157,RA_255,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab,275,337,Progression and relapse,,,"?Interval development of approximately 10 enhancing lesions within the supra and infratentorial brain, measuring up to 17 mm in the left posterior temporal lobe and right cerebellum ~ Regimen: Pembrolizumab",TRUE
16158,RA_255,Precision/Targeted Therapy,TRUE,"Dabrafenib Mesylate, Trametinib",,,Dabrafenib / Trametinib,344,586,Toxicity,,,Fevers and chills ~ Regimen: Dabrafenib / Trametinib,TRUE
16159,RA_255,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab [15 Cycles],435,675,Progression and relapse,,,"MRI Brain: Interval development of a 10 mm enhancing lesion with mild surrounding edema in the left inferior frontal gyrus. New punctate focus of enhancement in the left posterior superior temporal gyrus, which is concerning for a new metastatic lesion.  CT CAP:  Slight interval increase in size of the soft tissue component involving a left eighth rib lesion. Other osseous lesions appear essentially unchanged. Pulmonary nodules measuring up to 4 mm are unchanged.No new or enlarging pulmonary nodules. Multifocal lytic metastasis appears similar to before. Otherwise, no metastatic disease within the abdomen or pelvis. ~ Regimen: Pembrolizumab [15 Cycles]",TRUE
16160,RA_255,Precision/Targeted Therapy,TRUE,"Dabrafenib Mesylate, Trametinib",,,Dabrafenib / Trametinib,696,706,Toxicity,,,Fevers ~ Regimen: Dabrafenib / Trametinib,TRUE
16161,RA_255,,TRUE,"Cobimetinib, Vemurafenib",,,Vemurafenib / Cobimetinib,706,1121,Progression and relapse,,,"MRI Brain: at least 3 new enhancing lesions suspicious for metastases; CTCAP: Pathologic fracture of the left transverse process of T8 with increased adjacent soft tissue component consistent with progression of a bone metastasis.  Additional osseous metastases in multiple thoracic vertebral bodies are stable, ~ Regimen: Vemurafenib / Cobimetinib",TRUE
16162,RA_255,Chemotherapy,TRUE,"Carboplatin, Paclitaxel",,,Carboplatin/Taxol,1123,1123,Progression and relapse,,,"Increased nodular soft tissue in left paraspinal region, left T8-9 neural foramen, and left central spinal canal at T8 increase in size of a left paraspinal nodule or extrapleural lymph node at T9. Multiple 2-4 mm pulmonary nodules are increased. Hepatic metastatic disease burden has progressed. Increasing left adrenal nodularity is also suspicious for a metastasis.  Bony metastatic disease burden is unchanged ~ Regimen: Carboplatin/Taxol",TRUE
16163,RA_255,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,Ipilimumab + Nivolumab,1151,1151,Other,,,Patient chose not to pursue further treatment ~ Regimen: Ipilimumab + Nivolumab,TRUE
16164,RA_2736,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Gemcitabine [6 Cycles] - adjuvant,62,223,Completion of standard course,,,Regimen: Gemcitabine [6 Cycles] - adjuvant,TRUE
16165,RA_2736,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Gemcitabine / Cisplatin,875,882,Other,,,transitioned to hospice ~ Regimen: Gemcitabine / Cisplatin,TRUE
16166,RA_2754,Precision/Targeted Therapy,TRUE,Sorafenib,,,Sorafenib,24,80,Progression and relapse,,,"increase in size and distribution of the multifocal intrahepatic tumor; new focus of tumor thrombus in the right portal vein. Increased periportal, portacaval, gastrohepatic, paraesophageal and cardiophrenic metastatic lymphadenopathy.Increased in size of anterior peritoneal implant. ~ Regimen: Sorafenib",TRUE
16167,RA_2754,Precision/Targeted Therapy,TRUE,Sorafenib,,,Sorafenib,24,80,Progression and relapse,,,"increase in size and distribution of the multifocal intrahepatic tumor; new focus of tumor thrombus in the right portal vein. Increased periportal, portacaval, gastrohepatic, paraesophageal and cardiophrenic metastatic lymphadenopathy.Increased in size of anterior peritoneal implant. ~ Regimen: Sorafenib",TRUE
16168,RA_2754,Immunotherapy,TRUE,Nivolumab,,,Nivolumab (4 Cycles),87,197,Progression and relapse,,,DISEASE PROGRESSION AS EVIDENCED BY ENLARGING LIVER LESIONS AND PERITONEAL NODULES ~ Regimen: Nivolumab (4 Cycles),TRUE
16169,RA_2754,Immunotherapy,TRUE,Nivolumab,,,Nivolumab (4 Cycles),87,197,Progression and relapse,,,DISEASE PROGRESSION AS EVIDENCED BY ENLARGING LIVER LESIONS AND PERITONEAL NODULES ~ Regimen: Nivolumab (4 Cycles),TRUE
16170,RA_2754,"Immunotherapy, Precision/Targeted Therapy",TRUE,"Lenvatinib Mesylate, Nivolumab",,,Nivolumab + Lenvatinib (4 Cycles),200,311,Progression and relapse,,,Interval increase in retroperitoneal metastatic burden. Stable hepatic and osseous metastasis ~ Regimen: Nivolumab + Lenvatinib (4 Cycles),TRUE
16171,RA_2754,"Immunotherapy, Precision/Targeted Therapy",TRUE,"Lenvatinib Mesylate, Nivolumab",,,Nivolumab + Lenvatinib (4 Cycles),200,311,Progression and relapse,,,Interval increase in retroperitoneal metastatic burden. Stable hepatic and osseous metastasis ~ Regimen: Nivolumab + Lenvatinib (4 Cycles),TRUE
16172,RA_2754,,TRUE,Regorafenib,,,Regorafenib,317,322,Other,,,Stopped for inpatient admission ~ Regimen: Regorafenib,TRUE
16173,RA_2754,,TRUE,Regorafenib,,,Regorafenib,317,322,Other,,,Stopped for inpatient admission ~ Regimen: Regorafenib,TRUE
16174,RA_2785,Biological Therapy,TRUE,Bevacizumab,FOLFIRINOX,,FOLFIRINOX/FOLFOXIRI/FOLFIRI + Bevacizumab (13 Cycles),14,182,Progression and relapse,,,Progression in Liver ~ Regimen: FOLFIRINOX/FOLFOXIRI/FOLFIRI + Bevacizumab (13 Cycles),TRUE
16175,RA_2785,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,Ipilimumab + Nivolumab,219,306,Progression and relapse,,,Enlarging pulmonary nodules and mediastinal lymphadenopathy consistent with worsening metastatic disease; Interval progression of disease with marked interval increase in number and size of metastatic liver lesions and worsened retroperitoneal lymphadenopathy. ~ Regimen: Ipilimumab + Nivolumab,TRUE
16176,RA_2785,,TRUE,,FOLFOX,,FOLFOX (4 Cycles),315,355,Progression and relapse,,,CT scan demonstrates progression in liver ~ Regimen: FOLFOX (4 Cycles),TRUE
16177,RA_2785,Chemotherapy,TRUE,"Cetuximab, Irinotecan Hydrochloride",,,Irinotecan + Cetuximab (7 Cycles),369,464,Progression and relapse,,,Restating CT with progression in the liver ~ Regimen: Irinotecan + Cetuximab (7 Cycles),TRUE
16178,RA_2785,,TRUE,Panitumumab,,,Panitumumab (4 Cycles),506,546,Progression and relapse,,,Patient passed away prior to scans ~ Regimen: Panitumumab (4 Cycles),TRUE
16179,RA_2819,Precision/Targeted Therapy,TRUE,"Exemestane, Palbociclib",,,exemestane/palbociclicb,7024,7719,Progression and relapse,Recurrence,,Progression = Interval development of greater than 20 hepatic metastasis; New Lung nodules in the RIGHT middle lobe and Left Medial Lobe ~ Regimen: exemestane/palbociclicb,TRUE
16180,RA_2819,Chemotherapy,TRUE,Capecitabine,,,Xeloda,7748,7888,Progression and relapse,,,progression in the liver ~ Regimen: Xeloda,TRUE
16181,RA_2819,Chemotherapy,TRUE,Doxorubicin Hydrochloride Liposome,,,Doxil,7955,7984,Toxicity,,,D/C for Rising LFTS ~ Regimen: Doxil,TRUE
16182,RA_2819,Chemotherapy,TRUE,Eribulin Mesylate,,,Eribulin,7986,8131,Progression and relapse,,,"a decrease in the size of her hepatic metastases, however rising tumor markers ~ Regimen: Eribulin",TRUE
16183,RA_2819,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Abemaciclib, Fulvestrant",,,Abemaciclib/Fulvestrant,8161,8183,Toxicity,,,D/C for Rising LFTS ~ Regimen: Abemaciclib/Fulvestrant,TRUE
16184,RA_2819,Chemotherapy,TRUE,Paclitaxel,,,Paclitaxel,8186,8223,Other,,,Pursued Hospice ~ Regimen: Paclitaxel,TRUE
16185,RA_2917,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin",,,Neoadjuvant Adriamycin + Cytoxan [x 4 Cycles],4,46,Completion of standard course,,,Regimen: Neoadjuvant Adriamycin + Cytoxan [x 4 Cycles],TRUE
16186,RA_2917,Chemotherapy,TRUE,Paclitaxel,,,Taxol,63,141,Progression and relapse,,,New Liver Lesion ~ Regimen: Taxol,TRUE
16187,RA_2917,"Chemotherapy, Immunotherapy",TRUE,"Eribulin Mesylate, Pembrolizumab",,,Eribulin + pembrolizumab,185,276,Progression and relapse,,,increase in mediastinal node and nodules on left chest wall ~ Regimen: Eribulin + pembrolizumab,TRUE
16188,RA_2917,Chemotherapy,TRUE,Cisplatin,,,cisplatin/ATR inhibitor (2 Cycles),308,355,Progression and relapse,,,Regimen: cisplatin/ATR inhibitor (2 Cycles),TRUE
16189,RA_2917,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Navelbine,662,718,Progression and relapse,,,chest wall progression on exam ~ Regimen: Navelbine,TRUE
16190,RA_2917,Chemotherapy,TRUE,Doxorubicin Hydrochloride Liposome,,,Doxil,718,746,Other,,,Held for hyperbilirubinemia / not restarted ~ Regimen: Doxil,TRUE
16191,RA_2974,,TRUE,,TAC,,TAC - Taxotere + Adriamycin + Cytoxan (X 6 Cycles),7293,7398,NA,Recurrence,,Regimen: TAC - Taxotere + Adriamycin + Cytoxan (X 6 Cycles),TRUE
16192,RA_2974,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,Fulvestrant,7442,7504,NA,,,Regimen: Fulvestrant,TRUE
16193,RA_2974,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Fulvestrant, Palbociclib",,,Fulvestrant + Palbociclib,7505,7561,NA,,,Regimen: Fulvestrant + Palbociclib,TRUE
16194,RA_2974,Chemotherapy,TRUE,Capecitabine,,,Xeloda,7562,7959,NA,,,Regimen: Xeloda,TRUE
16195,RA_2974,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Navelbine,7974,8072,NA,,,Regimen: Navelbine,TRUE
16196,RA_2974,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,3 Cycles - MSC2363318A (p70S6K/Akt inhibitor) + Tamoxifen,8141,8203,NA,,,Clinical Trial: Best Response = SD (-5.84%) ~ Regimen: 3 Cycles - MSC2363318A (p70S6K/Akt inhibitor) + Tamoxifen,TRUE
16197,RA_3035,Immunotherapy,TRUE,Nivolumab,,,Nivolumab + CCR2 inhibitor (TAK202).,78,120,NA,,,"Metastatic at Diagnosis //  Clinical Trial: Best Response = PD (""Worsening of liver mets"") ~ Regimen: Nivolumab + CCR2 inhibitor (TAK202).",TRUE
16198,RA_3035,Immunotherapy,TRUE,Nivolumab,,,Nivolumab (monotherapy),120,173,NA,,,Regimen: Nivolumab (monotherapy),TRUE
16199,RA_3130,,TRUE,,FOLFOX,,adjuvant FOLFOX,280,386,Progression and relapse,,,incompletely characterized ill-defined hypo-attenuating area in hepatic segment IVa ~ Regimen: adjuvant FOLFOX,TRUE
16200,RA_3130,"Biological Therapy, Chemotherapy",TRUE,"Paclitaxel, Ramucirumab",,,Paclitaxel/Ramucirumab [6 Cycles],519,680,Progression and relapse,,,new mesenteric and worsening retroperitoneal lymphadenopathy ; no evidence of metastatic disease in the chest ~ Regimen: Paclitaxel/Ramucirumab [6 Cycles],TRUE
16201,RA_3130,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib and TAS-120 [3 Cycles],911,984,Progression and relapse,,,Patient Passed away ~ Regimen: Crizotinib and TAS-120 [3 Cycles],TRUE
16202,RA_3181,Chemotherapy,TRUE,"Carboplatin, Paclitaxel",,,Carboplatin AUC 6 & Taxol,30,146,Completion of standard course,,,Regimen: Carboplatin AUC 6 & Taxol,TRUE
16203,RA_3181,Biological Therapy,TRUE,Bevacizumab,,,IMGN853/Bevacizumab,357,602,Toxicity,,,discontinued due to neuropathy ~ Regimen: IMGN853/Bevacizumab,TRUE
16204,RA_3181,"Biological Therapy, Immunotherapy",TRUE,"Bevacizumab, Nivolumab",,,Nivolumab/Bevacizumab,686,791,Other,,,admitted and passed away inpatient (Encephalopathy) ~ Regimen: Nivolumab/Bevacizumab,TRUE
16205,RA_3226,"Chemotherapy, Other",TRUE,"Fluorouracil, Folinic Acid, Oxaliplatin",,,Folinic Acic/Fluorouracil/Oxaliplatin,22,300,Progression and relapse,,,Regimen: Folinic Acic/Fluorouracil/Oxaliplatin,TRUE
16206,RA_3226,"Biological Therapy, Chemotherapy",TRUE,"Bevacizumab, Fluorouracil",,,deGramont 5-fluorouracil/Bevacizumab,412,1213,Progression and relapse,,,Regimen: deGramont 5-fluorouracil/Bevacizumab,TRUE
16207,RA_3226,,TRUE,Cetuximab,,,Cetuximab,1379,1379,Toxicity,,,HSR 30 min into first dose ~ Regimen: Cetuximab,TRUE
16208,RA_3226,,TRUE,Panitumumab,,,Panitumumab,1388,1451,Progression and relapse,,,Regimen: Panitumumab,TRUE
16209,RA_3226,Precision/Targeted Therapy,TRUE,Trastuzumab,FU-LV,,Trastuzumab/5-Fluorouracil/L-Leucovorin,1514,1619,Progression and relapse,,,Regimen: Trastuzumab/5-Fluorouracil/L-Leucovorin,TRUE
16210,RA_3226,Precision/Targeted Therapy,TRUE,"Lapatinib Ditosylate, Trastuzumab",,,Lapatinib/Traztuzumab,1682,1910,Progression and relapse,,,Regimen: Lapatinib/Traztuzumab,TRUE
16211,RA_3226,Chemotherapy,TRUE,"Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium",,,Leucovorin Calcium/Fluorouracil/Irinotecan,1945,2122,Progression and relapse,,,Regimen: Leucovorin Calcium/Fluorouracil/Irinotecan,TRUE
16212,RA_3226,,TRUE,Trifluridine and Tipiracil Hydrochloride,,,Trifluridine/Tipiracil (Lonsurf),2153,2282,Other,,,"Mixed response (prev slow progression), switched to FOLFOX ~ Regimen: Trifluridine/Tipiracil (Lonsurf)",TRUE
16213,RA_3226,"Biological Therapy, Chemotherapy",TRUE,"Bevacizumab, Fluorouracil, Leucovorin Calcium, Oxaliplatin",,,Fluorouracil/Leucovorin Calcium/Oxaliplatin/Bevacizumab,2291,2513,Progression and relapse,,,Regimen: Fluorouracil/Leucovorin Calcium/Oxaliplatin/Bevacizumab,TRUE
16214,RA_3226,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,Ipilimumab/Nivolumab,2548,2548,Toxicity,,,"pneumonitis, didn't receive XRT that would've occurred later ~ Regimen: Ipilimumab/Nivolumab",TRUE
16215,RA_3231,Chemotherapy,TRUE,"Gemcitabine Hydrochloride, Paclitaxel Albumin-stabilized Nanoparticle Formulation",,,Gemcitabine/ Abraxane,35,35,Other,,,Palliative - single dose ~ Regimen: Gemcitabine/ Abraxane,TRUE
16216,RA_3244,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,Ipilimumab + Nivolumab [1 Cycle],3698,3698,Other,,,Patient passed away after one dose ~ Regimen: Ipilimumab + Nivolumab [1 Cycle],TRUE
16217,RA_3274,Precision/Targeted Therapy,TRUE,Gefitinib,,,nazartinib + gefitinib [7 Cycles],37,203,Progression and relapse,,,Partial Response (-44%) ~ Regimen: nazartinib + gefitinib [7 Cycles],TRUE
16218,RA_3328,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Cisplatin/Gemcitabine (X 8 Cycles),26,148,Progression and relapse,,,progression of disease in the abdomen ~ Regimen: Cisplatin/Gemcitabine (X 8 Cycles),TRUE
16219,RA_3328,,TRUE,,FOLFOX,,FOLFOX (X 4 Cycles),179,248,Progression and relapse,,,progressive hepatic metastases ~ Regimen: FOLFOX (X 4 Cycles),TRUE
16220,RA_3343,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Gemcitabine / Cisplatin [3 Cycles],28,91,Progression and relapse,,,showed disease progression in the liver by report;  increased in number and size of lung metastases. ~ Regimen: Gemcitabine / Cisplatin [3 Cycles],TRUE
16221,RA_3343,Chemotherapy,TRUE,"Capecitabine, Oxaliplatin",,,Capecitabine/ Oxaliplatin [1 Cycle],102,116,Toxicity,,,complications of phlebitis ~ Regimen: Capecitabine/ Oxaliplatin [1 Cycle],TRUE
16222,RA_3451,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Gemcitabine and Cisplatin,1,90,Progression and relapse,,,stable disease in the abdomen with several slightly enlarged lung nodules ~ Regimen: Gemcitabine and Cisplatin,TRUE
16223,RA_3451,,TRUE,,FOLFOX,,FOLFOX,251,251,Other,,,Single Dose - Patient Passed away ~ Regimen: FOLFOX,TRUE
16224,RA_3533,Immunotherapy,TRUE,Pembrolizumab,,,pembrolizumab [ 2 Cycles],411,456,Toxicity,,,checkpoint-induced encephalitis ~ Regimen: pembrolizumab [ 2 Cycles],TRUE
16225,RA_3612,Precision/Targeted Therapy,TRUE,Vandetanib,,,Vandetanib,337,2325,Progression and relapse,,,"evidence of progression on liver MRI and CEA and CTN are rising ; Multiple enhancing hepatic lesions, adjacent to ablation zone and elsewhere in both hepatic lobes, increased in size and number, suspicious for metastatic disease. CT Chest: Unchanged 8 mm left lower lobe nodule. Attention to new 3 mm left apical nodule can be made on follow-up. No new suspicious nodule. ~ Regimen: Vandetanib",TRUE
16226,RA_3612,,TRUE,Cabozantinib-S-Malate,,,Cabozantinib,2333,2427,Toxicity,,,oral dysesthesia/burning mouth secondary to carbozantinib ~ Regimen: Cabozantinib,TRUE
16227,RA_3612,,TRUE,Regorafenib,,,Regorafenib,2446,2565,Progression and relapse,,,Progression in liver and Lumbar spine ~ Regimen: Regorafenib,TRUE
16228,RA_3612,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,Ipilimumab/Nivolumab [2 Cycles],2580,2661,Progression and relapse,,,Progression of bone disease in Spine ~ Regimen: Ipilimumab/Nivolumab [2 Cycles],TRUE
16229,RA_3634,Chemotherapy,TRUE,Carboplatin,,,Carboplatin + Paclitaxel (5 Cycles),15,178,Progression and relapse,,,"Disease progression. Interval increase of the right hilar mass, now measuring 3.1 x 2.5 cm, previously 2.9 x 1.8 cm. Slightly increased mediastinal lymph nodes since November 2016. Numerous (more than 10) solid bilateral pulmonary nodules, many of which have increased in size since November 2016. ~ Regimen: Carboplatin + Paclitaxel (5 Cycles)",TRUE
16230,RA_3634,Immunotherapy,TRUE,Nivolumab,,,Nivolumab,190,392,Toxicity,,,responded to 2nd-line nivolumab which was ultimately held for skin rash ~ Regimen: Nivolumab,TRUE
16231,RA_3634,Immunotherapy,TRUE,Nivolumab,,,Nivolumab (Rechallenge),499,499,Toxicity,,,D/C for recurrent skin rash ~ Regimen: Nivolumab (Rechallenge),TRUE
16232,RA_3634,Chemotherapy,TRUE,Docetaxel,,,Taxotere,579,625,Progression and relapse,,,symptomatic neuropathy ad progressive disease; New faint patchy ground glass opacities in the right upper lobe favored to reflect post radiation change. Slightly nodular pleural thickening in the right minor and major fissures is noted is nonspecific but should be monitored on subsequent studies. Several pulmonary nodules have slightly increased in size; Approximately stable right axillary and right subpectoral lymphadenopathy ; Slightly increasing left axillary and left subpectoral lymphadenopathy. ~ Regimen: Taxotere,TRUE
16233,RA_3634,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Gemzar (1 dose),661,661,Progression and relapse,,,Enrolled in Hospice ~ Regimen: Gemzar (1 dose),TRUE
16234,RA_3649,Immunotherapy,TRUE,Ipilimumab,,,Ipilimumab [4 cycles],275,338,Progression and relapse,,,"Multiple intrinsically T1 hyperintense lesions in the supratentorial brain, consistent with intracranial metastatic; Interval increase in size and number of bilateral lung nodules, consistent with progression of metastases. Slight interval increase in size of 2.7 cm subcutaneous nodule in the posterior chest wall to represent a sebaceous cyst or focus of metastases. [No evidence of metastatic disease in the abdomen or pelvis] ~ Regimen: Ipilimumab [4 cycles]",TRUE
16235,RA_3649,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab [17 Cycles],364,725,Toxicity,,,held d/t increasing arthralgias ~ Regimen: Pembrolizumab [17 Cycles],TRUE
16236,RA_3649,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,ipilimumab + nivolumab [1 dose],1563,1563,Other,,,Patient Passed away ~ Regimen: ipilimumab + nivolumab [1 dose],TRUE
16237,RA_3689,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,gemcitabine/cisplatin [single dose],25,25,Progression and relapse,,,Marked interval progression of disease demonstrating extensive hepatic metastases which almost replace the entirety of the liver and demonstrate similar enhancing tumor throughout the portal venous system. ~ Regimen: gemcitabine/cisplatin [single dose],TRUE
16238,RA_3689,,TRUE,,FOLFOX,,FOLFOX [single dose],50,50,Progression and relapse,,,Regimen: FOLFOX [single dose],TRUE
16239,RA_3738,,TRUE,,R-CHOP,,RCHOP (6 cycles),214,318,Progression and relapse,,,large gastroesophageal mass ~ Regimen: RCHOP (6 cycles),TRUE
16240,RA_3738,Chemotherapy,TRUE,"Gemcitabine Hydrochloride, Oxaliplatin, Rituximab",,,Rituximab gemcitabine and oxaliplatin,388,388,Other,,,Maintenance Therapy ~ Regimen: Rituximab gemcitabine and oxaliplatin,TRUE
16241,RA_3738,,TRUE,Rituximab,,,Rituximab and ALX148 (CD47 Blocker),535,535,Other,,,Single Dose - patient passed away ~1 week later ~ Regimen: Rituximab and ALX148 (CD47 Blocker),TRUE
16242,RA_3773,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Gemcitabine/Cisplatin,25,292,Progression and relapse,,,progression in liver ~ Regimen: Gemcitabine/Cisplatin,TRUE
16243,RA_3773,Chemotherapy,TRUE,"Fluorouracil, Leucovorin Calcium, Oxaliplatin",,,Oxaliplatin/Fluorouracil/Leucovorin,376,376,Other,,,"single dose, d/c'ed on hospice ~ Regimen: Oxaliplatin/Fluorouracil/Leucovorin",TRUE
16244,RA_3781,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab [4 Cycles],3327,3399,Progression and relapse,,,INCREASING RIGHT HYDRONEPHROSIS SECONDARY TO TUMORS ARISING IN AND ADJACENT TO THE RIGHT KIDNEY. Increase interval increase in RIGHT hilar and subcarinal lymphadenopathy.  Stable subcentimeter cervical lymph nodes Stable enhancing subcutaneous nodules in the RIGHT shoulder region and the RIGHT ~ Regimen: Pembrolizumab [4 Cycles],TRUE
16245,RA_3781,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab + CMP001 [3 Cycles],3426,3468,Progression and relapse,,,"progression of intracranial metastatic disease; Enlargement of multiple abdominopelvic metastases/implants with a suspected new splenic metastasis. Worsening right moderate hydronephrosis with obstructive uropathy secondary to enlarging renal/perirenal metastases. CT neck/chest: Increased LEFT jugulodigastric lymph node increased RIGHT anterior chest wall nodule , increased RIGHT middle lobe metastasis and increased subcarinal lymph node. T ~ Regimen: Pembrolizumab + CMP001 [3 Cycles]",TRUE
16246,RA_3781,Immunotherapy,TRUE,Ipilimumab,,,Ipilimumab [2 Cycles],3488,3517,Progression and relapse,,,Multiple new supratentorial metastases as described above with the largest lesion measuring 17 mm within the right inferior frontal gyrus. The left medullary metastasis is also mildly increased in size ~ Regimen: Ipilimumab [2 Cycles],TRUE
16247,RA_3782,,TRUE,,FOLFOX,,FOLFOX (4 Cycles),6,55,Progression and relapse,,,worsening FDG avid peritoneal disease c/w progression // mixed response ~ Regimen: FOLFOX (4 Cycles),TRUE
16248,RA_3782,Chemotherapy,TRUE,"Carboplatin, Paclitaxel",,,Carboplatin + Paclitaxel,69,73,Other,,,Patient admitted/passed away 1 week after starting d/t primary disease ~ Regimen: Carboplatin + Paclitaxel,TRUE
16249,RA_3792,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Gemcitabine / Cisplatin [6 Cycles],23,264,Progression and relapse,,,"Partial right chest CT-Increased size and number of the pulmonary nodules since the previous study, most consistent w/increasing metastatic disease; Mild increase in the size of a subcarinal node; MRI Liver In the periphery of the posterior segment of the right hepatic lobe, there is a 2.7 x 2.9cm T2 heterogeneous signal intensity mass w/peripheral focus of decreased signal intensity on the delayed Eovist phase measuring 1.6 x 1.3cm concerning for tumor. There are scattered subcentimeter metastatic nodules w/in the right hepatic lobe. ~ Regimen: Gemcitabine / Cisplatin [6 Cycles]",TRUE
16250,RA_3792,Chemotherapy,TRUE,Capecitabine,,,Xeloda [5 Cycles],325,422,Progression and relapse,,,"dominant mass w/in the posterior segment of the right lobe is unchanged; there are multiple new lesions w/in both lobes of the liver. In addition, previously noted lesions w/in both lobes of increased in size. The findings are consistent w/progression of disease in the liver; Pulmonary nodules increased in size ~ Regimen: Xeloda [5 Cycles]",TRUE
16251,RA_3792,Immunotherapy,TRUE,"Atezolizumab, Cobimetinib",,,Atezolizumab / Cobimetinib [1 Cycle],448,476,Toxicity,,,grade 2/3 diarrhea and grade 3 thrombocytopenia ~ Regimen: Atezolizumab / Cobimetinib [1 Cycle],TRUE
16252,RA_3817,,TRUE,,R-CHOP,,RCHOP (6 Cycles),8,114,Completion of standard course,,,Regimen: RCHOP (6 Cycles),TRUE
16253,RA_3817,Chemotherapy,TRUE,Methotrexate,,,HD Methotrexate (4 Cycles),63,137,Completion of standard course,,,Regimen: HD Methotrexate (4 Cycles),TRUE
16254,RA_3817,Chemotherapy,TRUE,"Cytarabine, Etoposide",,,Cytarabine (X3) /Etoposide (X2),243,294,Progression and relapse,,,Disease Progression extra-nodal recurrence ~ Regimen: Cytarabine (X3) /Etoposide (X2),TRUE
16255,RA_3817,,TRUE,Ibrutinib,,,Iburitnib,309,400,Progression and relapse,,,Palliative Intent ~ Regimen: Iburitnib,TRUE
16256,RA_3817,Immunotherapy,TRUE,Nivolumab,,,Nivolumab [1 dose],400,400,Other,,,Single dose day before passsing away ~ Regimen: Nivolumab [1 dose],TRUE
16257,RA_3859,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab,419,504,Progression and relapse,,,New and enlarging hepatic and osseous metastasis ~ Regimen: Pembrolizumab,TRUE
16258,RA_3861,"Chemotherapy, Other",TRUE,"Fluorouracil, Folinic Acid, Oxaliplatin",,,Folinic Acic/Fluorouracil/Oxaliplatin,72,240,Completion of standard course,,,Regimen: Folinic Acic/Fluorouracil/Oxaliplatin,TRUE
16259,RA_3861,"Biological Therapy, Chemotherapy",TRUE,"Bevacizumab, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Oxaliplatin",,,Fluorouracil/Leucovorin Calcium/Oxaliplatin/Irinotecan/Bevacizumab,940,1034,Other,,,used as bridge to clinical trial ~ Regimen: Fluorouracil/Leucovorin Calcium/Oxaliplatin/Irinotecan/Bevacizumab,TRUE
16260,RA_3861,Precision/Targeted Therapy,TRUE,"Dabrafenib Mesylate, Trametinib",,,Debrafinib/Tremitinib/PDR001,1127,1237,Other,,,Physician Decision (pt not clinically benefiting) ~ Regimen: Debrafinib/Tremitinib/PDR001,TRUE
16261,RA_3861,"Biological Therapy, Chemotherapy",TRUE,"Bevacizumab, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Oxaliplatin",,,Fluorouracil/Leucovorin Calcium/Oxaliplatin/Irinotecan/Bevacizumab,1269,1325,Progression and relapse,,,Regimen: Fluorouracil/Leucovorin Calcium/Oxaliplatin/Irinotecan/Bevacizumab,TRUE
16262,RA_3873,Immunotherapy,TRUE,Nivolumab,,,Anti-KIR (lirilumab) + Nivolumab [1 Cycle],12209,12313,Toxicity,,,Pneumonitis ~ Regimen: Anti-KIR (lirilumab) + Nivolumab [1 Cycle],TRUE
16263,RA_3873,Immunotherapy,TRUE,Ipilimumab,,,ipilimumab [4 Cycles],12556,12646,Progression and relapse,,,"mixed response, overall SD. Unchanged left lateral abdominal wall intramuscular metastases. Increased size of right ventricular metastatic lesion and increased sclerosis of the T2 vertebral body sclerotic lesion. Slightly increased likely metastatic pericardial effusion. Additional sites of disease, including the left ventricular apex, right T5 lamina, and soft tissue nodule posterior to the T3 spinous process, are not significantly changed; Slight interval decrease in the overall size of the soft tissue mass related to the right-sided posterior elements at T4 and T5 with no significant change in the region of soft tissue enhancement along the right posterolateral epidural space. Interval decrease in the size of the enhancing lesion in the soft tissues overlying the T3 and T4 spinous process. ~ Regimen: ipilimumab [4 Cycles]",TRUE
16264,RA_3912,Chemotherapy,TRUE,Paclitaxel,,,paclitaxel,131,208,Completion of standard course,,,Regimen: paclitaxel,TRUE
16265,RA_3912,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,290,1153,Progression and relapse,,,"metastatic recurrence in the brain with additional disease in liver, T7 vertabrae, and L hilar and R scv nodes. ~ Regimen: Tamoxifen",TRUE
16266,RA_3912,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab [1 dose],1280,1280,Other,,,Patient Passed Away ~ Regimen: Pembrolizumab [1 dose],TRUE
16267,RA_4215,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,Ipilimumab + nivolumab [2 Cycles],1479,1500,Other,,,Patient Passed Away ~ Regimen: Ipilimumab + nivolumab [2 Cycles],TRUE
16268,RA_4248,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Gemcitabine/Cisplatin,21,287,Progression and relapse,,,Regimen: Gemcitabine/Cisplatin,TRUE
16269,RA_4338,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,Nivolumab/Ipilimumab,5,5,Other,,,"Control Therapy, patient passed away ~one week later ~ Regimen: Nivolumab/Ipilimumab",TRUE
16270,RA_4340,,TRUE,,FOLFOX,,FOLFOX,27,54,Progression and relapse,,,enlarging pancreatic mass. Associated small volume pneumoperitoneum and ascites. Interval increase in size of pelvic peritoneal nodules. Increase in size of epicardial nodal metastasis. ~ Regimen: FOLFOX,TRUE
16271,RA_4426,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin",,,Adriamycin/ Cyclophosphamide [4 Cycles],7,49,Completion of standard course,,,Regimen: Adriamycin/ Cyclophosphamide [4 Cycles],TRUE
16272,RA_4426,Chemotherapy,TRUE,Paclitaxel,,,Taxol [4 Cycles],63,105,Completion of standard course,,,Regimen: Taxol [4 Cycles],TRUE
16273,RA_4426,Chemotherapy,TRUE,Capecitabine,,,Capecitabine (Xeloda),250,277,Progression and relapse,,,Regimen: Capecitabine (Xeloda),TRUE
16274,RA_4430,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pembrolizumab/Pemetrexed,3061,3147,Completion of standard course,,,Regimen: Carboplatin/Pembrolizumab/Pemetrexed,TRUE
16275,RA_4443,"Chemotherapy, Other, Precision/Targeted Therapy",TRUE,"Fluorouracil, Folinic Acid, Oxaliplatin, Trastuzumab",,,Folinic Acid/Fluorouracil/Oxaliplatin + Trastuzumab,0,1920,Progression and relapse,,initial and persistent response,"intermittent administration, intermittent inclusion of oxaliplatin, was NED at one point, multiple tx holds",TRUE
16276,RA_4443,"Chemotherapy, Precision/Targeted Therapy",TRUE,"Capecitabine, Trastuzumab",,,Capecitabine/Trastuzumab,1757,1795,Completion of standard course,,,,TRUE
16277,RA_4443,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab,1969,2011,Progression and relapse,,,,TRUE
16278,RA_4443,"Biological Therapy, Chemotherapy",TRUE,"Paclitaxel, Ramucirumab",,,Ramucirumab/Paclitaxel,2502,2549,Progression and relapse,,,,TRUE
16279,RA_4443,"Chemotherapy, Precision/Targeted Therapy",TRUE,"Paclitaxel, Trastuzumab",,,Trastuzumab/Paclitaxel,2562,2576,Other,,Clinical Progression,,TRUE
16280,RA_4484,,TRUE,Vemurafenib,,,Vemurafinib (Zelboraf),43,114,Other,,,~90% response in renal metastases - switched to I/O with hope for more durable response ~ Regimen: Vemurafinib (Zelboraf),TRUE
16281,RA_4484,Immunotherapy,TRUE,Ipilimumab,,,Ipilimumab,115,178,Progression and relapse,,,"Mixed Response, Progression in Kideys and Abdominal Wall ~ Regimen: Ipilimumab",TRUE
16282,RA_4484,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab [5 Cycles],324,419,Progression and relapse,,,Continued increase in size of the (R) occipital lobe rim-enhancing lesion ~ Regimen: Pembrolizumab [5 Cycles],TRUE
16283,RA_4484,Precision/Targeted Therapy,TRUE,"Binimetinib, Encorafenib",,,Encorafenib (BRAF inhibitor) + Binimetinib (MEK inhibitor) [71 Cycles],555,2543,Other,,,Partial Response (-72.3%) - came off due to need to commence imatinib for CML ~ Regimen: Encorafenib (BRAF inhibitor) + Binimetinib (MEK inhibitor) [71 Cycles],TRUE
16284,RA_4484,,TRUE,Imatinib Mesylate,,,Imatinib,2543,2832,Other,,,for secondary diagnosis of CML ~ Regimen: Imatinib,TRUE
16285,RA_4484,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,Ipilimumab + Nivolumab,2727,2769,Toxicity,,,duodenitis and colitis ~ Regimen: Ipilimumab + Nivolumab,TRUE
16286,RA_4484,Precision/Targeted Therapy,TRUE,"Binimetinib, Encorafenib",,,encorafenib + binimetinib + infliximab,2776,2844,Progression and relapse,,,Rapidly growing leptomeningeal disease ~ Regimen: encorafenib + binimetinib + infliximab,TRUE
16287,RA_4518,,TRUE,Bicalutamide,,,Bicalutamide,2,413,Progression and relapse,,,PSA elevated ~ Regimen: Bicalutamide,TRUE
16288,RA_4518,Chemotherapy,TRUE,Docetaxel,,,Docetaxel,41,145,Completion of standard course,,,Regimen: Docetaxel,TRUE
16289,RA_4518,,TRUE,Abiraterone Acetate,,,Abiraterone,413,1086,Progression and relapse,,,PSA elevated ~ Regimen: Abiraterone,TRUE
16290,RA_4518,,TRUE,Enzalutamide,,,Enzalutamide,1093,1271,Progression and relapse,,,PSA elevated ~ Regimen: Enzalutamide,TRUE
16291,RA_4518,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab,1527,1527,Toxicity,,,admitted for myocarditis ~ Regimen: Pembrolizumab,TRUE
16292,RA_4523,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,Ipilimumab/Nivolumab,89,89,Toxicity,,,IO-related pneumonitis ? ~ Regimen: Ipilimumab/Nivolumab,TRUE
16293,RA_4575,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab,122,122,Other,,,Single Dose - Control ~ Regimen: Pembrolizumab,TRUE
16294,RA_4816,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,Gemcitabine/Cisplatin,15,70,Progression and relapse,,,,TRUE
16295,RA_4816,"Chemotherapy, Other",TRUE,"Fluorouracil, Folinic Acid, Oxaliplatin",,,Folinic Acid/Fluorouracil/Oxaliplatin,85,120,Other,,Clinical Progression,,TRUE
16296,RA_4848,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin",,,Adriamycin/Cyclophosphamide,0,92,Completion of standard course,,,Regimen: Adriamycin/Cyclophosphamide,TRUE
16297,RA_4848,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,Anastrozole,182,2008,Completion of standard course,,,Regimen: Anastrozole,TRUE
16298,RA_4848,Chemotherapy,TRUE,"Cyclophosphamide, Docetaxel",,,docetaxel/cyclophosphamide,2377,2441,Completion of standard course,,,Regimen: docetaxel/cyclophosphamide,TRUE
16299,RA_4848,Hormone/Endocrine Therapy,TRUE,Tamoxifen Citrate,,,Tamoxifen,2441,3439,Progression and relapse,,,Regimen: Tamoxifen,TRUE
16300,RA_4848,Chemotherapy,TRUE,"Gemcitabine Hydrochloride, Paclitaxel",,,Gemcitabine/Paclitaxel,3472,3611,Toxicity,,,Regimen: Gemcitabine/Paclitaxel,TRUE
16301,RA_4848,"Hormone/Endocrine Therapy, Precision/Targeted Therapy",TRUE,"Fulvestrant, Palbociclib",,,Palbociclib/Fulvestrant,3630,3926,Progression and relapse,,,Regimen: Palbociclib/Fulvestrant,TRUE
16302,RA_4848,Chemotherapy,TRUE,Capecitabine,,,Capecitabine,3926,4045,Progression and relapse,,,complicated by side effects (incl. skin blisters) but d/c'ed d/t PD ~ Regimen: Capecitabine,TRUE
16303,RA_4848,Chemotherapy,TRUE,Doxorubicin,,,Doxorubicin,4050,4110,Progression and relapse,,,Regimen: Doxorubicin,TRUE
16304,RA_4848,Chemotherapy,TRUE,Eribulin Mesylate,,,Eribulin,4177,4353,Progression and relapse,,,Regimen: Eribulin,TRUE
16305,RA_4848,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,Ipatasertib/Fulvesterant,4367,4382,Other,,,Regimen: Ipatasertib/Fulvesterant,TRUE
16306,RA_4875,Chemotherapy,TRUE,"Fluorouracil, Leucovorin Calcium, Oxaliplatin",,,Leucovorin Calcium/Fluorouracil/Oxaliplatin,11,12,Other,,,Regimen: Leucovorin Calcium/Fluorouracil/Oxaliplatin,TRUE
16307,RA_4957,Precision/Targeted Therapy,TRUE,"Dabrafenib Mesylate, Trametinib",,,Dabrafenib and Trametinib,184,323,Progression and relapse,,,"Two enhancing soft tissue nodule in the left inguinal postsurgical bed, concerning for metastasis. ~ Regimen: Dabrafenib and Trametinib",TRUE
16308,RA_4957,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab [4 Cycles],338,400,Progression and relapse,,,"progression of malignancy, with marked increase in the degree and extent of FDG uptake in 2 foci in the left groin/inguinal region and 2 additional foci of uptake in the medial left thigh. ~ Regimen: Pembrolizumab [4 Cycles]",TRUE
16309,RA_4957,,TRUE,"Cobimetinib, Vemurafenib",,,Vemurafenib and Cobimetinib,433,456,Toxicity,,,"Fevers, Total body rash, pharyngitis, and marked fatigue ~ Regimen: Vemurafenib and Cobimetinib",TRUE
16310,RA_4957,Immunotherapy,TRUE,"Entinostat, Pembrolizumab",,,Pembrolizumab + Entinostat,723,762,Progression and relapse,,,"Interval progression of disease, as evidenced by progression of pulmonary metastatic disease; soft tissue disease at the left posterior chest wall, left groin resection site, and anteromedial left thigh; nodal disease at the left external iliac/inguinal nodal stations, and more intense uptake associated with a probable bony metastasis at the intertrochanteric left femur ~ Regimen: Pembrolizumab + Entinostat",TRUE
16311,RA_4957,Precision/Targeted Therapy,TRUE,"Dabrafenib Mesylate, Trametinib",,,Dabrafenib + Trametinib,774,1095,Progression and relapse,,,Regimen: Dabrafenib + Trametinib,TRUE
16312,RA_4957,Precision/Targeted Therapy,TRUE,"Binimetinib, Encorafenib",,,Encorafenib + Binimetinib,1143,1401,Progression and relapse,,,"Recurrence of Left Upper Back Lesion, mild progression on CT imaging ~ Regimen: Encorafenib + Binimetinib",TRUE
16313,RA_4957,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,Nivolumab / Ipilimumab,1464,1464,Toxicity,,,checkpoint inhibitor colitis ~ Regimen: Nivolumab / Ipilimumab,TRUE
16314,RA_4965,Immunotherapy,TRUE,"Axitinib, Pembrolizumab",,,Axitinib/Pembrolizumab,37,84,Toxicity,,,Regimen: Axitinib/Pembrolizumab,TRUE
16315,RA_4979,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab [5 Cycles],944,1031,Progression and relapse,,,Multiple new hepatic lesions; Interval decrease in the perihilar LEFT lower lobe nodule and LEFT hilar lymph nodes consistent with response to therapy.  New lytic lesion in the T4 vertebra; New nodules in the LEFT lower lobe and along the LEFT major fissure (Lung) ~ Regimen: Pembrolizumab [5 Cycles],TRUE
16316,RA_4979,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,Ipilimumab/Nivolumab,1052,1052,Toxicity,,,Gastritis and duodenitis secondary to ICI ~ Regimen: Ipilimumab/Nivolumab,TRUE
16317,RA_4979,Precision/Targeted Therapy,TRUE,Binimetinib,,,Binimetinib (MEK inhibitor),1123,1218,Progression and relapse,,,"interval enlargement of metastatic disease involving the liver, pancreas, left adrenal gland, kidneys and perirenal spaces, appendix, axial and appendicular skeleton, and multiple muscle groups. New portacaval lymphadenopathy ~ Regimen: Binimetinib (MEK inhibitor)",TRUE
16318,RA_498,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,Ipilimumab and Nivolumab [2 Cycles],4527,4527,Progression and relapse,,,"Interval progression of subcutaneous nodules. Stable to increased small bowel metastases. Mesenteric lymphadenopathy. Unchanged indeterminate liver lesion. Interval slightly decreased size and number of chest wall subcutaneous nodules along with slightly decreased right axillary lymphadenopathy. Interval slightly decreased prominence of right upper lobe metastatic mass,. Interval slightly decreased mediastinal lymphadenopathy. ;  Brain MRI: Redemonstrated postsurgical findings of prior right temporal craniotomy and resection of a lesion in the superior temporal gyrus without evidence of local recurrence at this site. Interval increase in size and associated mass effect of a lesion in the right inferior parietal lobule with increased effacement of the posterior right lateral ventricle. Other metastatic lesions along the cerebral falx and in the left post central gyrus have decreased in the interval, and have decreased associated vasogenic edema but remain increased compared to baseline ~ Regimen: Ipilimumab and Nivolumab [2 Cycles]",TRUE
16319,RA_498,Precision/Targeted Therapy,TRUE,"Dabrafenib Mesylate, Trametinib",,,Dabrafenib and Trametinib,4606,4707,Other,,,Discontinued to enroll on clinical trial ; Response = improvement in the brain lesions; regression of abdominal metastasis but lung disease is stable ~ Regimen: Dabrafenib and Trametinib,TRUE
16320,RA_498,Precision/Targeted Therapy,TRUE,"Dabrafenib Mesylate, Trametinib",,,AT13387 + DABRAFENIB + TRAMETINIB,4708,4820,Progression and relapse,,,"CT CAP: New small bowel/mesenteric metastases, slightly increased size of dominant right upper lobe mass. Stable SC nodules.   Brain MRI: increase in the size and T2 FLAIR hyperintensity in the enhancing left postcentral gyrus lesion, with a possible focus of leptomeningeal extension along the left central sulcus.  Other lesions stable. ~ Regimen: AT13387 + DABRAFENIB + TRAMETINIB",TRUE
16321,RA_552,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab [6 Cycles],1984,2110,Progression and relapse,,,Regimen: Pembrolizumab [6 Cycles],TRUE
16322,RA_571,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab,16713,16713,Other,,,Single Dose - Patient Passed Away ~ Regimen: Pembrolizumab,TRUE
16323,RA_858,,TRUE,Imiquimod,,,Imiquimod,1045,1171,Progression and relapse,,,new lesions on her R lateral thigh ~ Regimen: Imiquimod,TRUE
16324,RA_858,Immunotherapy,TRUE,"Ipilimumab, Nivolumab",,,ipilimumab + Nivolumab [2 Cycles],1217,1253,Toxicity,,,immune related hepatitis and colitis ~ Regimen: ipilimumab + Nivolumab [2 Cycles],TRUE
16325,RA_858,Immunotherapy,TRUE,Nivolumab,,,nivolumab monotherapy,1594,1661,Toxicity,,,immune related hepatitis ~ Regimen: nivolumab monotherapy,TRUE
16326,RA_858,Precision/Targeted Therapy,TRUE,"Dabrafenib Mesylate, Trametinib",,,Dabrafenib + Trametinib,1810,2205,Progression and relapse,,,increase in size of (R) breast metastasis; (R) adnexal cystic structure without change since prior scan (likely physiologic changes); no other clear sites of disease progression. Brain MRI negative ~ Regimen: Dabrafenib + Trametinib,TRUE
16327,RA_858,,TRUE,"Cobimetinib, Vemurafenib",,,vemurafenib+cobimetinib+CSF1R inhibitor (LY3022855) [4 Cycles],2206,2324,Progression and relapse,,,"increasing size and number of liver metastases, newly enlarged upper abdominal lymph nodes, as well as increased size of splenic and subcutaneous metastases. increasing pulmonary metastases, axillary, hilar and internal mammary adenopathy and soft tissue masses ~ Regimen: vemurafenib+cobimetinib+CSF1R inhibitor (LY3022855) [4 Cycles]",TRUE
16328,RA_858,Chemotherapy,TRUE,"Carboplatin, Paclitaxel",,,Carboplatin AUC 6/Paclitaxel [6 Cycles],2442,2557,Progression and relapse,,,"Mixed Response: New anterior chest lesions, however ongoing regression of disease at all visceral sites ~ Regimen: Carboplatin AUC 6/Paclitaxel [6 Cycles]",TRUE
16329,RA_858,,TRUE,Vemurafenib,,,VEMURAFENIB (control),2543,2564,Other,,,Added Cobimetinib ~ Regimen: VEMURAFENIB (control),TRUE
16330,RA_858,,TRUE,"Cobimetinib, Vemurafenib",,,VEMURAFENIB/COBIMETINIB (control),2596,2635,Other,,,Regimen: VEMURAFENIB/COBIMETINIB (control),TRUE
16331,RA_1045,Precision/Targeted Therapy,TRUE,"Dalotuzumab, Ridaforolimus",,,"Ridaforolimus, Dalotuzumab",1231,1514,NA,Recurrence,,Clinical Trial:  Best Response = SD (0%) // Progression new L. Supraclavicular Node lesion ~ Regimen: Ridaforolimus + Dalotuzumab,TRUE
16332,RA_1526,Precision/Targeted Therapy,TRUE,"Alpelisib, Binimetinib",,,"MEK162, BYL719",2059,2838,NA,,,"Clinical Trial:  Best Response = Partial Response (-30.3%) // Progression = -4.2% from BL, 37.5% from Nadir -- PD mult. Pulmonary nodules ~ Regimen: MEK162 + BYL719",TRUE
16333,RA_3873,,TRUE,MAGE TCR,,,MAGE TCR Protocol,11177,11181,Completion of standard course,,,adoptive Tcell transfer -  patient developed neurotoxicity // eventual progression with new L adrenal nodule ~ Regimen: MAGE TCR Protocol [62 x 10E9 MAGE Cells] + 6 X Doses IL-2,TRUE
16334,RA_2402,,TRUE,"LSZ102, Ribociclib",,,"LSZ102, LEE011",1164,1218,Progression and relapse,,,Best/Final Response = PD (+17.15 % from BL + New Liver Lesions) ~ Regimen: LSZ102 + LEE011 [2 Cycles],TRUE
16335,MGHCC0002,,TRUE,SRN-927,,,SRN-927,7125,7181,Progression and relapse,,,,TRUE
16336,MGHCC0003,Hormone/Endocrine Therapy,TRUE,Brilanestrant,,,ARN810,6208,6376,Progression and relapse,,,,TRUE
16337,MGHCC0005,Chemotherapy,TRUE,buthionine sulfoximine,,,BSO,2476,2476,NA,,,metastatic adenocarcinoma left ovary with extensive involvement of ovarian parenchyma consistent w/ breast,TRUE
16338,MGHCC0006,,TRUE,LFA-102,,,LFA102,2182,2210,NA,,,,TRUE
16339,MGHCC1006,Hormone/Endocrine Therapy,TRUE,H3B-6545,,,H3B-6545,5671,5895,Progression and relapse,,,,TRUE
16340,MGHCC1009,ADC,TRUE,IMMU-132,,,IMMU132,1947,2006,Progression and relapse,,,,TRUE
16341,MGHCC1015,Chemotherapy,TRUE,buthionine sulfoximine,,,BSO,4158,4158,NA,,,,TRUE
16342,MGHCC1015,Precision/Targeted Therapy,TRUE,Taselisib,,,GDC0032,4598,5063,NA,,,,TRUE
16343,MGHCC1041,Hormone/Endocrine Therapy,TRUE,Brilanestrant,,,ARN810,2079,2135,Progression and relapse,,,,TRUE
16344,MGHCC1041,ADC,TRUE,IMMU-132,,,IMMU132,2181,2349,Progression and relapse,,,,TRUE
16345,MGHCC1041,Immunotherapy,TRUE,"Atezolizumab, Emactuzumab",,,RO5509554/MPDL3280A,2433,2461,Progression and relapse,,,,TRUE
16346,MGHCC1099,,TRUE,LSZ102,,,LSZ102,2512,2540,NA,,,progression in liver,TRUE
16347,MGHCC1108,,TRUE,Halotestin,,,Halotestin,3617,3666,NA,,,,TRUE
16348,MGHCC1173,Hormone/Endocrine Therapy,TRUE,Brilanestrant,,,ARN810,1219,1269,Progression and relapse,,,,TRUE
16349,MGHCC1328,Hormone/Endocrine Therapy,TRUE,H3B-6545,,,H3B-6545,7302,7469,NA,,,,TRUE
16350,MGHCC1328,,TRUE,"LSZ102, Ribociclib",,,"LSZ102/LEE011, CDK 4/6",7495,7547,NA,,,,TRUE
16351,MGHCC1573,Precision/Targeted Therapy,TRUE,"Dalotuzumab, Ridaforolimus",,,"Ridaforolimus/dalotuzumab, PIK3CA/mTOR",973,1407,NA,,,,TRUE
16352,MGHCC1573,Hormone/Endocrine Therapy,TRUE,Brilanestrant,,,ARN810 (13-043),1447,1510,NA,,,,TRUE
16353,MGHCC1573,ADC,TRUE,IMMU-132,,,IMMU132,2357,2422,Progression and relapse,,,,TRUE
16354,RA_1002,,TRUE,LSZ102,,,LSZ102,10217,10258,NA,,,"Clinical Trial  - Best Response = PD (+60.11%) and New Lesions: Cervical LN, Mediastinum, Mediast & Hilar LN, Lung (mult sites) ~ Regimen: LSZ102",TRUE
16355,RA_1002,,TRUE,Lurbinectedin,,,PM01183 (2 Cycles),10449,10494,NA,,,"Clinical Trial - Best Response = Progression of Chest wall (multiple sites) and abdominal wall (multiple sites), +1.07% from BL ~ Regimen: PM01183 (2 Cycles)",TRUE
16356,RA_1011,ADC,TRUE,IMMU-132,,,IMMU-132 [anti- Trop-2 ADC],1066,1099,Progression and relapse,,,Interval increase in left lung pleural effusion and metastatic disease (Pleura). PD per RECIST (+78% increase of Left Pleura lesion) ~ Regimen: IMMU-132 [anti- Trop-2 ADC],TRUE
16357,RA_1035,,TRUE,CLR-457,,,CLR457 [PI3K Inhibitor],3562,3590,Progression and relapse,,,D/C for symptomatic progression of her disease ~ Regimen: CLR457 [PI3K Inhibitor],TRUE
16358,RA_1035,,TRUE,CLR-457,,,CLR457 [PI3K Inhibitor],3562,3590,Progression and relapse,,,D/C for symptomatic progression of her disease ~ Regimen: CLR457 [PI3K Inhibitor],TRUE
16359,RA_1078,,TRUE,CLR-457,,,CLR457 (PI3K Inhibitor) X 4 Cycles,6232,6329,NA,,,Clinical Trial : Best Response = SD (0.0%) -- D/C for grade 3 diarrhea/ Pneumonitis ~ Regimen: CLR457 (PI3K Inhibitor) X 4 Cycles,TRUE
16360,RA_1113,Precision/Targeted Therapy,TRUE,"Sapanisertib, Serabelisib",,,MLN1117(mTORC1/2 Inhibitor) / MLN128 (PI3K? Inhibitor),3642,3656,Progression and relapse,,,Regimen: MLN1117(mTORC1/2 Inhibitor) / MLN128 (PI3K? Inhibitor),TRUE
16361,RA_1113,Precision/Targeted Therapy,TRUE,"Sapanisertib, Serabelisib",,,MLN1117(mTORC1/2 Inhibitor) / MLN128 (PI3K? Inhibitor),3642,3656,Progression and relapse,,,Regimen: MLN1117(mTORC1/2 Inhibitor) / MLN128 (PI3K? Inhibitor),TRUE
16362,RA_1184,Precision/Targeted Therapy,TRUE,MK-2206,,,MK2206 [AKT inhibitor] (2 Cycles),944,992,Progression and relapse,,,Mixed response with decrease in size of left pelvic node and  peritoneal node. But interval increase in size of left para-aortic node (15 mm x 18 mm) which measured 7 mm x 10 mm in baseline. Interval increase in retroperitoneal & pelvic nodes. Increase in size of some peritoneal nodules. Overall progression ~ Regimen: MK2206 [AKT inhibitor] (2 Cycles),TRUE
16363,RA_1184,Precision/Targeted Therapy,TRUE,"Dinaciclib, Veliparib",,,Velaparib ABT888 [PARP Inhib]/Dinaciclib -SCH727965 [CDK Inhibitor]  (10 Cycles),1077,1355,Progression and relapse,,,increase in her current tumor burden as well as the presence of a new pathologic lymph node ~ Regimen: Velaparib ABT888 [PARP Inhib]/Dinaciclib -SCH727965 [CDK Inhibitor]  (10 Cycles),TRUE
16364,RA_1184,Precision/Targeted Therapy,TRUE,Serabelisib,,,MLN1117 (PI3K? Inhibitor) (4 Cycles),1384,1468,Toxicity,,,off study for Grade 3 LFTs ; significant interval decrease in retroperitoneal lymphadenopathy and left pelvic sidewall mass. ~ Regimen: MLN1117 (PI3K? Inhibitor) (4 Cycles),TRUE
16365,RA_1184,ADC,TRUE,IMMU-132,,,IMMU-132 [anti- Trop-2 ADC],2010,2094,Progression and relapse,,,"Best Response = SD per RECIST (-23.2%) // Final Response =  Mixed Response - interval increase in subcarinal lymph node mass with new borderline left hilar node, however significant improvement of the abdominal and pelvic metastasis ~ Regimen: IMMU-132 [anti- Trop-2 ADC]",TRUE
16366,RA_1187,,TRUE,Infigratinib,,,BGJ398 [4 Cycles] - FGFRi,806,915,Progression and relapse,,,Best Response: -27% RECIST // Progression = progression of at least 1 hepatic met and has a new hepatic dome lesion; lung nodules are stable ~ Regimen: BGJ398 [4 Cycles] - FGFRi,TRUE
16367,RA_1326,Hormone/Endocrine Therapy,TRUE,Brilanestrant,,,ARN810 (X 16 Cycles),1089,1553,NA,,,Clinical Trial: Best Response = SD (-4%) // Progression = new liver lesions (multiple sites) and (+18.2%) % change from BL ~ Regimen: ARN-810 (X 16 Cycles),TRUE
16368,RA_1326,,TRUE,Seviteronel,,,VT-464 (X 1 Cycle),1995,2036,NA,,,Clinical Trial Best Response = PD (+22%) and New Right liver Lesion ~ Regimen: VT-464 (X 1 Cycle),TRUE
16369,RA_1373,Precision/Targeted Therapy,TRUE,Taselisib,,,GDC-0032,6871,6981,NA,,,"Clinical Trial Best Response = SD (+2.9%) // Progression = New Liver lesions and (+ 19.3 %) change from BL ""increase in hepatic tumor burden. Stable sclerotic bony metastasis"" ~ Regimen: GDC-0032",TRUE
16370,RA_1511,Precision/Targeted Therapy,TRUE,Taselisib,,,GDC-0032 (PIK3CAi),138,181,Progression and relapse,,,"Progression = (+25% Increase from Baseline) increase in size of multiple hepatic metastases, New Lesion in Liver Segment 6, Increased size of both adrenal masses // decrease in the size of multiple mediastinal and right hilar lymph nodes and slight decrease in right lung nodules, consistent with response to therapy ~ Regimen: GDC-0032 (PIK3CAi)",TRUE
16371,RA_1534,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,Faslodex (Fulvestrant),556,607,NA,,,"Progression of bone disease with new L rib fractures, rising markers ~ Regimen: Faslodex (Fulvestrant)",TRUE
16372,RA_1542,,TRUE,Futibatinib,,,TAS-120,92,169,Progression and relapse,,,Best Response = SD (-2.6% from BL) // Progression = New Liver Lesions/ PD of Liver Lesions (Overall +1.7% from BL / +4.4% from Nadir) ~ Regimen: TAS-120,TRUE
16373,RA_1558,,TRUE,LSZ102,,,LSZ102 (Single Agent) [4 Cycles],3993,4105,Progression and relapse,,,Best Response = SD (+13.31% from BL) // Final Response = PD (+32.96 % from BL) ~ Regimen: LSZ102 (Single Agent) [4 Cycles],TRUE
16374,RA_1558,Hormone/Endocrine Therapy,TRUE,H3B-6545,,,H3B-6545 [8 Cycles],4441,4665,Progression and relapse,,,Best Response = PR (-30.98% from BL) // Final Response = PD (+8.3% from Nadir) ~ Regimen: H3B-6545 [8 Cycles],TRUE
16375,RA_1939,,TRUE,Futibatinib,,,TAS-120 (2 Cycles),748,1152,Progression and relapse,,,Best Response = Stable Disease (-21 % from BL) Progression = PD of Liver Multiple Sites + New Liver Lesions (RECIST1.1 +6.5% from BL // +34.4% from Nadir) ~ Regimen: TAS-120 (2 Cycles),TRUE
16376,RA_1939,,TRUE,SAR-439459,,,SAR439459 (single agent) - 1.5 Cycles,1320,1334,Progression and relapse,,,Regimen: SAR439459 (single agent) - 1.5 Cycles,TRUE
16377,RA_2024,,TRUE,Floxuridine,,,chemoradiation with infusional 5-FU,296,331,Completion of standard course,,,Regimen: chemoradiation with infusional 5-FU,TRUE
16378,RA_2024,,FALSE,,,,chemoradiation with infusional 5-FU,296,331,Completion of standard course,,,Regimen: chemoradiation with infusional 5-FU,TRUE
16379,RA_2024,,TRUE,Trifluridine and Tipiracil Hydrochloride,,,LONSURF (trifluridine and tipiracil),917,943,Progression and relapse,,,"interval increase in size of paraesophageal lymph nodes, new retroperitoneal lymphadenopathy and abdominal wall soft tissue nodularity, consistent with progressive metastatic disease; multiple slightly enlarging retroperitoneal, mesenteric, pelvic lymph nodes ~ Regimen: LONSURF (trifluridine and tipiracil)",TRUE
16380,RA_2024,,TRUE,Trifluridine and Tipiracil Hydrochloride,,,LONSURF (trifluridine and tipiracil),917,943,Progression and relapse,,,"interval increase in size of paraesophageal lymph nodes, new retroperitoneal lymphadenopathy and abdominal wall soft tissue nodularity, consistent with progressive metastatic disease; multiple slightly enlarging retroperitoneal, mesenteric, pelvic lymph nodes ~ Regimen: LONSURF (trifluridine and tipiracil)",TRUE
16381,RA_2024,,TRUE,Losatuxizumab Vedotin,,,ABBV-221,996,1011,Toxicity,,,anaphylactic reaction to ABBV-221 ~ Regimen: ABBV-221,TRUE
16382,RA_2024,,TRUE,Losatuxizumab Vedotin,,,ABBV-221,996,1011,Toxicity,,,anaphylactic reaction to ABBV-221 ~ Regimen: ABBV-221,TRUE
16383,RA_2098,,TRUE,Mevociclib,,,SY-1365 (CDK7 Inhibitor),828,879,Progression and relapse,,,"Progression = +29.36 % from BL (New Retroperitoneal LN, Mesenteric LN and Peritoneum/Omentum Lesions) ~ Regimen: SY-1365 (CDK7 Inhibitor)",TRUE
16384,RA_2168,,TRUE,Debio-1347,,,Debio 1347 (4 Cycles),266,368,Progression and relapse,,,"Best Response = Stable Disease ""Increase in size of mesenteric node bears watching, Increase in sclerosis of some of the bone lesions which could be due to treatment response, need to follow up""   Progression = PD of Retroperitoneal LN, Mesenteric LN and Peritoneum ~ Regimen: Debio 1347 (4 Cycles)",TRUE
16385,RA_2177,,TRUE,Tislelizumab,,,BGB-A317 (FGFRi) - [18 Cycles],231,578,Progression and relapse,,,Best Response = Partial Response // Progression = progression of disease in liver ~ Regimen: BGB-A317 (FGFRi) - [18 Cycles],TRUE
16386,RA_2177,,TRUE,AFP-C332,,,AFPc332T,742,742,Completion of standard course,,,Eventual Progression 4 months post trx = Numerous (greater than 50) new arterially enhancing liver lesions consistent with hepatic metastases ~ Regimen: AFPc332T,TRUE
16387,RA_2402,,TRUE,Inavolisib,,,GDC-0077 (Single Agent) [8 Cycles],671,891,Progression and relapse,,,Best Response = SD (+1.39%) // Final Respone = PD (+50.4% from BL + New Liver Lesions) ~ Regimen: GDC-0077 (Single Agent) [8 Cycles],TRUE
16388,RA_2408,,TRUE,LY-3214996,,,ERK 1/2 Inhibitor (LY3214996) X 3 Cycles,211,276,Progression and relapse,,,"Best Response = Progression; New nodules in the lower lobes are indeterminate but concerning for metastases;  progression of metastatic disease in the thorax, interval increase in size/ number LYTIC metastases involving the thoracic skeleton and left lower lobe nodule ; Worsening hepatic and bony metastases ~ Regimen: ERK 1/2 Inhibitor (LY3214996) X 3 Cycles",TRUE
16389,RA_2460,,TRUE,Futibatinib,,,TAS-120 (4 Cycles),85,246,Progression and relapse,,,"Best Response = Stable Disease (-22%) Progression = new 1.4cm segment VIII lesion, Progression in Liver Multiple sites (Overall RECIST Response = -22.77% from BL// -0.99% from Nadir) ~ Regimen: TAS-120 (4 Cycles)",TRUE
16390,RA_2542,,TRUE,Inavolisib,,,GDC-0077 (Single Agent) [19 Cycles],7841,8384,Progression and relapse,,,Best/Final Response = SD (+0.0% from BL) -- patient has bone only disease ~ Regimen: GDC-0077 (Single Agent) [19 Cycles],TRUE
16391,RA_2544,,TRUE,Dostarlimab,,,TSR-042,836,962,Progression and relapse,,,"Progression = -8.54% from BL// New Pleura Lesion, Interval increase in left pleural mass ~ Regimen: TSR-042",TRUE
16392,RA_2544,,TRUE,"Cemiplimab-rwlc, SAR-439459",,,SAR439459 and REGN2810,1135,1178,Progression and relapse,,,Progression = -0.82% from BL // enlargement of the left anterior mediastinal pleural mass and multiple new left pleural nodules. Increased size of subpleural LLL nodule along with a new 2 cm subpleural left lower lobe nodul New anterior pericardial lymph node metastasis. ~ Regimen: SAR439459 and REGN2810,TRUE
16393,RA_2544,,TRUE,Mevociclib,,,SY-1365 (CDK7 Inhibitor),1225,1225,Other,,,Pt. only received a single dose ~ Regimen: SY-1365 (CDK7 Inhibitor),TRUE
16394,RA_2736,,TRUE,Futibatinib,,,TAS-120 (FGFRi) - [10 Cycles],483,693,Progression and relapse,,,Continued past progression (Cycle 7) progression in number and size of lesions in liver and lungs ~ Regimen: TAS-120 (FGFRi) - [10 Cycles],TRUE
16395,RA_2736,Immunotherapy,TRUE,"CAR-T, Interleukin 2",,,Autologous T cell infusion / 5 doses of IL-2,804,813,Completion of standard course,,,Regimen: Autologous T cell infusion / 5 doses of IL-2,TRUE
16396,RA_2819,,TRUE,LSZ102,,,LSZ102,7909,7952,Progression and relapse,,,"Progression = +23.51% from BL, progression of liver lesions + New Liver Lesions ~ Regimen: LSZ102",TRUE
16397,RA_2917,ADC,TRUE,Ladiratuzumab vedotin,,,SGN-LIV1A (ADC),358,396,Progression and relapse,,,new nodule in the right breast ~ Regimen: SGN-LIV1A (ADC),TRUE
16398,RA_2917,ADC,TRUE,IMMU-132,,,IMMU-132 (9 Cycles),417,617,Progression and relapse,,,Best Response = Partial Response (-45.7) // Final Response = progression in lungs/chest wall and progressive brain mets ~ Regimen: IMMU-132 (9 Cycles),TRUE
16399,RA_3130,Chemotherapy,TRUE,"Capecitabine, Epirubicin",ECF,,Neoadjuvant ECF (3 Cycles) / ECX (3 Cycles),42,182,Completion of standard course,,,Regimen: Neoadjuvant ECF (3 Cycles) / ECX (3 Cycles),TRUE
16400,RA_3130,,TRUE,Futibatinib,,,TAS-120 [7 Cycles] - FGFRi,724,898,Progression and relapse,,,Treated x 5 Cycles with progression of retroperitoneal and mesenteric lymphadenopathy; Treated 2 cycles past progression with further PD of lymphadenopathy ~ Regimen: TAS-120 [7 Cycles] - FGFRi,TRUE
16401,RA_321,,TRUE,Sotrastaurin acetate,,,AEB071 (Protein Kinase Ci) - [<1 Cycle],11851,11865,Other,,,Withdrew Consent ~ Regimen: AEB071 (Protein Kinase Ci) - [<1 Cycle],TRUE
16402,RA_3328,,TRUE,Futibatinib,,,TAS120,306,376,Progression and relapse,,,Best Response = -25.4% from Baseline Progression = New Peritoneum/Omentum Lesions (RECIST -22.93% from BL // _3.31% from Nadir) ~ Regimen: TAS120,TRUE
16403,RA_3343,,TRUE,Futibatinib,,,TAS-120 (FGFRi) - [9 Cycles],161,343,Progression and relapse,,,disease progression in his liver.  His CA19-9 is rising ~ Regimen: TAS-120 (FGFRi) - [9 Cycles],TRUE
16404,RA_3343,,TRUE,Mevociclib,,,SY-1365 (CDK7i) - [2 Cycles],354,399,Progression and relapse,,,Interval progression with enlarging and new hepatic metastasis as well as new peritoneal nodules and enlarging retroperitoneal lymphadenopathy Enlarging bilateral pulmonary parenchymal metastases as described involving all lobes of the lungs. Slight interval enlargement of a right paratracheal lymph node. Other mediastinal lymph nodes remain stable. ~ Regimen: SY-1365 (CDK7i) - [2 Cycles],TRUE
16405,RA_3451,,TRUE,Futibatinib,,,TAS-120 (FGFRi),140,228,Progression and relapse,,,Multiple 3-20 mm pulmonary nodules consistent with metastasis.  multiple nodules are increased in size. Increased mediastinal and hilar lymphadenopathy. Multiple new lytic bone lesions consistent with bone metastasis. ; New Liver lesions ~ Regimen: TAS-120 (FGFRi),TRUE
16406,RA_3612,Precision/Targeted Therapy,TRUE,Selpercatinib,,,LOXO-292 (RETi) - [2 Cycles],2724,2780,Toxicity,,,stopped for hepatotoxicity (LFTs) with biopsy showing immune infiltrate - checkpoint hepatitis ~ Regimen: LOXO-292 (RETi) - [2 Cycles],TRUE
16407,RA_3612,Precision/Targeted Therapy,TRUE,Selpercatinib,,,LOXO-292 (RETi),2881,2933,Toxicity,,,presumed autoimmune hepatitis ~ Regimen: LOXO-292 (RETi),TRUE
16408,RA_3738,,TRUE,,R-ICE,,R-ICE (2 Cycles),350,382,Progression and relapse,,,decreased avidity in the gastroesophageal junction extending to the proximal stomach but remains far above hepatic background ~ Regimen: R-ICE (2 Cycles),TRUE
16409,RA_3738,Immunotherapy,TRUE,Lisocabtagene maraleucel,,,CAR T (JCAR017) - chimeric antigen receptor T cells,416,416,Progression and relapse,,,FDG avidity at the gastroesophageal junction suspicious for persistent disease ~ Regimen: CAR T (JCAR017) - chimeric antigen receptor T cells,TRUE
16410,RA_3773,,TRUE,Olutasidenib,,,FT2102,341,376,Progression and relapse,,,Regimen: FT2102,TRUE
16411,RA_3817,,TRUE,Tisagenlecleucel,,,KYMRIAH [CAR-T],377,377,Progression and relapse,,,Regimen: KYMRIAH [CAR-T],TRUE
16412,RA_3859,,TRUE,Ulixertinib,,,BVD523 (ERK 1/2 Inhibitor),519,575,Toxicity,,,Grade 4 AST/ALT ~ Regimen: BVD523 (ERK 1/2 Inhibitor),TRUE
16413,RA_3861,,TRUE,"Cobicistat, PLX-8394",,,PLX8394/Cobcicstat,756,924,Progression and relapse,,,progression in omentum ~ Regimen: PLX8394/Cobcicstat,TRUE
16414,RA_3873,,TRUE,Roferon-A,,,Adjuvant High Dose Interferon-alpha 2b,8439,8527,Toxicity,,,Regimen: Adjuvant High Dose Interferon-alpha 2b,TRUE
16415,RA_3873,,TRUE,Interleukin 2,,,Interleukin 2,9314,9388,Progression and relapse,,,"partial/mixed response: regression of the two largest pulmonary metastases, and stability of the smaller nodules. However, there is further progression of the subcarinal node, now measuring 2.5 cm ~ Regimen: Interleukin 2",TRUE
16416,RA_3912,,TRUE,,AC-T,,ADJUVANT  ddAC,75,117,Completion of standard course,,,Regimen: ADJUVANT  ddAC,TRUE
16417,RA_4248,Immunotherapy,TRUE,"DKN-01, Nivolumab",,,DKN-01/Nivolumab,298,329,Progression and relapse,,,Regimen: DKN-01/Nivolumab,TRUE
16418,RA_4248,,TRUE,Subasumstat,,,TAK-981,361,371,Progression and relapse,,,d/c'ed on hospice ~ Regimen: TAK-981,TRUE
16419,RA_4443,,TRUE,XMT-1522,,,XMT-1522,2025,2095,Toxicity,,,,TRUE
16420,RA_4443,,TRUE,ALX-148,,,ALX148,2254,2485,Progression and relapse,,"initial SD w/ overall decrease in tumor burden, did treat past progression",,TRUE
16421,RA_4957,,TRUE,Talimogene Laherparepvec,,,TVEC: Left Upper Back,1410,1458,Progression and relapse,,,Regimen: TVEC: Left Upper Back,TRUE
16422,MGHCC0002,,FALSE,,,,SIRT to right liver,8216,8216,NA,,,,TRUE
16423,MGHCC0003,,FALSE,,,,XRT to left chest wall,317,348,NA,,,,TRUE
16424,MGHCC0003,,FALSE,,,,xrt to right humerus,4886,4886,NA,,,,TRUE
16425,MGHCC0003,,FALSE,,,,WBRT,6710,6734,NA,,,,TRUE
16426,MGHCC0004,,FALSE,,,,Spine XRT,8491,8491,NA,,,,TRUE
16427,MGHCC0004,,FALSE,,,,WBRT,9162,9162,NA,,,,TRUE
16428,MGHCC0005,,FALSE,,,,XRT,384,384,NA,,,,TRUE
16429,MGHCC0005,,FALSE,,,,proton therapy to left eye,2736,2737,NA,,,metastases to the choroid,TRUE
16430,MGHCC0006,,FALSE,,,,whole brain radiation,1754,1754,NA,,,,TRUE
16431,MGHCC0007,,FALSE,,,,"palliative xrt to l chest wall, cervical and axillary nodes",651,696,NA,,,,TRUE
16432,MGHCC0007,,FALSE,,,,xeloda,651,695,NA,,,,TRUE
16433,MGHCC1005,,FALSE,,,,"xrt to r chest wall, axilla, supraclavicular LNs",206,245,NA,,,,TRUE
16434,MGHCC1005,,FALSE,,,,"XRT to T6-T11, L1-L3, C6-T4, base of skull",724,749,NA,,,,TRUE
16435,MGHCC1009,,FALSE,,,,SRS to brain lesions,2196,2196,NA,,,,TRUE
16436,MGHCC1015,,FALSE,,,,XRT,254,254,NA,,,,TRUE
16437,MGHCC1015,,FALSE,,,,SBRT to Liver,5384,5392,NA,,,,TRUE
16438,MGHCC1015,,FALSE,,,,Xeloda,5751,5800,NA,,,,TRUE
16439,MGHCC1015,,FALSE,,,,XRT to Neck,5793,5794,NA,,,,TRUE
16440,MGHCC1015,,FALSE,,,,WBRT,5810,5830,NA,,,,TRUE
16441,MGHCC1030,,FALSE,,,,radiation to right breast,156,186,NA,,,,TRUE
16442,MGHCC1030,,FALSE,,,,radiation to left breast,927,927,NA,,,,TRUE
16443,MGHCC1030,,FALSE,,,,cranial xrt,6155,6173,Progression and relapse,,,transition to hospice,TRUE
16444,MGHCC1041,,FALSE,,,,XRT to breast,172,222,NA,,,,TRUE
16445,MGHCC1041,,FALSE,,,,radiation to lumbo-sacral spine,1202,1215,NA,,,,TRUE
16446,MGHCC1041,,FALSE,,,,palliative XRT to right scapula,1754,1768,Progression and relapse,,,,TRUE
16447,MGHCC1099,,FALSE,,,,xrt to left chest wall,326,360,NA,,,,TRUE
16448,MGHCC1101,,FALSE,,,,"radiation to left chest wall, left axilla, subclavian area",2550,2597,NA,,,,TRUE
16449,MGHCC1101,,FALSE,,,,radiation to frontal skull mets,3726,3741,NA,,,,TRUE
16450,MGHCC1101,,FALSE,,,,whole brain radiation,3827,3858,NA,,,,TRUE
16451,MGHCC1101,,FALSE,,,,radiation to T10-L2 & mediastinum,4314,4323,NA,,,,TRUE
16452,MGHCC1108,,FALSE,,,,radiation to breast,207,253,NA,,,,TRUE
16453,MGHCC1108,,FALSE,,,,"xrt to skull, right femur, and hemipelvis",2169,2188,NA,,,,TRUE
16454,MGHCC1108,,FALSE,,,,xrt to skull,2858,2884,NA,,,,TRUE
16455,MGHCC1108,,FALSE,,,,palliative xrt to left shoulder/skin and right hip/glute,2918,2931,NA,,,,TRUE
16456,MGHCC1112,,FALSE,,,,palliative xrt to right hip,1900,1912,NA,,,,TRUE
16457,MGHCC1173,,FALSE,,,,XRT to right breast & right SC Lymph Nodes,124,167,NA,,,,TRUE
16458,MGHCC1173,,FALSE,,,,"XRT to T7-9, L-13",1164,1184,NA,,,,TRUE
16459,MGHCC1173,,FALSE,,,,XRT to left proximal tibia/fibula,1876,1882,NA,,,,TRUE
16460,MGHCC1173,,FALSE,,,,"XRT to brain, calvarium, and left arm",2179,2191,NA,,,,TRUE
16461,MGHCC1328,,FALSE,,,,xrt to right breast,14,29,NA,,,,TRUE
16462,MGHCC1328,,FALSE,,,,XRT to spine,7627,7649,NA,,,,TRUE
16463,MGHCC1573,,FALSE,,,,xrt to chest wall,215,259,NA,,,,TRUE
16464,MGHCC1573,Chemotherapy,TRUE,Capecitabine,,,xeloda,1644,2061,Progression and relapse,,,,TRUE
16465,RA_1002,,FALSE,,,,Radiation (to Right Breast),0,0,NA,,,Regimen: Radiation (to Right Breast),TRUE
16466,RA_1002,,FALSE,,,,Radiation,5478,5478,NA,,,Regimen: Radiation,TRUE
16467,RA_1011,,FALSE,,,,postoperative XRT,292,315,Completion of standard course,,,Regimen: postoperative XRT,TRUE
16468,RA_1011,,FALSE,,,,XRT to the R scalp lesion and L hip,1114,1139,Completion of standard course,,,Regimen: XRT to the R scalp lesion and L hip,TRUE
16469,RA_1035,,FALSE,,,,Postmastectomy radiation therapy,212,291,Completion of standard course,,,Regimen: Postmastectomy radiation therapy,TRUE
16470,RA_1035,,FALSE,,,,Postmastectomy radiation therapy,212,291,Completion of standard course,,,Regimen: Postmastectomy radiation therapy,TRUE
16471,RA_1045,,FALSE,,,,Radiation + Concurrent Trastuzumab/Capecitabine,217,260,NA,,,Regimen: Radiation + Concurrent Trastuzumab/Capecitabine,TRUE
16472,RA_1078,,FALSE,,,,Radiation (50 Gy),252,288,NA,,,Regimen: Radiation (50 Gy),TRUE
16473,RA_1078,,FALSE,,,,Cyberknife stereotactic therapy,5249,5251,NA,,,Regimen: Cyberknife stereotactic therapy,TRUE
16474,RA_1078,,FALSE,,,,Palliative radiotherapy to the R humerus,6167,6173,NA,,,Regimen: Palliative radiotherapy to the R humerus,TRUE
16475,RA_1078,,FALSE,,,,XRT to Cerebellum (30 Gy X 10 Fractions),6437,6452,NA,,,Regimen: XRT to Cerebellum (30 Gy X 10 Fractions),TRUE
16476,RA_1113,,FALSE,,,,WBRT,3658,3684,Completion of standard course,,,Regimen: WBRT,TRUE
16477,RA_1113,,FALSE,,,,WBRT,3658,3684,Completion of standard course,,,Regimen: WBRT,TRUE
16478,RA_1184,,FALSE,,,,vaginal brachytherapy,192,192,Completion of standard course,,,Regimen: vaginal brachytherapy,TRUE
16479,RA_1187,,FALSE,,,,Microwave ablation (liver lesion),464,464,Completion of standard course,,,Regimen: Microwave ablation (liver lesion),TRUE
16480,RA_1187,,FALSE,,,,SIRT to liver,654,654,Completion of standard course,,,Regimen: SIRT to liver,TRUE
16481,RA_1373,,FALSE,,,,XRT to the R iliac crest,6589,6609,NA,,,Regimen: XRT to the R iliac crest,TRUE
16482,RA_1526,,FALSE,,,,IMRT: 42.5 Gy.  (proximal/distal vagina),142,184,NA,,,Regimen: IMRT: 42.5 Gy.  (proximal/distal vagina),TRUE
16483,RA_1547,,FALSE,,,,Radiation Therapy (Left Breast),188,232,NA,,,Regimen: Radiation Therapy (Left Breast),TRUE
16484,RA_1547,,FALSE,,,,Radiation Therapy (Cervical Spine),1020,1043,NA,,,Regimen: Radiation Therapy (Cervical Spine),TRUE
16485,RA_1547,,FALSE,,,,RT Therapy Right Humerus Lesion,1826,1846,NA,,,Regimen: RT Therapy Right Humerus Lesion,TRUE
16486,RA_1558,,FALSE,,,,Radiation: Left parasternal mass and IMN's,3269,3306,Completion of standard course,,,Regimen: Radiation: Left parasternal mass and IMN's,TRUE
16487,RA_1558,,FALSE,,,,palliative XRT to pubis/R ischium,4083,4097,Completion of standard course,,,Regimen: palliative XRT to pubis/R ischium,TRUE
16488,RA_1558,,FALSE,,,,XRT to sacrum,4791,4797,Completion of standard course,,,Regimen: XRT to sacrum,TRUE
16489,RA_1568,,FALSE,,,,L breast Radiation Therapy,224,268,Completion of standard course,,,Regimen: L breast Radiation Therapy,TRUE
16490,RA_1598,,FALSE,,,,Radiation,183,233,NA,,,Regimen: Radiation,TRUE
16491,RA_1598,,FALSE,,,,XRT (Right Hip) - 30 Gy,735,735,NA,,,Regimen: XRT (Right Hip) - 30 Gy,TRUE
16492,RA_1598,,FALSE,,,,XRT (Right Hip),2100,2107,NA,,,Regimen: XRT (Right Hip),TRUE
16493,RA_1598,,FALSE,,,,XRT to left hip,4023,4027,NA,,,Regimen: XRT to left hip,TRUE
16494,RA_1644,,FALSE,,,,Radiation: Right chest wall and SCV,259,301,NA,,,Regimen: Radiation: Right chest wall and SCV,TRUE
16495,RA_1644,,FALSE,,,,Radiation (50.4 Gy to chest wall & LN + 10 Gy boost to area of reccurence),1985,2036,NA,,,Regimen: Radiation (50.4 Gy to chest wall & LN + 10 Gy boost to area of reccurence),TRUE
16496,RA_1926,,FALSE,,,,Radiation,86,127,Completion of standard course,,,Regimen: Radiation,TRUE
16497,RA_1926,,FALSE,,,,Radiation (Esophagous),1577,1616,Completion of standard course,,,Regimen: Radiation (Esophagous),TRUE
16498,RA_1939,,FALSE,,,,Radiation (liver) + CI 5FU,283,327,Completion of standard course,,,Regimen: Radiation (liver) + CI 5FU,TRUE
16499,RA_2085,,FALSE,,,,Radiation: Liver lesions,527,536,NA,,,Regimen: Radiation: Liver lesions,TRUE
16500,RA_2085,,FALSE,,,,Radiation: Liver,1187,1207,Completion of standard course,,,67.5 Gy / 15 fractions ~ Regimen: Radiation: Liver,TRUE
16501,RA_2085,,FALSE,,,,Radiation: perihepatic lymph node,1498,1516,Completion of standard course,,,52.5 Gy in 15 fractions ~ Regimen: Radiation: perihepatic lymph node,TRUE
16502,RA_2085,,FALSE,,,,Radiation: Liver,1701,1701,Completion of standard course,,,8 Gy X 3 fractions ~ Regimen: Radiation: Liver,TRUE
16503,RA_2098,,FALSE,,,,XRT to the L pelvic mass,555,569,Completion of standard course,,,Regimen: XRT to the L pelvic mass,TRUE
16504,RA_2098,,FALSE,,,,Radiation to abdominal lesions,723,745,Completion of standard course,,,Regimen: Radiation to abdominal lesions,TRUE
16505,RA_2389,,FALSE,,,,Left chest wall radiation,611,637,Completion of standard course,,,Regimen: Left chest wall radiation,TRUE
16506,RA_2544,,FALSE,,,,Palliative radiation therapy to the oblique right flank,20,24,Completion of standard course,,,Regimen: Palliative radiation therapy to the oblique right flank,TRUE
16507,RA_2544,,FALSE,,,,XRT to R adrenal gland and L lung,1074,1084,Completion of standard course,,,Regimen: XRT to R adrenal gland and L lung,TRUE
16508,RA_255,,FALSE,,,,SRS 18 Gy to brain met,1087,1087,NA,,,Regimen: SRS 18 Gy to brain met,TRUE
16509,RA_255,,FALSE,,,,Palliative XRT for T8 pathologic fracture,1147,1156,NA,,,Regimen: Palliative XRT for T8 pathologic fracture,TRUE
16510,RA_255,,FALSE,,,,RT to T-spine lesion,1157,1158,NA,,,Regimen: RT to T-spine lesion,TRUE
16511,RA_2736,,FALSE,,,,SRS to L3-L4 lesion,853,854,Completion of standard course,,,Regimen: SRS to L3-L4 lesion,TRUE
16512,RA_2785,,FALSE,,,,palliative xrt to primary,271,282,Completion of standard course,,,Regimen: palliative xrt to primary,TRUE
16513,RA_2917,,FALSE,,,,Radiation (Cerebellum),540,553,Completion of standard course,,,Regimen: Radiation (Cerebellum),TRUE
16514,RA_2917,,FALSE,,,,Stereotactic Body Radiation Therapy (Liver),639,639,Completion of standard course,,,Regimen: Stereotactic Body Radiation Therapy (Liver),TRUE
16515,RA_2974,,FALSE,,,,Radiation (Left Breast),85,85,NA,,,Regimen: Radiation (Left Breast),TRUE
16516,RA_3130,,FALSE,,,,Radiation: L Supraclav Node,898,906,Completion of standard course,,,Regimen: Radiation: L Supraclav Node,TRUE
16517,RA_321,,FALSE,,,,Radiation: abdominal metastatic disease  (IMRT),13252,13272,Completion of standard course,,,Regimen: Radiation: abdominal metastatic disease  (IMRT),TRUE
16518,RA_321,,FALSE,,,,Radiation:  left hepatic lobe (SIRT),13411,13411,Completion of standard course,,,Regimen: Radiation:  left hepatic lobe (SIRT),TRUE
16519,RA_321,,FALSE,,,,Radiation:  right hepatic lobe (SIRT),13481,13481,Completion of standard course,,,Progression of metastases in the chest ~ Regimen: Radiation:  right hepatic lobe (SIRT),TRUE
16520,RA_3226,,FALSE,,,,radiation to rectum,40,44,NA,,,short course xrt ~ Regimen: radiation to rectum,TRUE
16521,RA_3226,,FALSE,,,,IMRT to dominant lung mass (LLL),1195,1238,NA,,,Regimen: IMRT to dominant lung mass (LLL),TRUE
16522,RA_3533,,FALSE,,,,SRS to R. Frontal Brain Metastasis,561,561,Completion of standard course,,,17 Gy x 1 ~ Regimen: SRS to R. Frontal Brain Metastasis,TRUE
16523,RA_3612,,FALSE,,,,Adjuvant neck RT,78,120,Completion of standard course,,,Regimen: Adjuvant neck RT,TRUE
16524,RA_3612,,FALSE,,,,Palliative RT: T12-L3 for lesions in L1&2,2618,2620,Completion of standard course,,,5 fxs to 2000 cGy ~ Regimen: Palliative RT: T12-L3 for lesions in L1&2,TRUE
16525,RA_3612,,FALSE,,,,Palliative RT: Pelvis/Femur,2842,2863,Completion of standard course,,,14 fx to 3500 cGy ~ Regimen: Palliative RT: Pelvis/Femur,TRUE
16526,RA_3634,,FALSE,,,,XRT to right hilum of lung,526,540,Completion of standard course,,,Regimen: XRT to right hilum of lung,TRUE
16527,RA_3634,,FALSE,,,,Palliative RT to right axillary adenopathy,601,605,Completion of standard course,,,Regimen: Palliative RT to right axillary adenopathy,TRUE
16528,RA_3649,,FALSE,,,,SRS to Brain,443,443,Completion of standard course,,,"R frontal #1 18 Gy, R frontal #2 18 Gy, L parietal 18 Gy, and L temporal cavity 30 Gy over 10 fractions ~ Regimen: SRS to Brain",TRUE
16529,RA_3738,,FALSE,,,,Radiotherapy (stomach),460,497,Completion of standard course,,,Regimen: Radiotherapy (stomach),TRUE
16530,RA_3781,,FALSE,,,,Radiation Therapy (Brain),3481,3501,Completion of standard course,,,Regimen: Radiation Therapy (Brain),TRUE
16531,RA_3782,,FALSE,,,,RFA Ablation,-1776,-1776,Completion of standard course,,,Regimen: RFA Ablation,TRUE
16532,RA_3782,,FALSE,,,,Radiation (Stomach),65,73,Completion of standard course,,,Regimen: Radiation (Stomach),TRUE
16533,RA_3792,,FALSE,,,,CyberKnife (SBRT),205,205,Completion of standard course,,,Regimen: CyberKnife (SBRT),TRUE
16534,RA_3812,,FALSE,,,,Photon Radiation: Liver,55,78,Completion of standard course,,,Regimen: Photon Radiation: Liver,TRUE
16535,RA_3859,,FALSE,,,,Radiation: Right uveal melanoma,14,20,Completion of standard course,,,Regimen: Radiation: Right uveal melanoma,TRUE
16536,RA_3859,,FALSE,,,,Radiation: left iliac metastasis,540,552,Completion of standard course,,,Regimen: Radiation: left iliac metastasis,TRUE
16537,RA_3859,,FALSE,,,,SIRT: right lobe of liver,623,623,Completion of standard course,,,Regimen: SIRT: right lobe of liver,TRUE
16538,RA_3859,,FALSE,,,,SBRT (Palliative): T12-L1 and L5-S2,664,664,Completion of standard course,,,Regimen: SBRT (Palliative): T12-L1 and L5-S2,TRUE
16539,RA_3873,,FALSE,,,,"SRS to cervical spine (C4-C6), 18 Gy in one fraction",12137,12137,Completion of standard course,,,"Regimen: SRS to cervical spine (C4-C6), 18 Gy in one fraction",TRUE
16540,RA_3873,,FALSE,,,,Proton SRS to L frontal lobe resection cavity 21 Gy in 3 fractions,12139,12143,Completion of standard course,,,Regimen: Proton SRS to L frontal lobe resection cavity 21 Gy in 3 fractions,TRUE
16541,RA_3873,,FALSE,,,,Radiation single fraction (1800cGy)to T4-T5,12571,12571,Completion of standard course,,,Regimen: Radiation single fraction (1800cGy)to T4-T5,TRUE
16542,RA_3873,,FALSE,,,,Gated XRT to cardiac met,12682,12710,Completion of standard course,,,20 fractions for a total of 40 Gy ~ Regimen: Gated XRT to cardiac met,TRUE
16543,RA_3873,,FALSE,,,,Cardiac met ITV2 - 1000 cGy,12781,12788,Completion of standard course,,,Regimen: Cardiac met ITV2 - 1000 cGy,TRUE
16544,RA_3873,,FALSE,,,,30 Gy SBRT in 4 fractions to C3-C5,12926,12930,Completion of standard course,,,Regimen: 30 Gy SBRT in 4 fractions to C3-C5,TRUE
16545,RA_3912,,FALSE,,,,right breast XRT,228,269,Completion of standard course,,,Regimen: right breast XRT,TRUE
16546,RA_3912,,FALSE,,,,WBRT,1156,1162,Completion of standard course,,,Regimen: WBRT,TRUE
16547,RA_4426,,FALSE,,,,Radiation: Mastectomy Site,178,217,Completion of standard course,,,Regimen: Radiation: Mastectomy Site,TRUE
16548,RA_4430,,FALSE,,,,IMRT to LUL tumor,228,265,Completion of standard course,,,Regimen: IMRT to LUL tumor,TRUE
16549,RA_4443,,FALSE,,,,Radiation to Esophagus,1757,1792,Completion of standard course,,,,TRUE
16550,RA_4443,,FALSE,,,,Radiation to Right Adrenal Gland,1785,1794,Completion of standard course,,,,TRUE
16551,RA_4443,,FALSE,,,,Radiation to Esophagus (Cone Down),1793,1795,Completion of standard course,,,,TRUE
16552,RA_4484,,FALSE,,,,Proton SRS:  (L) anterior sub-insular Brain Lesion,81,81,Completion of standard course,,,Regimen: Proton SRS:  (L) anterior sub-insular Brain Lesion,TRUE
16553,RA_4484,,FALSE,,,,"SRS to lesions: R frontal, (R) occipital lobe & cerebellar vermis",207,207,Completion of standard course,,,"Regimen: SRS to lesions: R frontal, (R) occipital lobe & cerebellar vermis",TRUE
16554,RA_4484,,FALSE,,,,SRS: new brain metastases,498,498,Completion of standard course,,,Regimen: SRS: new brain metastases,TRUE
16555,RA_4484,,FALSE,,,,SRS R posterior temporal metastasis,1915,1915,Completion of standard course,,,Regimen: SRS R posterior temporal metastasis,TRUE
16556,RA_4484,,FALSE,,,,post-operative radiation to resection bed,2499,2517,Completion of standard course,,,Regimen: post-operative radiation to resection bed,TRUE
16557,RA_4484,,FALSE,,,,SRS to L temporal horn and R temporal horn,2734,2734,Completion of standard course,,,New bilateral temporal horn lesions ~ Regimen: SRS to L temporal horn and R temporal horn,TRUE
16558,RA_4518,,FALSE,,,,RA223,1271,1425,Completion of standard course,,,Regimen: RA223,TRUE
16559,RA_4518,,FALSE,,,,Radiation to T9-S2,1489,1502,NA,,,Regimen: Radiation to T9-S2,TRUE
16560,RA_4523,,FALSE,,,,C7-T1 xrt,0,0,NA,,,Regimen: C7-T1 xrt,TRUE
16561,RA_4523,,FALSE,,,,XRT to R 4th Rib & L3 Vertebrae,0,0,NA,,,Regimen: XRT to R 4th Rib & L3 Vertebrae,TRUE
16562,RA_4848,,FALSE,,,,Breast Radiation,121,121,NA,,,Regimen: Breast Radiation,TRUE
16563,RA_4848,,FALSE,,,,L Axillary Radiotherapy,2441,2441,NA,,,Regimen: L Axillary Radiotherapy,TRUE
16564,RA_4957,,FALSE,,,,Radiation (Adjuvant),501,545,Completion of standard course,,,Regimen: Radiation (Adjuvant),TRUE
16565,RA_4965,,FALSE,,,,SRS to multiple brain lesions,23,24,NA,,,Regimen: SRS to multiple brain lesions,TRUE
16566,RA_4965,,FALSE,,,,SRS to R femur lesion,27,36,NA,,,Regimen: SRS to R femur lesion,TRUE
16567,RA_4979,,FALSE,,,,XRT to third rib,1205,1210,Completion of standard course,,,Regimen: XRT to third rib,TRUE
16568,RA_498,,FALSE,,,,"SRS to right frontal, right parietal and left parietal lesions",4651,4651,NA,,,"Regimen: SRS to right frontal, right parietal and left parietal lesions",TRUE
16569,RA_552,,FALSE,,,,XRT to cerebellar surgical resection,1919,1936,NA,,,Regimen: XRT to cerebellar surgical resection,TRUE
16570,RA_552,,FALSE,,,,SRS to R parietal metastasis,2053,2053,NA,,,Regimen: SRS to R parietal metastasis,TRUE
16571,RA_552,,FALSE,,,,SRS to R parietal metastasis,2202,2202,NA,,,Regimen: SRS to R parietal metastasis,TRUE
16572,RA_858,,FALSE,,,,XRT to R breast,2364,2368,Completion of standard course,,,Regimen: XRT to R breast,TRUE
16573,RA_4484,,TRUE,Interleukin 2,,,IL-2,273,277,Toxicity,,,"10 of 14 doses of planned course, complicated by diarrhea, hypotension, mental status changes.  (Suspected Colitis) ~ Regimen: IL-2",TRUE
16574,RA_858,,TRUE,Interleukin 2,,,High dose IL-2,2329,2347,Progression and relapse,,,"increased tumor burden, evidenced by increase in size of lung nodules/masses, thoracic and abdominal lymphadenopathy, hepatic lesions, splenic lesion, right breast masses, and subcutaneous nodules. New possible ulceration at the right nipple. New lytic area in the L1 vertebral body likely represents a metastasis. New gastric nodule at the lesser curvature could represent a metastasis ~ Regimen: High dose IL-2",TRUE
16575,RA_1373,ADC,TRUE,IMMU-132,,,IMMU-132 (X 7 Cycles),6638,6791,NA,,,"Clinical Trial, Best Response = SD (-21.9%) // Progression = New liver lesions and (+ 0.5%)  change from BL ""Increased size of some of the multiple metastases involving both lobes of the liver"" ~ Regimen: IMMU-132 (X 7 Cycles)",TRUE
16576,RA_1547,ADC,TRUE,IMMU-132,,,IMMU-132 (X 8 Cycles),1988,2177,Progression and relapse,,,Clinical Trial #: Best Response = SD (-15.8%) - D/C for Increasing tumor markers ~ Regimen: IMMU-132 (X 8 Cycles),TRUE
16577,RA_209,,TRUE,Roferon-A,,,Interferon  (Adjuvant),168,210,Toxicity,,,Nausea/Vomiting ~ Regimen: Interferon  (Adjuvant),TRUE
16578,RA_3244,,TRUE,Roferon-A,,,Interferon,706,1016,Toxicity,,,D/C due to transaminitis ~ Regimen: Ineterferon,TRUE
16579,RA_2785,,TRUE,Lamivudine,,,Lamivudine,482,503,Progression and relapse,,,"New and increasing hepatic metastases.  Increased periportal and aortocaval lymphadenopathy.  New small volume ascites with stranding and nodularity in the lower abdomen/pelvis, suggestive of new peritoneal disease ~ Regimen: Lamivudine",TRUE
16580,RA_209,,TRUE,Talimogene Laherparepvec,,,TVEC - Left Breast lesion [5 Cycles],5751,5821,Completion of standard course,,,Regimen: TVEC - Left Breast lesion [5 Cycles],TRUE
16581,RA_3533,,TRUE,Talimogene Laherparepvec,,,TVEC to R foot nodules - [6 Cycles],520,597,Progression and relapse,,,"Progression in Brain: Progression Multiple new and enlarging intracranial metastases as described above, which measure up to 3.2 cm in diameter within the right middle frontal gyrus. Several of these metastases demonstrate intrinsic T1 hyperintense signal and susceptibility, consistent with intralesional hemorrhage. There is also suggestion of new leptomeningeal and pachymeningeal disease, most notably along the right frontal operculum. ~ Regimen: TVEC to R foot nodules - [6 Cycles]",TRUE
16582,RA_209,,TRUE,WDVAX,,,WDVAX,5468,5510,Progression and relapse,,,Interval increase in number and extent of multiple intensely FDG avid soft tissue and pelvic metastases ~ Regimen: WDVAX,TRUE
16583,RA_1045,,FALSE,,,,,162,162,NA,,,Partial mastectomy,TRUE
16584,RA_1045,,FALSE,,,,,181,181,NA,,,Mastectomy,TRUE
16585,RA_1078,,FALSE,,,,,51,51,NA,,,Left Modified Radical Mastectomy,TRUE
16586,RA_1373,,FALSE,,,,,17,17,NA,,,Mastectomy,TRUE
16587,RA_1526,,FALSE,,,,,26,26,NA,,,Hysterectomy,TRUE
16588,RA_1547,,FALSE,,,,Lumpectomy,15,15,NA,,,Lumpectomy,TRUE
16589,RA_1547,,FALSE,,,,R. Breast Reduction,257,257,NA,,,R. Breast Reduction,TRUE
16590,RA_1598,,FALSE,,,,,28,28,NA,,,Simple mastectomy,TRUE
16591,RA_1644,,FALSE,,,,,26,26,NA,,,Bilateral Mastectomy,TRUE
16592,RA_1644,,FALSE,,,,,819,819,NA,,,Total abdominal hysterectomy/ Bilateral Salpingo-oophorectomy,TRUE
16593,RA_1644,,FALSE,,,,,1860,1860,NA,,,Pectoralis major resection,TRUE
16594,RA_2974,,FALSE,,,,,85,85,NA,,,"Left Lumpectomy, Partial mastectomy",TRUE
16595,RA_1002,,FALSE,,,,,0,0,NA,,,Lumpectomy,TRUE
16596,RA_1002,,FALSE,,,,,5478,5478,NA,,,Lumpectomy,TRUE
16597,RA_1002,,FALSE,,,,,8920,8920,NA,,,Bilateral Mastectomy,TRUE
16598,RA_2408,,FALSE,,,,,0,0,NA,,,Endoscopic Resection of Ampullary Mass,TRUE
16599,RA_1939,,FALSE,,,,,20,20,NA,,,right hepatectomy,TRUE
16600,RA_1939,,FALSE,,,,,1288,1288,NA,,,Cryoablation of pelvic met - ablation,TRUE
16601,RA_1568,,FALSE,,,,,173,173,NA,,,Left lumpectomy,TRUE
16602,RA_1926,,FALSE,,,,,188,188,NA,,,"esophagectomy, jejunostomy, and omental pedicle to anastomosis",TRUE
16603,RA_2098,,FALSE,,,,,0,0,NA,,,Laparoscopic ovarian cystectomy,TRUE
16604,RA_2098,,FALSE,,,,,34,34,NA,,,laparoscopic salpingo-oophorectomy,TRUE
16605,RA_2819,,FALSE,,,,,26,26,NA,,,R breast mastectomy,TRUE
16606,RA_3130,,FALSE,,,,,231,231,NA,,,Subtotal gastrectomy,TRUE
16607,RA_1113,,FALSE,,,,,0,0,NA,,,Mastectomy,TRUE
16608,RA_1113,,FALSE,,,,,0,0,NA,,,Mastectomy,TRUE
16609,RA_1035,,FALSE,,,,,151,151,NA,,,Right breast lumpectomy,TRUE
16610,RA_1035,,FALSE,,,,,151,151,NA,,,Right breast lumpectomy,TRUE
16611,RA_1035,,FALSE,,,,,210,210,NA,,,Right Mastectomy,TRUE
16612,RA_1035,,FALSE,,,,,210,210,NA,,,Right Mastectomy,TRUE
16613,RA_1011,,FALSE,,,,,0,0,NA,,,R-sided Lumpectomy,TRUE
16614,RA_1011,,FALSE,,,,,276,276,NA,,,Mastectomy,TRUE
16615,RA_1011,,FALSE,,,,,943,943,NA,,,left lower lobe (Lung) superior segmentectomy,TRUE
16616,RA_1184,,FALSE,,,,,30,30,NA,,,"Laparoscopic hysterectomy, BSO, lymph adenectomy, omentectomy",TRUE
16617,RA_1184,,FALSE,,,,,408,408,NA,,,"exploratory laparotomy - removal of abdominal mass, bowel resection",TRUE
16618,RA_2024,,FALSE,,,,,95,95,NA,,,Left/ Right Hepatectomy,TRUE
16619,RA_2024,,FALSE,,,,,95,95,NA,,,Left/ Right Hepatectomy,TRUE
16620,RA_2024,,FALSE,,,,,234,234,NA,,,Low anterior Resection of the rectum,TRUE
16621,RA_2024,,FALSE,,,,,234,234,NA,,,Low anterior Resection of the rectum,TRUE
16622,RA_2917,,FALSE,,,,,161,161,NA,,,Left Mastectomy,TRUE
16623,RA_3781,,FALSE,,,,,17,17,NA,,,Posterior Neck Melanoma Local Excision,TRUE
16624,RA_3781,,FALSE,,,,,3299,3299,NA,,,BILATERAL SUBOCCIPITAL CRANIOTOMY,TRUE
16625,RA_3873,,FALSE,,,,,8363,8363,NA,,,Resection of in transit metastasis from (Left) inner thigh,TRUE
16626,RA_3873,,FALSE,,,,,9420,9420,NA,,,Thoracotomy - (Right) middle lobectomy,TRUE
16627,RA_3873,,FALSE,,,,,10120,10120,NA,,,resection of proximal jejunal metastasis,TRUE
16628,RA_3873,,FALSE,,,,,11646,11646,NA,,,Left adrenalectomy (melanoma metastasis),TRUE
16629,RA_3873,,FALSE,,,,,12090,12090,NA,,,(L) frontal craniotomy,TRUE
16630,RA_3873,,FALSE,,,,,12114,12114,NA,,,Anterior cervical partial C4 and complete C5 vertebrectomy,TRUE
16631,RA_3873,,FALSE,,,,,12887,12887,NA,,,C4 + C6 corpectomy / posterior C3-T1 fusion,TRUE
16632,RA_3873,,FALSE,,,,,12951,12951,NA,,,Local excision of metastasis on left side of scalp,TRUE
16633,RA_1187,,FALSE,,,,,45,45,NA,,,Left lobe liver resection and hilar lymphadenectomy,TRUE
16634,RA_1187,,FALSE,,,,,310,310,NA,,,"Recurrence: Liver, Pulmonary Nodules",TRUE
16635,RA_3649,,FALSE,,,,,0,0,NA,,,Left shoulder lesion biopsy showing malignant melanoma,TRUE
16636,RA_3649,,FALSE,,,,,45,45,NA,,,Wide excision,TRUE
16637,RA_3649,,FALSE,,,,,78,78,NA,,,Re-excision of primary,TRUE
16638,RA_2085,,FALSE,,,,,99,99,NA,,,Left hepatectomy and cholecystectomy,TRUE
16639,RA_2085,,FALSE,,,,,444,444,NA,,,Recurrence: Liver,TRUE
16640,RA_2085,,FALSE,,,,,469,469,NA,,,Partial right hepatectomy,TRUE
16641,RA_2177,,FALSE,,,,,683,683,NA,,,Right sided TACE - chemoembolization,TRUE
16642,RA_3612,,FALSE,,,,,0,0,NA,,,Thyroidectomy and neck dissection,TRUE
16643,RA_3612,,FALSE,,,,,45,45,NA,,,Excision of R submandibular mass,TRUE
16644,RA_3612,,FALSE,,,,,217,217,NA,,,Revision neck surgery,TRUE
16645,RA_3612,,FALSE,,,,,2166,2166,NA,,,Cryoablation: Liver lesions in segments 5/6 - ablation,TRUE
16646,RA_2736,,FALSE,,,,,17,17,NA,,,Left Hepatectomy,TRUE
16647,RA_2736,,FALSE,,,,,727,727,NA,,,Lung Resection,TRUE
16648,RA_4340,,FALSE,,,,,-5195,-5195,NA,,,L sigmoid colectomy,TRUE
16649,RA_3244,,FALSE,,,,,14,14,NA,,,Excision (Upper Back),TRUE
16650,RA_3244,,FALSE,,,,,638,638,NA,,,Excision (Left Lower Back),TRUE
16651,RA_3533,,FALSE,,,,,47,47,NA,,,Excision of right heel melanoma,TRUE
16652,RA_3533,,FALSE,,,,,392,392,NA,,,Resection: Right Temporal Mass,TRUE
16653,RA_4215,,FALSE,,,,,35,35,NA,,,wide excision - RIGHT UPPER BACK,TRUE
16654,RA_4215,,FALSE,,,,,1470,1470,NA,,,Craniotomy and resection (Brain Right Frontal),TRUE
16655,RA_209,,FALSE,,,,,53,53,NA,,,Excision: Left Upper Back,TRUE
16656,RA_209,,FALSE,,,,,2970,2970,NA,,,Resection: SC nodule of (L) upper back,TRUE
16657,RA_209,,FALSE,,,,,3248,3248,NA,,,lingular wedge resection (left),TRUE
16658,RA_209,,FALSE,,,,,3921,3921,NA,,,Resection: Right Adrenal gland,TRUE
16659,RA_209,,FALSE,,,,,4543,4543,NA,,,Excision of (R) axillary & (R) back melanoma,TRUE
16660,RA_209,,FALSE,,,,,5434,5434,NA,,,Resection: Left Back tumor,TRUE
16661,RA_321,,FALSE,,,,,0,0,NA,,,Enucleation,TRUE
16662,RA_321,,FALSE,,,,,10605,10605,NA,,,Distal pancreatectomy with splenectomy,TRUE
16663,RA_321,,FALSE,,,,,13124,13124,NA,,,Gastrectomy,TRUE
16664,RA_571,,FALSE,,,,,0,0,NA,,,excision: Left Shoulder Melanoma,TRUE
16665,RA_571,,FALSE,,,,,14536,14536,NA,,,Excision: right flank melanoma,TRUE
16666,RA_552,,FALSE,,,,,1882,1882,NA,,,Midline suboccipital craniotomy,TRUE
16667,RA_552,,FALSE,,,,,2159,2159,NA,,,R frontal craniotomy,TRUE
16668,RA_498,,FALSE,,,,,0,0,NA,,,Excision of T2a melanoma of the back,TRUE
16669,RA_498,,FALSE,,,,,4498,4498,NA,,,Craniotomy and resection of R temporal lesion,TRUE
16670,RA_498,,FALSE,,,,,4608,4608,NA,,,Right parietal craniotomy,TRUE
16671,RA_4426,,FALSE,,,,,124,124,NA,,,Left mastectomy,TRUE
16672,RA_2542,,FALSE,,,,,0,0,NA,,,left modified radical mastectomy,TRUE
16673,RA_2542,,FALSE,,,,,243,243,NA,,,peripheral stem cell transplant,TRUE
16674,RA_2542,,FALSE,,,,,4898,4898,NA,,,hysterectomy and bilateral salpingo-oophorectomy,TRUE
16675,RA_4443,,FALSE,,,,,495,495,NA,,,Laparaoscopic BSO (L Fallopian Tube & Ovary),TRUE
16676,RA_4443,,FALSE,,,,,1004,1004,NA,,,Left Adrenalectomy,TRUE
16677,RA_3861,,FALSE,,,,,34,34,NA,,,Right Colon Resection,TRUE
16678,RA_3861,,FALSE,,,,,667,667,NA,,,Lung Wedge Resections,TRUE
16679,RA_4848,,FALSE,,,,,0,0,NA,,,Lumpectomy/Sentinel Lymph Node Procedure,TRUE
16680,RA_4848,,FALSE,,,,,2345,2345,NA,,,Left Axillary Resection,TRUE
16681,RA_4484,,FALSE,,,,,445,445,NA,,,Right occipital craniotomy,TRUE
16682,RA_4484,,FALSE,,,,,795,795,NA,,,Laparoscopic BSO,TRUE
16683,RA_4484,,FALSE,,,,,1694,1694,NA,,,Craniotomy: Right Frontal Lesion,TRUE
16684,RA_4484,,FALSE,,,,,2466,2466,NA,,,craniotomy tumor resection,TRUE
16685,RA_3226,,FALSE,,,,,47,47,NA,,,Laparoscopic low anterior resection with total mesorectal excision,TRUE
16686,RA_3226,,FALSE,,,,,187,187,NA,,,Flexible bronchoscopy/clamshell thoracotomy/multiple bilateral wedge resections,TRUE
16687,RA_4430,,FALSE,,,,,0,0,NA,,,LUL wedge resection,TRUE
16688,RA_4430,,FALSE,,,,,166,166,NA,,,mediastinoscopy,TRUE
16689,RA_4430,,FALSE,,,,,194,194,NA,,,thoracotomy + ACA in LUL,TRUE
16690,RA_4430,,FALSE,,,,,3037,3037,NA,,,RLL Lung Lobectomy,TRUE
16691,RA_858,,FALSE,,,,,33,33,NA,,,Wide excision of Right hip melanoma,TRUE
16692,RA_858,,FALSE,,,,,2113,2113,NA,,,Resection: right breast,TRUE
16693,RA_858,,FALSE,,,,,2378,2378,NA,,,Resection: left side of back,TRUE
16694,RA_4957,,FALSE,,,,,458,458,NA,,,Resection: left inguinal disease,TRUE
16695,RA_4957,,FALSE,,,,,1547,1547,NA,,,Cryo ablation: right upper back mass - ablation,TRUE
16696,RA_4979,,FALSE,,,,,1094,1094,NA,,,T3 to T7 decompression and fusion,TRUE
16697,RA_3181,,FALSE,,,,,16,16,NA,,,Bilateral Salpingo-Oophorectomy,TRUE
16698,MGHCC0001,,FALSE,,,,,831,831,NA,,,mastectomy,TRUE
16699,MGHCC0002,,FALSE,,,,,41,41,NA,,,left mastectomy and TRAM reconstruction,TRUE
16700,MGHCC0003,,FALSE,,,,,0,0,NA,,,left lumpectomy,TRUE
16701,MGHCC0003,,FALSE,,,,,13,13,NA,,,axillary lymph node dissection,TRUE
16702,MGHCC0003,,FALSE,,,,,137,137,NA,,,left breats re-excision,TRUE
16703,MGHCC0003,,FALSE,,,,,154,154,NA,,,left partial mastectomy w/ TRAM flap reconstruction,TRUE
16704,MGHCC0004,,FALSE,,,,,0,0,NA,,,mastectomy (PPX),TRUE
16705,MGHCC0005,,FALSE,,,,,384,384,NA,,,R modified radical mastectomy,TRUE
16706,MGHCC0006,,FALSE,,,,,0,0,NA,,,right lumpectomy,TRUE
16707,MGHCC0006,,FALSE,,,,,35,35,NA,,,re-excision/axillary dissection,TRUE
16708,MGHCC0007,,FALSE,,,,,49,49,NA,,,left mastectomy,TRUE
16709,MGHCC1006,,FALSE,,,,,29,29,NA,,,mastectomy,TRUE
16710,MGHCC1009,,FALSE,,,,,21,21,NA,,,bilateral mastectomy,TRUE
16711,MGHCC1009,,FALSE,,,,,947,947,NA,,,bilateral salpingo-oophorectomy,TRUE
16712,MGHCC1015,,FALSE,,,,,20,20,NA,,,mastectomy & reconstruction,TRUE
16713,MGHCC1015,,FALSE,,,,,489,489,NA,,,left axillary lymph node excision,TRUE
16714,MGHCC1030,,FALSE,,,,,0,0,NA,,,lumpectomy,TRUE
16715,MGHCC1030,,FALSE,,,,,20,20,NA,,,re-excision,TRUE
16716,MGHCC1030,,FALSE,,,,,41,41,NA,,,re-excision,TRUE
16717,MGHCC1030,,FALSE,,,,,156,156,NA,,,right mastectomy,TRUE
16718,MGHCC1030,,FALSE,,,,,807,807,NA,,,lumpectomy,TRUE
16719,MGHCC1030,,FALSE,,,,,828,828,NA,,,lymph node excision,TRUE
16720,MGHCC1030,,FALSE,,,,,1928,1928,NA,,,bilateral salpingo-oophorectomy,TRUE
16721,MGHCC1041,,FALSE,,,,,0,0,NA,,,right lumpectomy w/ right axillary LN dissection,TRUE
16722,MGHCC1099,,FALSE,,,,,70,70,NA,,,bilateral mastectomy,TRUE
16723,MGHCC1099,,FALSE,,,,,102,102,NA,,,lymph node dissection,TRUE
16724,MGHCC1099,,FALSE,,,,,1670,1670,NA,,,bilateral salpingo-oophorectomy,TRUE
16725,MGHCC1101,,FALSE,,,,,57,57,NA,,,right lumpectomy,TRUE
16726,MGHCC1101,,FALSE,,,,,92,92,NA,,,right mastectomy,TRUE
16727,MGHCC1101,,FALSE,,,,,2381,2381,NA,,,left mastectomy,TRUE
16728,MGHCC1108,,FALSE,,,,,26,26,NA,,,mastectomy,TRUE
16729,MGHCC1112,,FALSE,,,,,0,0,NA,,,bilateral mastectomy,TRUE
16730,MGHCC1112,,FALSE,,,,,730,730,NA,,,oophorectomy,TRUE
16731,MGHCC1173,,FALSE,,,,,43,43,NA,,,lumpectomy,TRUE
16732,MGHCC1173,,FALSE,,,,,1143,1143,NA,,,spinal cord decompression L1-L3,TRUE
16733,MGHCC1328,,FALSE,,,,,0,0,NA,,,right lumpectomy and axillary dissection,TRUE
16734,MGHCC1328,,FALSE,,,,,882,882,NA,,,right mastectomy,TRUE
16735,MGHCC1328,,FALSE,,,,,1615,1615,NA,,,right simple masectomy  and TRAM reconstruction,TRUE
16736,MGHCC1328,,FALSE,,,,,7589,7589,NA,,,spinal decompression/resection of epidural tumor,TRUE
16737,MGHCC1573,,FALSE,,,,,167,167,NA,,,right radical mastectomy,TRUE
16738,MGHCC1573,,FALSE,,,,,278,278,NA,,,"total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO)",TRUE
16739,RA_1039,,FALSE,,,,XRT to T spine,3,24,NA,,,Regimen: XRT to T spine,TRUE
16740,RA_1039,"Chemotherapy, Precision/Targeted Therapy",TRUE,"Paclitaxel, Trastuzumab",,,trastuzumab/taxol,5,42,NA,,,Regimen: trastuzumab/taxol,TRUE
16741,RA_1039,Precision/Targeted Therapy,TRUE,Trastuzumab,,,trastuzumab,74,85,NA,,,Regimen: trastuzumab,TRUE
16742,RA_1039,"Chemotherapy, Precision/Targeted Therapy",TRUE,"Capecitabine, Trastuzumab",,,trastuzumab/capecitabine,85,1158,Progression and relapse,,,Regimen: trastuzumab/capecitabine,TRUE
16743,RA_1039,Precision/Targeted Therapy,TRUE,"Lapatinib Ditosylate, Trastuzumab",,,trastuzumab/lapatinib,1174,1288,NA,,,Regimen: trastuzumab/lapatinib,TRUE
16744,RA_1039,,FALSE,,,,BYL single agent,1323,1740,Progression and relapse,,,CT c/a/p: progressive disease per RECIST with increasing liver and adnexal lesions ~ Regimen: BYL single agent,TRUE
16745,RA_1039,Precision/Targeted Therapy,TRUE,"Lapatinib Ditosylate, Trastuzumab",,,trastuzumab/lapatinib,1786,1901,NA,,,Regimen: trastuzumab/lapatinib,TRUE
16746,RA_1039,,FALSE,,,,LJM716 (anti-HER3),1935,1984,Progression and relapse,,,Regimen: LJM716 (anti-HER3),TRUE
16747,RA_1039,,FALSE,,,,TDM1,1991,2129,Progression and relapse,,,Regimen: TDM1,TRUE
16748,RA_1039,"Chemotherapy, Precision/Targeted Therapy",TRUE,"Eribulin Mesylate, Pertuzumab, Trastuzumab",,,trastuzumab/pertuzumab/eribulin,2166,2449,Progression and relapse,,,Regimen: trastuzumab/pertuzumab/eribulin,TRUE
16749,RA_1039,"Chemotherapy, Precision/Targeted Therapy",TRUE,"Trastuzumab, Vinorelbine Tartrate",,,trastuzumab/vinorelbine,2551,2588,NA,,,Regimen: trastuzumab/vinorelbine,TRUE
16750,RA_4793,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,"gemcitabine, cisplatin (4 cycles)",21,82,Progression and relapse,,,,TRUE
16751,RA_4793,,FALSE,,,,SIRT with Y-90,170,170,Completion of standard course,,,,TRUE
16752,RA_4793,,FALSE,,,,SIRT with Y-90,207,207,Completion of standard course,,,,TRUE
16753,RA_4793,,TRUE,Futibatinib,,,Futibatinib (TAS-120) 20mg daily on protocol 14-135,393,849,Progression and relapse,,,,TRUE
16754,RA_4793,,TRUE,RLY-4008,,,"20-577, a phase I protocol of a new covalent FGFR inhibitor, RLY-4008",904,1325,Progression and relapse,,,,TRUE
16755,RA_4793,,FALSE,,,,SIRT with Y-90,1325,1325,Completion of standard course,,,,TRUE
16756,RA_4793,,FALSE,,,,SIRT with Y-90,1373,1373,Completion of standard course,,,,TRUE
16757,RA_1547,,FALSE,,,,Recurrence (New T10 Spinal Cord Lesion),813,813,NA,,,Regimen: Recurrence (New T10 Spinal Cord Lesion),TRUE
16758,RA_2917,Chemotherapy,TRUE,unknown_chemotherapy,,,Chemotherapy + Immunotherapy,34,143,Progression and relapse,,,,TRUE
16759,RA_2917,Immunotherapy,TRUE,unknown_immunotherapy,,,Chemotherapy + Immunotherapy,34,143,Progression and relapse,,,,TRUE
16760,RA_2917,Chemotherapy,TRUE,unknown_chemotherapy,,,Chemotherapy + Targeted Therapy,157,204,Progression and relapse,,,,TRUE
16761,RA_2917,Precision/Targeted Therapy,TRUE,unknown_targeted,,,Chemotherapy + Targeted Therapy,157,204,Progression and relapse,,,,TRUE
16762,RA_2917,ADC,TRUE,unknown_ADC,,,ADC,207,252,Progression and relapse,,,,TRUE
16763,RA_2917,ADC,TRUE,IMMU-132,,,IMMU-132 (9 Cycles),398,676,Progression and relapse,,,,TRUE
16764,RA_2917,Chemotherapy,TRUE,unknown_chemotherapy,,,Chemotherapy,511,567,Progression and relapse,,,,TRUE
16765,RA_2917,,FALSE,,,,Radiation (Cerebellum),540,553,Completion of standard course,,,,TRUE
16766,RA_2917,Chemotherapy,TRUE,unknown_chemotherapy,,,Chemotherapy,567,606,Progression and relapse,,,,TRUE
16767,RA_2917,Chemotherapy,TRUE,unknown_chemotherapy,,,Chemotherapy,608,632,Progression and relapse,,,,TRUE
16768,RA_1133,Chemotherapy,TRUE,Cisplatin,,,Cisplatin/Pemetrexed,18,39,Other,,,EGFR results returned after 1 week,TRUE
16769,RA_1133,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib,53,529,Progression and relapse,,,,TRUE
16770,RA_1133,Precision/Targeted Therapy,TRUE,Nazartinib,,,EGF816,529,1564,Progression and relapse,,,,TRUE
16771,RA_1133,,FALSE,,,,RT 50 Gy to liver lesion,1315,1325,Completion of standard course,,,,TRUE
16772,RA_1133,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pemetrexed,1566,1566,Toxicity,,,,TRUE
16773,RA_1133,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib,1574,1751,Progression and relapse,,,,TRUE
16774,RA_2700,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib,10,104,Progression and relapse,,,,TRUE
16775,RA_2700,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Gemcitabine,106,134,Progression and relapse,,,,TRUE
16776,RA_2700,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib/Savolitinib,179,220,Progression and relapse,,,,TRUE
16777,RA_2700,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab,227,227,Progression and relapse,,,,TRUE
16778,RA_2700,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib,250,296,Other,,,Taken until date of death,TRUE
16779,RA_2700,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Abraxane,267,267,Progression and relapse,,,alongside Osimertinib,TRUE
16780,RA_1592,Precision/Targeted Therapy,TRUE,Afatinib Dimaleate,,,Afatinib,19,299,Progression and relapse,,,,TRUE
16781,RA_1592,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib,309,390,Progression and relapse,,,,TRUE
16782,RA_1592,,FALSE,,,,30 Gy to C3 post-op bed and 30 Gy to T10 post-op bed,343,357,Completion of standard course,,,,TRUE
16783,RA_1592,Chemotherapy,TRUE,Carboplatin,,,Carbo/taxol/osimertinib,391,543,Progression and relapse,,,,TRUE
16784,RA_1592,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Gemcitabine/osimertinib,545,643,Progression and relapse,,,,TRUE
16785,RA_1592,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Navelbine/osimertinib,643,679,Progression and relapse,,,,TRUE
16786,RA_1592,,FALSE,,,,8 Gy x 1 to scapular lesion,648,648,Completion of standard course,,,,TRUE
16787,RA_1592,Immunotherapy,TRUE,Nivolumab,,,Nivolumab,679,679,Progression and relapse,,,,TRUE
16788,RA_5432,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/pemetrexed,19,39,Other,,,"Day 0: RLL mass biopsy - PDL1 5%, ALK and ROS negative, EGFR negative",TRUE
16789,RA_5432,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib - EGFR inhibitor,41,244,Progression and relapse,,"Day 244: PETCT with decreased FDG at L anterior rib, RUL nodule, L iliac, R iliac, but FDG avidity at T12, L3, R side of T10, ? L adrenal. MRI with T10 and T12, L3 and L5 mets, no cord compression","Day 35: Snapshot EGFR Leu861Gln and TP53; CTs show response in lung and liver, brain MRI with decreased mets; Day 469 dose increased 80 -> 160mg qd due to interval progression in MRI brain, with the two largest lesions measuring 9 x 7 mm and 1.1 x 0.9 cm. Saw subsequent SD with decrease in mets",TRUE
16790,RA_5432,,FALSE,,,,RT to T9-L1,263,270,Completion of standard course,,,"Day 273: ctDNA - EGFR L861Q, PDGFR I476I, TMB 5.3, MSS",TRUE
16791,RA_5432,,FALSE,,,,"SRS to left parietal, left frontal parasagittal and left vertex metastases, 18 Gy x 1 to each",425,425,Completion of standard course,,,,TRUE
16792,RA_5432,,FALSE,,,,"SRS to right cerebellar and left cerebellar metastases, 18 Gy x 1",700,700,Completion of standard course,,,,TRUE
16793,RA_5432,Precision/Targeted Therapy,TRUE,osimertinib,,,PEMETREXED/CARBOPLATIN/OSIMERTINIB,780,992,Progression and relapse,,Brain MRI with increase in mets,,TRUE
16794,RA_5432,Chemotherapy,TRUE,Carboplatin,,,PEMETREXED/CARBOPLATIN/OSIMERTINIB,780,992,Progression and relapse,,Brain MRI with increase in mets,,TRUE
16795,RA_5432,,FALSE,,,,WBRT 3000cGy in 10 fractions,885,896,Completion of standard course,,,,TRUE
16796,RA_5432,Precision/Targeted Therapy,TRUE,osimertinib,,,PEMETREXED/OSIMERTINIB,901,1013,Progression and relapse,,shortness of breath,,TRUE
16797,RA_5432,Chemotherapy,TRUE,Pemetrexed,,,PEMETREXED/OSIMERTINIB,901,1013,Progression and relapse,,shortness of breath,,TRUE
16798,RA_6667,Precision/Targeted Therapy,TRUE,Trastuzumab,,,,5441,5495,NA,,,Patient had refused treatment for 15 years until the right breast mass grew outside her skin for at least 6 months. There was discoloration and drainage which weeps into her clothes.,TRUE
16799,RA_6667,Precision/Targeted Therapy,TRUE,Pertuzumab,,,,5441,5495,NA,,,Patient had refused treatment for 15 years until the right breast mass grew outside her skin for at least 6 months. There was discoloration and drainage which weeps into her clothes.,TRUE
16800,RA_6667,Chemotherapy,TRUE,Paclitaxel,,,,5481,5495,NA,,,,TRUE
16801,RA_6667,Precision/Targeted Therapy,TRUE,"Pertuzumab, Trastuzumab",,,,5481,5495,NA,,,,TRUE
16802,RA_6667,Hormone/Endocrine Therapy,TRUE,Letrozole,,,,5495,5648,NA,,,,TRUE
16803,RA_6667,Precision/Targeted Therapy,TRUE,"Pertuzumab, Trastuzumab",,,,5495,5648,NA,,,,TRUE
16804,RA_6667,Precision/Targeted Therapy,TRUE,"Pertuzumab, Trastuzumab",,,,5658,5707,NA,,,,TRUE
16805,RA_6667,Chemotherapy,TRUE,Paclitaxel,,,,5658,5707,NA,,,,TRUE
16806,RA_6667,ADC,TRUE,Trastuzumab Emtansine,,,,5728,5770,NA,,,,TRUE
16807,RA_6667,Precision/Targeted Therapy,TRUE,"Pertuzumab, Trastuzumab",,,,5798,5932,NA,,,,TRUE
16808,RA_6667,Chemotherapy,TRUE,Paclitaxel,,,,5798,5932,NA,,,,TRUE
16809,RA_6667,Precision/Targeted Therapy,TRUE,"Trastuzumab, Tucatinib",,,,5966,6352,NA,,,,TRUE
16810,RA_6667,Chemotherapy,TRUE,Capecitabine,,,,5966,6352,NA,,,,TRUE
16811,RA_6667,Precision/Targeted Therapy,TRUE,"Pertuzumab, Trastuzumab",,,,6008,6175,NA,,,,TRUE
16812,RA_6667,Chemotherapy,TRUE,Capecitabine,,,,6008,6175,NA,,,,TRUE
16813,RA_6667,Precision/Targeted Therapy,TRUE,"Trastuzumab, Tucatinib",,,,6197,6281,NA,,,,TRUE
16814,RA_6667,Chemotherapy,TRUE,Capecitabine,,,,6197,6281,NA,,,,TRUE
16815,RA_6667,Precision/Targeted Therapy,TRUE,Trastuzumab,,,,6301,6624,NA,,,,TRUE
16816,RA_6667,,TRUE,Margetuximab,,,,6649,6706,NA,,,,TRUE
16817,RA_6667,Chemotherapy,TRUE,Eribulin Mesylate,,,,6649,6706,NA,,,,TRUE
16818,RA_6667,Precision/Targeted Therapy,TRUE,Trastuzumab,,,,6723,6827,Progression and relapse,,,,TRUE
16819,RA_6667,Chemotherapy,TRUE,Doxorubicin Hydrochloride Liposome,,,,6723,6827,Progression and relapse,,,,TRUE
16820,RA_6667,Precision/Targeted Therapy,TRUE,RLY-2608,,,,6827,6980,Progression and relapse,,,,TRUE
16821,RA_6870,Chemotherapy,TRUE,"Cyclophosphamide, Doxorubicin",,,,64,121,NA,,,,TRUE
16822,RA_6870,Chemotherapy,TRUE,Paclitaxel,,,,121,184,NA,,,,TRUE
16823,RA_6870,,FALSE,,,,,317,317,Completion of standard course,,,Right chest wall 5000 cGy Draining lymphatics 4500 cGy,TRUE
16824,RA_6870,Hormone/Endocrine Therapy,TRUE,Anastrozole,,,,344,1385,Completion of standard course,,,Day 1941: Diffusely abnormal marrow signal suspicious for marrow infiltrative process such as metastasis or lymphoma Day 1994: PET/CT- Extensive osseous metastatic disease.,TRUE
16825,RA_6870,,FALSE,,,,,2015,2015,Completion of standard course,,,"Right iliac, left iliac 800 cGy 1 fraction",TRUE
16826,RA_6870,Precision/Targeted Therapy,TRUE,Palbociclib,,,,2013,2283,Progression and relapse,,,Held drug for due to ANC 0.42 from day 2054-2106,TRUE
16827,RA_6870,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,,2013,2283,Progression and relapse,,,Held drug for due to ANC 0.42 from day 2054-2106,TRUE
16828,RA_6870,Precision/Targeted Therapy,TRUE,RLY-2608,,,,2355,2523,Progression and relapse,,,Held drug Day 2376 due to Gr. 3 AST/ALT - not related to drug. Restarted Day 2411 Had PR - complete resolution of measurable disease Held drug Day 2495 due to Gr. 3 AST. Resumed Day 2505 200mg Day 2523 admitted due to transaminitis in addition to hyperbilirubinemia on C7D1,TRUE
16829,RA_6870,Hormone/Endocrine Therapy,TRUE,Fulvestrant,,,,2355,2523,Progression and relapse,,,Held drug Day 2376 due to Gr. 3 AST/ALT - not related to drug. Restarted Day 2411 Had PR - complete resolution of measurable disease Held drug Day 2495 due to Gr. 3 AST. Resumed Day 2505 200mg Day 2523 admitted due to transaminitis in addition to hyperbilirubinemia on C7D1,TRUE
16833,RA_4430,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pembrolizumab/Pemetrexed,3061,3147,Completion of standard course,,,Regimen: Carboplatin/Pembrolizumab/Pemetrexed,TRUE
16834,RA_2113,Immunotherapy,TRUE,Nivolumab,,,Nivolumab + Ipilimumab,56,69,Toxicity,,,stopped after a single dose of ipi/nivo due to increased dyspnea and likely autoimmune pneumonitis ~ Regimen: Nivolumab + Ipilimumab,TRUE
16835,RA_3274,Precision/Targeted Therapy,TRUE,Nazartinib,,,nazartinib + gefitinib [7 Cycles],37,203,Progression and relapse,,,Partial Response (-44%) ~ Regimen: nazartinib + gefitinib [7 Cycles],TRUE
16836,RA_3634,Chemotherapy,TRUE,Paclitaxel,,,Carboplatin + Paclitaxel (5 Cycles),15,178,Progression and relapse,,,"Disease progression. Interval increase of the right hilar mass, now measuring 3.1 x 2.5 cm, previously 2.9 x 1.8 cm. Slightly increased mediastinal lymph nodes since November 2016. Numerous (more than 10) solid bilateral pulmonary nodules, many of which have increased in size since November 2016. ~ Regimen: Carboplatin + Paclitaxel (5 Cycles)",TRUE
16837,RA_4430,Immunotherapy,TRUE,Pembrolizumab,,,Carboplatin/Pembrolizumab/Pemetrexed,3061,3147,Completion of standard course,,,Regimen: Carboplatin/Pembrolizumab/Pemetrexed,TRUE
16838,RA_1133,Chemotherapy,TRUE,Pemetrexed,,,Cisplatin/Pemetrexed,18,39,Other,,,EGFR results returned after 1 week,TRUE
16839,RA_1133,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pemetrexed,1566,1566,Toxicity,,,,TRUE
16840,RA_2700,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Carboplatin/Gemcitabine,106,134,Progression and relapse,,,,TRUE
16841,RA_2700,Precision/Targeted Therapy,TRUE,savolitinib,,,Osimertinib/Savolitinib,179,220,Progression and relapse,,,,TRUE
16842,RA_2700,Chemotherapy,TRUE,Paclitaxel,,,Carboplatin/Abraxane,267,267,Progression and relapse,,,alongside Osimertinib,TRUE
16843,RA_1592,Chemotherapy,TRUE,Paclitaxel,,,Carbo/taxol/osimertinib,391,543,Progression and relapse,,,,TRUE
16844,RA_1592,Precision/Targeted Therapy,TRUE,osimertinib,,,Carbo/taxol/osimertinib,391,543,Progression and relapse,,,,TRUE
16845,RA_1592,Precision/Targeted Therapy,TRUE,osimertinib,,,Gemcitabine/osimertinib,545,643,Progression and relapse,,,,TRUE
16846,RA_1592,Precision/Targeted Therapy,TRUE,osimertinib,,,Navelbine/osimertinib,643,679,Progression and relapse,,,,TRUE
16847,RA_1511,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pemetrexed/Avastin,15,95,Progression and relapse,,,"Progression = New Liver Mets, increased size of liver mets, R. Adrenal Met, Mesenteric Nodule // decreased size right lower lobe lung nodules, right paratracheal and right hilar lymphadenopathy consistent with treatment response ~ Regimen: Carboplatin/Pemetrexed/Avastin",TRUE
16848,RA_1511,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pemetrexed/Avastin,15,95,Progression and relapse,,,"Progression = New Liver Mets, increased size of liver mets, R. Adrenal Met, Mesenteric Nodule // decreased size right lower lobe lung nodules, right paratracheal and right hilar lymphadenopathy consistent with treatment response ~ Regimen: Carboplatin/Pemetrexed/Avastin",TRUE
16849,MGH600,,FALSE,,,,,0,0,NA,nave,,,TRUE
16850,MGH600,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,747,4564,Progression and relapse,,T790M,prolonged response to erlotinib,TRUE
16851,MGH770,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,39,2013,Progression and relapse,nave,T790M,,TRUE
16852,MGH714,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,1,811,Progression and relapse,nave,T790M,,TRUE
16853,MGH783,,FALSE,,,,,0,0,NA,nave,,,TRUE
16854,MGH783,Precision/Targeted Therapy,TRUE,Afatinib Dimaleate,,,afatinib,79,1058,Toxicity,,discontinue for toxicity,,TRUE
16855,MGH783,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,1081,1149,Toxicity,,T790M,,TRUE
16856,MGH801,Precision/Targeted Therapy,TRUE,Nazartinib,,,EGF816,1345,1592,Progression and relapse,T790M,,"s/p erlotinib, afatinib",TRUE
16857,MGH754,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,26,776,Progression and relapse,nave,T790M,,TRUE
16858,MGH754,Precision/Targeted Therapy,TRUE,osimertinib,,,osimertinib,785,1310,Progression and relapse,,MET amplification negative,,TRUE
16859,MGH754,Precision/Targeted Therapy,TRUE,Nazartinib,,,EGF816,1310,1331,Progression and relapse,,,,TRUE
16860,MGH769,,FALSE,,,,,0,0,NA,nave,T3N0M0,,TRUE
16861,MGH769,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,101,822,Progression and relapse,adjuvant,,,TRUE
16862,MGH769,,FALSE,,,,,1032,1032,NA,,T2N0M0,,TRUE
16863,MGH769,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,1555,2290,Progression and relapse,,T790M,,TRUE
16864,MGH769,Precision/Targeted Therapy,TRUE,osimertinib,,,osimertinib,2299,2867,Progression and relapse,,"MET amplification, T790M loss",,TRUE
16865,MGH806,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,45,846,Progression and relapse,,"T790M, extended response to osimertinib",,TRUE
16866,MGH141,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,31,198,Completion of standard course,,T790M,,TRUE
16867,MGH799,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,149,287,Progression and relapse,SCC,T790M,,TRUE
16868,MGH808,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,33,287,Progression and relapse,,T90M,,TRUE
16869,MGH808,Precision/Targeted Therapy,TRUE,Nazartinib,,,EGF816,289,1153,Progression and relapse,,C797S; T790M retained,,TRUE
16870,MGH808,Precision/Targeted Therapy,TRUE,osimertinib,,,osimertinib,1154,1608,Progression and relapse,,continued,,TRUE
16871,MGH808,Chemotherapy,TRUE,Pemetrexed,,,pemetrexed,1154,1608,Progression and relapse,,continued,,TRUE
16872,MGH742,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,53,442,Progression and relapse,,T790M,,TRUE
16873,MGH742,Precision/Targeted Therapy,TRUE,Rociletinib,,,CO-1686,446,788,Progression and relapse,,,,TRUE
16874,MGH716,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,16,351,Progression and relapse,nave,T790M,,TRUE
16875,MGH716,Precision/Targeted Therapy,TRUE,Rociletinib,,,CO-1686,357,482,Toxicity,,,,TRUE
16876,MGH778,Chemotherapy,TRUE,Cisplatin,,,cisplatin,12,75,Other,,,,TRUE
16877,MGH778,Chemotherapy,TRUE,Pemetrexed,,,pemetrexed,12,75,Other,,,,TRUE
16878,MGH778,Precision/Targeted Therapy,TRUE,Afatinib Dimaleate,,,afatinib,112,878,Progression and relapse,,,,TRUE
16879,MGH778,Precision/Targeted Therapy,TRUE,Nazartinib,,,EGF816,886,1224,Progression and relapse,,MET amplification,,TRUE
16880,MGH778,Precision/Targeted Therapy,TRUE,osimertinib,,,osimertinib,1229,1366,Progression and relapse,,MET amplification negative,,TRUE
16881,MGH778,Precision/Targeted Therapy,TRUE,savolitinib,,,savolitinib,1229,1366,Progression and relapse,,MET amplification negative,,TRUE
16882,MGH10008,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,193,3093,Progression and relapse,chemotherapy,T790M negative in liver met,SRS to CNS at 2177 days,TRUE
16883,MGH10008,,FALSE,,,,,1314,1314,NA,recurrance,T1N3M0; T790M positive,lobectomy,TRUE
16884,MGH804,,FALSE,,,,,0,0,NA,,T1aN0M0,,TRUE
16885,MGH804,Chemotherapy,TRUE,Carboplatin,,,carboplatin,31,67,Completion of standard course,,,,TRUE
16886,MGH804,Chemotherapy,TRUE,Paclitaxel,,,paclitaxel,31,67,Completion of standard course,,,,TRUE
16887,MGH804,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,453,1155,Progression and relapse,,T790M,no treatment between day 67 and day 453,TRUE
16888,MGH804,Precision/Targeted Therapy,TRUE,Nazartinib,,,EGF816,1156,1382,Progression and relapse,,,,TRUE
16889,MGH130,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,157,882,Progression and relapse,"surgery, chemotherapy","no evidence of diease, surveillance","adjuvant, surgery done in 2007 (conducted before day 0)",TRUE
16890,MGH130,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,1484,3467,Progression and relapse,,T790M,no treatment between day 882 and day 1484,TRUE
16891,MGH938,Precision/Targeted Therapy,TRUE,Crizotinib,,,crizotinib,58,1285,Progression and relapse,,,,TRUE
16892,MGH983,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, gemcitabine",38,68,Progression and relapse,,,,TRUE
16893,MGH983,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, paclitaxel",130,173,Progression and relapse,,,,TRUE
16894,MGH983,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, paclitaxel",189,219,Progression and relapse,,,,TRUE
16895,MGH983,Immunotherapy,TRUE,Nivolumab,,,nivolumab,311,361,Toxicity,,,,TRUE
16896,MGH983,Chemotherapy,TRUE,Vinorelbine Tartrate,,,navelbine,418,454,Progression and relapse,,,,TRUE
16897,MGH983,Precision/Targeted Therapy,TRUE,Crizotinib,,,crizotinib,547,584,Progression and relapse,,,,TRUE
16898,MGH959,Chemotherapy,TRUE,Paclitaxel,,,taxol,22,52,Other,,,,TRUE
16899,MGH959,Immunotherapy,TRUE,Atezolizumab,,,atezolizumab (MPDL3280A),479,509,Progression and relapse,,,,TRUE
16900,MGH959,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,gemcitabine,540,782,Progression and relapse,,,,TRUE
16901,MGH959,Precision/Targeted Therapy,TRUE,Crizotinib,,,crizotinib,824,1119,Progression and relapse,,,,TRUE
16902,MGH959,Precision/Targeted Therapy,TRUE,sitravatinib,,,sitravatinib (MGCD516),1133,1181,Progression and relapse,,,,TRUE
16903,MGH959,ADC,TRUE,Telisotuzumab,,,ABV399,1203,1357,Progression and relapse,,,,TRUE
16904,MGH959,Precision/Targeted Therapy,TRUE,Capmatinib,,,capmatinib,1384,1425,Patient noncompliance,,,,TRUE
16905,MGH997,Chemotherapy,TRUE,Cisplatin,,,"etoposide, cisplatin",21,79,Progression and relapse,,,,TRUE
16906,MGH997,Precision/Targeted Therapy,TRUE,Crizotinib,,,crizotinib,905,1019,Toxicity,,,no treatment between day 79 and day 905,TRUE
16907,MGH997,Precision/Targeted Therapy,TRUE,Capmatinib,,,capmatinib,1156,1171,Toxicity,,,,TRUE
16908,MGH997,Precision/Targeted Therapy,TRUE,Crizotinib,,,crizotinib,1325,1431,Progression and relapse,,,,TRUE
16909,MGH997,Chemotherapy,TRUE,Pemetrexed,,,pemetrexed,1438,1466,Completion of standard course,,,,TRUE
16910,MGH9020,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",61,180,Completion of standard course,,,,TRUE
16911,MGH9020,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",596,637,Progression and relapse,,,,TRUE
16912,MGH9020,Precision/Targeted Therapy,TRUE,Crizotinib,,,crizotinib,807,1024,Progression and relapse,,,,TRUE
16913,MGH9020,ADC,TRUE,Telisotuzumab,,,ABBV399,1043,1064,Progression and relapse,,,,TRUE
16914,MGH9020,Immunotherapy,TRUE,Nivolumab,,,nivolumab,1099,1288,Progression and relapse,,,,TRUE
16915,MGH9001,Precision/Targeted Therapy,TRUE,Crizotinib,,,crizotinib,144,284,Toxicity,,,,TRUE
16916,MGH9001,Precision/Targeted Therapy,TRUE,Capmatinib,,,capmatinib,331,366,Progression and relapse,,,,TRUE
16917,MGH9052,Immunotherapy,TRUE,Pembrolizumab,,,pembrolizumab,22,147,Progression and relapse,,,,TRUE
16918,MGH9052,Precision/Targeted Therapy,TRUE,Crizotinib,,,crizotinib,189,426,Progression and relapse,,,,TRUE
16919,RA_2243,Precision/Targeted Therapy,TRUE,Crizotinib,,,crizotinib,80,234,Progression and relapse,,,,TRUE
16920,RA_2243,Precision/Targeted Therapy,TRUE,Capmatinib,,,capmatinib,242,276,Progression and relapse,,,,TRUE
16921,RA_2243,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",296,414,Progression and relapse,,,,TRUE
16922,RA_3500,Precision/Targeted Therapy,TRUE,Crizotinib,,,crizotinib,16,210,Progression and relapse,,,,TRUE
16923,RA_3500,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",214,348,Completion of standard course,,,,TRUE
16924,RA_3500,Precision/Targeted Therapy,TRUE,Capmatinib,,,capmatinib,365,421,Progression and relapse,,,,TRUE
16925,RA_3870,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,10,271,Progression and relapse,,,,TRUE
16926,RA_3870,Chemotherapy,TRUE,Carboplatin,,,carboplatin/pemetrexed,272,421,Progression and relapse,,,,TRUE
16927,RA_3870,,FALSE,,,,microwave ablation to liver,415,415,Completion of standard course,,,,TRUE
16928,RA_3870,Chemotherapy,TRUE,Docetaxel,,,chemotherapy,451,619,Progression and relapse,,,,TRUE
16929,RA_3870,Precision/Targeted Therapy,TRUE,osimertinib,,,targeted (navelbine/osimertinib 160mg (double dose)),620,791,Progression and relapse,,,,TRUE
16930,RA_2218,,FALSE,,,,whole brain radiation 35 Gy,17,34,Completion of standard course,,,,TRUE
16931,RA_2218,Precision/Targeted Therapy,TRUE,Afatinib Dimaleate,,,afatinib,49,2868,Progression and relapse,,,,TRUE
16932,RA_2218,Precision/Targeted Therapy,TRUE,osimertinib,,,osimertinib,2895,3483,Progression and relapse,,,,TRUE
16933,RA_2218,,FALSE,,,,radiation to brain,3035,3035,Completion of standard course,,,,TRUE
16934,RA_2218,,FALSE,,,,radiation to lung,3041,3051,Completion of standard course,,,,TRUE
16935,RA_2218,Chemotherapy,TRUE,Carboplatin,,,chemotherapy,3484,3547,Completion of standard course,,,,TRUE
16936,RA_2218,Precision/Targeted Therapy,TRUE,osimertinib,,,osimertinib,3548,3695,Progression and relapse,,,,TRUE
16937,RA_2218,Precision/Targeted Therapy,TRUE,Erlotinib,,,weekly dose erlotinib,3696,3715,Progression and relapse,,,,TRUE
16938,RA_1348,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib,17,662,Progression and relapse,,,,TRUE
16939,RA_1348,Precision/Targeted Therapy,TRUE,Rociletinib,,,CO-1686,662,815,Progression and relapse,,,,TRUE
16941,RA_1348,Precision/Targeted Therapy,TRUE,savolitinib,,,osimertinib/savolitinib,1596,1665,Progression and relapse,,,,TRUE
16942,RA_1348,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,chemotherapy + targeted gemcitabinel/osimertinib),2268,2513,Progression and relapse,,,,TRUE
16943,RA_1348,Chemotherapy,TRUE,Docetaxel,,,chemotherapy + targeted (docetaxel/osimertinib),2527,2583,Progression and relapse,,,,TRUE
16944,RA_1348,,FALSE,,,,whole brain radiation,2592,2607,Completion of standard course,,,,TRUE
16945,RA_1348,Precision/Targeted Therapy,TRUE,osimertinib,,,chemotherapy + targeted (navelbine/osimertinib),2632,2646,Progression and relapse,,,,TRUE
16946,RA_3500,Immunotherapy,TRUE,Pembrolizumab,,,pembrolizumab,214,348,Progression and relapse,,,,TRUE
16947,RA_3870,Precision/Targeted Therapy,TRUE,osimertinib,,,targeted (docetaxel/osimertinib),451,619,Progression and relapse,,,,TRUE
16948,RA_3870,Chemotherapy,TRUE,Vinorelbine Tartrate,,,"chemotherapy, targeted (navelbine/osimertinib 160mg (double dose))",620,791,Progression and relapse,,,,TRUE
16949,RA_2218,Precision/Targeted Therapy,TRUE,osimertinib,,,targeted therapy (carboplatin/pemetrexed/osimertinib),3484,3547,Completion of standard course,,,,TRUE
16950,RA_1348,Precision/Targeted Therapy,TRUE,osimertinib,,,targeted therapy (carboplatin/pemetrexed/osimertinib),850,2267,Progression and relapse,prolonged response to multiple TKIs,,"s/p erlotinib (T790M, HER2 amp), CO-1686, osimertinib (MET amp), osimertinib/savolitinib (MET amp loss)",TRUE
16951,RA_6070,Precision/Targeted Therapy,TRUE,Erlotinib,,,Tarceva,19,53,Progression and relapse,,,,TRUE
16952,RA_6070,Precision/Targeted Therapy,TRUE,Crizotinib,,,erlotinib + crizotinib,53,374,Progression and relapse,,,,TRUE
16953,RA_6070,,FALSE,,,,Hippocampal-sparing WBRT (30 Gy) w/ dose intensification to gross brain metastases (37.5 Gy),381,401,Completion of standard course,,,,TRUE
16954,RA_6070,Precision/Targeted Therapy,TRUE,Erlotinib,,,14-438: erlotinib 75 mg qd w ABBV399 q21days,423,633,Progression and relapse,,,,TRUE
16955,RA_6070,,FALSE,,,,SRS to R temporal and putamen lesions,641,641,Completion of standard course,,,,TRUE
16956,RA_6070,,FALSE,,,,"SRS to L pontine, L temporal, L frontal and R parietal lesions",668,668,Completion of standard course,,,,TRUE
16957,RA_6070,Chemotherapy,TRUE,Carboplatin,,,Carboplatin /pemetrexed /pembrolizumab,676,830,Progression and relapse,,,CNS progression,TRUE
16958,RA_6070,,FALSE,,,,"Left lung radiation SBRT-like, 45 Gy in 6 fx",766,780,Completion of standard course,,,,TRUE
16959,RA_6070,Precision/Targeted Therapy,TRUE,Capmatinib,,,INC280 + gefitinib,843,2005,Progression and relapse,,,,TRUE
16960,RA_6070,Precision/Targeted Therapy,TRUE,Capmatinib,,,Capmatinib,2020,2300,Progression and relapse,,,,TRUE
16961,RA_6070,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib,2020,2300,Progression and relapse,,,,TRUE
16962,RA_6070,,FALSE,,,,SRS to 8 CNS lesions,2191,2206,Completion of standard course,,,,TRUE
16963,RA_2244,Precision/Targeted Therapy,TRUE,Crizotinib,,,crizotinib 250mg PO BID,41,195,Progression and relapse,,,minimal interval enlargement of L hilar and high R paratracheal node,TRUE
16964,RA_2244,Precision/Targeted Therapy,TRUE,Alectinib,,,Alectinib,196,342,Progression and relapse,,,Worsening pleural effusion. Pathology - adenocarcinoma,TRUE
16965,RA_2244,Precision/Targeted Therapy,TRUE,Ceritinib,,,ceritinib,343,506,Progression and relapse,,,Interval progression in L pleura and hilar node. Brain MRI w/ 4 new brain metastases.,TRUE
16966,RA_2244,Chemotherapy,TRUE,Carboplatin,,,carbo/pemetrexed,507,619,Progression and relapse,,,Brain MRI: Stable to improved; Chest CT mild progression,TRUE
16967,RA_2244,Chemotherapy,TRUE,Pemetrexed,,,pemetrexed,640,668,Progression and relapse,,,pemetrexe given as maintenance,TRUE
16968,RA_2244,Precision/Targeted Therapy,TRUE,Lorlatinib,,,lorlatinib,668,843,Progression and relapse,,,admitted to ED for SOB - passed on day 851,TRUE
16969,RA_3624,Chemotherapy,TRUE,Cisplatin,,,4 cycles of cisplatin/etoposide,30,121,Completion of standard course,,,,TRUE
16970,RA_3624,,FALSE,,,,"6,600 cGy to the LLL mass and 6,200 cGy to the supraclavicular area",30,121,Completion of standard course,,,,TRUE
16971,RA_3624,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,264,451,Progression and relapse,,,developed local progression as well as a new left adrenal nodule and upper abdominal lymph node,TRUE
16972,RA_3624,Chemotherapy,TRUE,Carboplatin,,,carboplatin (AUC 5) and pemetrexed 500 mg/m2,553,637,Completion of standard course,,,,TRUE
16973,RA_3624,Precision/Targeted Therapy,TRUE,Ceritinib,,,LDK378 (Ceritinib),653,2402,Progression and relapse,,,,TRUE
16974,RA_3624,,FALSE,,,,L adrenal SBRT,2278,2285,Completion of standard course,,,,TRUE
16975,RA_3624,Precision/Targeted Therapy,TRUE,Alectinib,,,Alectinib,2404,2667,Progression and relapse,,,,TRUE
16976,RA_3624,Precision/Targeted Therapy,TRUE,Lorlatinib,,,Lorlatinib,2671,3030,Progression and relapse,,,,TRUE
16977,RA_3624,Precision/Targeted Therapy,TRUE,Lorlatinib,,,Lorlatinib + Pemetrexed,3017,3030,Progression and relapse,,,,TRUE
16978,RA_3663,Chemotherapy,TRUE,Cisplatin,,,cisplatin/taxotere q 3 wk x 4 cycles,48,110,Completion of standard course,,,Tolerated well,TRUE
16979,RA_3663,Precision/Targeted Therapy,TRUE,Erlotinib,,,Tarceva,1170,1189,Other,,,ALK Positive tumor revealed whilst on Tarceva,TRUE
16980,RA_3663,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,1191,2304,Progression and relapse,,,Progression of multifocal lung lesions,TRUE
16981,RA_3663,Precision/Targeted Therapy,TRUE,Ceritinib,,,LDK378,2323,2784,Progression and relapse,,,,TRUE
16982,RA_3663,Chemotherapy,TRUE,Carboplatin,,,carbo (AUC 5) and alimta (500mg/m2,2791,2884,Completion of standard course,,,,TRUE
16983,RA_3663,Chemotherapy,TRUE,Pemetrexed,,,alimta (500 mg/m2),2884,2954,Progression and relapse,,,Alimta given as maintenance,TRUE
16984,RA_3663,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,3225,3295,Other,,,,TRUE
16985,RA_3663,Precision/Targeted Therapy,TRUE,Lorlatinib,,,PF3922 (75mg) (Lorlatinib),3316,5395,Progression and relapse,,,Patient switched to another clinical trial due to slow progression over the course of treatment,TRUE
16986,RA_3663,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pemetrexed,5334,5383,Progression and relapse,,,Ongoing chemo with Lorlatinib,TRUE
16987,RA_3663,ADC,TRUE,datopotamab,,,"DS-1062A, TROP2 ADC, 8 mg/kg",5402,5670,Progression and relapse,,,,TRUE
16988,RA_3663,Precision/Targeted Therapy,TRUE,Binimetinib,,,lorlatinib/binimetinib,5681,5789,Toxicity,,,D/C binimetinib for grade 2 retinopathy,TRUE
16989,RA_3663,Precision/Targeted Therapy,TRUE,Lorlatinib,,,Lorlatinib,5789,5887,Progression and relapse,,,Continued Lorlatinib alone,TRUE
16990,RA_3663,Precision/Targeted Therapy,TRUE,Lorlatinib,,,lorlatinib 50 mg qd + TNO155 40 mg qd 2 weeks on/1 week off,5887,5946,Progression and relapse,,,,TRUE
16991,RA_3663,Precision/Targeted Therapy,TRUE,zotizalkib,,,TPX-0131 1 mg qd,5950,5957,Toxicity,,,"grade 3 ataxia, grade 2 cognitive disturbance.",TRUE
16992,RA_4098,,FALSE,,,,WBRT,9,22,Completion of standard course,,,,TRUE
16993,RA_4098,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pembro/Pemetrexed,24,136,Progression and relapse,,,Mixed response to therapy with slight progression,TRUE
16994,RA_4098,Precision/Targeted Therapy,TRUE,Selpercatinib,,,Loxo292,161,214,Toxicity,,,Drug held due to new PE in the setting of thrombocytopenia. Patient passed away on 03/07/2019 during hospital admission from 02/22/2019-03/07/2019,TRUE
16995,RA_1405,Chemotherapy,TRUE,Cisplatin,,,Cisplatin/Alimta x 4 cycles,14,124,Completion of standard course,,,,TRUE
16996,RA_1405,,FALSE,,,,,70,124,Completion of standard course,,,Concurrent RT treatment started at C3 Cisplatin/Alimta,TRUE
16997,RA_1405,Precision/Targeted Therapy,TRUE,Ponatinib,,,ponatinib 30mg daily,565,714,Progression and relapse,,,Best response 23% reduction systemically but CNS PD on first restaging,TRUE
16998,RA_1405,,FALSE,,,,whole-brain radiation therapy (WBRT),631,653,Completion of standard course,,,hippocampus-sparing WBRT,TRUE
16999,RA_1405,Precision/Targeted Therapy,TRUE,Alectinib,,,alectinib,721,992,Progression and relapse,,,Progression in chest and brain,TRUE
17000,RA_1405,Precision/Targeted Therapy,TRUE,Alectinib,,,Carboplatin/Pemetrexed + Alectinib,994,1019,Progression and relapse,,,,TRUE
17001,RA_1405,Biological Therapy,TRUE,Bevacizumab,,,taxol/bevacizumab,1043,1378,Progression and relapse,,,Progressed primarily in chest,TRUE
17002,RA_1405,Precision/Targeted Therapy,TRUE,Everolimus,,,Vandetanib 300 mg daily and everolimus 10 mg daily,1392,1504,Patient noncompliance,,,Poor tolerance by patient,TRUE
17003,RA_1405,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Navelbine 30mg/m2,1511,1535,Patient noncompliance,,,Poor tolerance by patient,TRUE
17004,RA_1405,Precision/Targeted Therapy,TRUE,pralsetinib,,,BLU-667 200mg,1547,1662,Progression and relapse,,,CNS progression,TRUE
17005,RA_1405,Precision/Targeted Therapy,TRUE,Selpercatinib,,,LOXO-292,1666,2203,Progression and relapse,,,Growing CNS lesions,TRUE
17006,RA_1405,Biological Therapy,TRUE,Bevacizumab,,,LOXO-292 + bevacizumab,2203,2442,Progression and relapse,,,Continued treatment until death,TRUE
17007,RA_1779,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib,22,596,Progression and relapse,,,Brain MRI with new brain metastases,TRUE
17008,RA_1779,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib,608,1969,Progression and relapse,,,,TRUE
17009,RA_1779,,FALSE,,,,SRS to brain metastasis,1845,1849,Completion of standard course,,,SRS during ongoing Osimertinib treatment,TRUE
17010,RA_5603,Precision/Targeted Therapy,TRUE,Nazartinib,,,EGF816,20,588,Progression and relapse,,,,TRUE
17011,RA_5603,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib 80mg + savolitinib (MET inhib) 600mg,601,886,Progression and relapse,,,Progressed after 6 cycles and further progression after 10 cycles,TRUE
17012,RA_5603,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/pemetrexed/osimertinib x 3 cycles,887,949,Progression and relapse,,,,TRUE
17013,RA_5603,Chemotherapy,TRUE,Docetaxel,,,Docetaxel/ramucirumab/osi,956,1006,Progression and relapse,,,ramucirumab dropped on 11/13/2019 due to blood clot,TRUE
17014,RA_5603,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Gemcitabine,1029,1032,Progression and relapse,,,received one cycle before passing away on 12/11/2019,TRUE
17015,RA_1694,Chemotherapy,TRUE,Cisplatin,,,Cisplatin/Pemetrexed,33,418,Toxicity,,,Took a holiday from therapy in may 2017 for rising Cr and was able to stay of fall therapy with stable disease x 1 year,TRUE
17016,RA_1694,Precision/Targeted Therapy,TRUE,mobocertinib,,,TAK788,769,1013,Progression and relapse,,,Bx upon progression no clear mech of resistance,TRUE
17017,RA_1694,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib,1027,1152,Progression and relapse,,,Progression in lung and chest,TRUE
17018,RA_1694,Chemotherapy,TRUE,Pemetrexed,,,Osimertinib + Pemetrexed,1153,1860,Toxicity,,,chronic renal insuff in summer 2021 and decision made to stop pem permanently.,TRUE
17019,RA_1694,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib alone,1861,2027,Progression and relapse,,,,TRUE
17020,RA_1694,Precision/Targeted Therapy,TRUE,amivantamab,,,Amivantamab,2028,2122,Progression and relapse,,,stable disease in chest and brain but progression in peritoneal carcinomatosis,TRUE
17021,RA_1694,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Gemcitabine,2133,2161,Progression and relapse,,,progression after 2 cycles,TRUE
17022,RA_1694,Chemotherapy,TRUE,Docetaxel,,,Docetaxel + Osimertinib,2175,2301,Progression and relapse,,,progression after 4 months. Passed away on 08/20/2022,TRUE
17023,RA_5180,Biological Therapy,TRUE,Bevacizumab,,,Carbo/Taxol/Avastin,42,70,Completion of standard course,,,,TRUE
17024,RA_5180,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,106,1871,Progression and relapse,,,,TRUE
17025,RA_5180,Precision/Targeted Therapy,TRUE,Lorlatinib,,,Lorlatinib,1901,3050,Progression and relapse,,,,TRUE
17026,RA_5180,Chemotherapy,TRUE,Carboplatin,,,Carbo/Alimta,2943,3017,Completion of standard course,,,,TRUE
17027,RA_5180,Precision/Targeted Therapy,TRUE,repotrectinib,,,TPX-005 (Repotrectinib),3056,3315,Progression and relapse,,,,TRUE
17028,RA_5180,Chemotherapy,TRUE,Pemetrexed,,,Alimta,3332,3357,Progression and relapse,,,,TRUE
17029,MGH013,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, paclitaxel",10,73,Progression and relapse,,,,TRUE
17030,MGH013,Biological Therapy,TRUE,Bevacizumab,,,Bevacizumab,10,73,Progression and relapse,,,,TRUE
17031,MGH013,Chemotherapy,TRUE,Pemetrexed,,,Pemetrexed,94,521,Progression and relapse,,,,TRUE
17032,MGH013,Biological Therapy,TRUE,Bevacizumab,,,Bevacizumab,94,521,Progression and relapse,,,,TRUE
17033,MGH013,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib,557,640,Progression and relapse,,,,TRUE
17036,MGH013,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,926,975,Progression and relapse,,,,TRUE
17037,MGH013,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Navelbine,976,1169,Progression and relapse,,,,TRUE
17038,MGH013,Precision/Targeted Therapy,TRUE,Ceritinib,,,Ceritinib,1218,1557,Completion of standard course,,,,TRUE
17039,MGH013,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,1618,1684,Progression and relapse,,,,TRUE
17041,MGH020,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,163,559,Progression and relapse,,,,TRUE
17042,MGH020,Precision/Targeted Therapy,TRUE,Ceritinib,,,Ceritinib,906,1398,Progression and relapse,,,,TRUE
17043,MGH020,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, paclitaxel",10,30,Completion of standard course,,,,TRUE
17044,MGH037,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,54,925,Progression and relapse,,,,TRUE
17045,MGH037,Chemotherapy,TRUE,Pemetrexed,,,Pemetrexed,926,947,Progression and relapse,,,,TRUE
17046,MGH048,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,26,362,Progression and relapse,,,,TRUE
17047,MGH048,Precision/Targeted Therapy,TRUE,Alectinib,,,Alectinib,604,875,Progression and relapse,,,,TRUE
17048,MGH048,Precision/Targeted Therapy,TRUE,Lorlatinib,,,Lorlatinib,888,962,Progression and relapse,,,,TRUE
17049,MGH048,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",963,991,Completion of standard course,,,,TRUE
17050,MGH048,Precision/Targeted Therapy,TRUE,Entrectinib,,,Entrectinib,1015,1034,Progression and relapse,,,,TRUE
17051,MGH048,Chemotherapy,TRUE,Docetaxel,,,Docetaxel,1036,1038,Progression and relapse,,,,TRUE
17052,MGH048,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,1039,1067,Progression and relapse,,,,TRUE
17053,MGH048,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab,1047,1118,Progression and relapse,,,,TRUE
17054,MGH048,Precision/Targeted Therapy,TRUE,Ceritinib,,,Ceritinib,1068,1112,Progression and relapse,,,,TRUE
17055,MGH051,Chemotherapy,TRUE,Cisplatin,,,"cisplatin, pemetrexed",13,33,Toxicity,,,,TRUE
17056,MGH051,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",34,47,Progression and relapse,,,,TRUE
17057,MGH051,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,48,132,Progression and relapse,,,,TRUE
17058,MGH051,Precision/Targeted Therapy,TRUE,Ceritinib,,,Ceritinib,146,340,Progression and relapse,,,,TRUE
17059,MGH051,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,345,381,Progression and relapse,,,,TRUE
17060,MGH051,Chemotherapy,TRUE,Pemetrexed,,,Pemetrexed,350,371,Progression and relapse,,,,TRUE
17061,MGH051,Chemotherapy,TRUE,Docetaxel,,,Docetaxel,403,424,Progression and relapse,,,,TRUE
17062,MGH051,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,403,420,Progression and relapse,,,,TRUE
17063,MGH055,Chemotherapy,TRUE,Cisplatin,,,"cisplatin, pemetrexed",17,38,Toxicity,,,,TRUE
17064,MGH055,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,39,253,Progression and relapse,,,,TRUE
17065,MGH055,Precision/Targeted Therapy,TRUE,Ceritinib,,,Ceritinib,262,395,Progression and relapse,,,,TRUE
17066,MGH058,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, paclitaxel",30,75,Completion of standard course,,,,TRUE
17067,MGH058,Chemotherapy,TRUE,Pemetrexed,,,Pemetrexed,486,912,Progression and relapse,,,no treatment between day 75 and day 486,TRUE
17068,MGH058,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,1034,1872,Progression and relapse,,,,TRUE
17069,MGH058,Precision/Targeted Therapy,TRUE,Ceritinib,,,Ceritinib,1873,2601,Progression and relapse,,,,TRUE
17070,MGH061,Chemotherapy,TRUE,Cisplatin,,,"cisplatin, pemetrexed",114,177,Completion of standard course,,,,TRUE
17071,MGH061,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,310,579,Progression and relapse,,,,TRUE
17072,MGH061,Precision/Targeted Therapy,TRUE,Ceritinib,,,Ceritinib,580,861,Progression and relapse,,,,TRUE
17073,MGH062,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",81,110,Progression and relapse,,,,TRUE
17074,MGH062,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,111,668,Progression and relapse,,,,TRUE
17075,MGH062,Precision/Targeted Therapy,TRUE,Ceritinib,,,Ceritinib,676,756,Progression and relapse,,,,TRUE
17076,MGH062,Precision/Targeted Therapy,TRUE,luminespib,,,AUY992 (should it be luminespib/AUY922?),767,781,Progression and relapse,,,,TRUE
17077,MGH062,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",790,910,Progression and relapse,,,,TRUE
17078,MGH062,Chemotherapy,TRUE,Pemetrexed,,,Pemetrexed,931,971,Progression and relapse,,,,TRUE
17079,MGH062,Chemotherapy,TRUE,Docetaxel,,,Docetaxel,995,1007,Toxicity,,,,TRUE
17080,MGH062,Precision/Targeted Therapy,TRUE,Lorlatinib,,,Lorlatinib,1043,1331,Progression and relapse,,,,TRUE
17081,MGH062,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,1342,1559,Progression and relapse,,,,TRUE
17082,MGH062,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Navelbine,1351,1470,Toxicity,,,,TRUE
17083,MGH068,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",18,213,Progression and relapse,,,,TRUE
17084,MGH068,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,46,361,Progression and relapse,,,,TRUE
17085,MGH068,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",387,450,Progression and relapse,,,,TRUE
17086,MGH068,Chemotherapy,TRUE,Pemetrexed,,,Pemetrexed,472,635,Progression and relapse,,,,TRUE
17087,MGH068,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,472,635,Progression and relapse,,,,TRUE
17088,MGH068,Precision/Targeted Therapy,TRUE,Ceritinib,,,Ceritinib,639,1079,Progression and relapse,,,,TRUE
17089,MGH085,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,25,161,Progression and relapse,,,,TRUE
17090,MGH085,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",162,324,Completion of standard course,,,,TRUE
17091,MGH085,Chemotherapy,TRUE,Docetaxel,,,Docetaxel,368,417,Toxicity,,,,TRUE
17092,MGH085,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,418,465,Progression and relapse,,,,TRUE
17093,MGH085,Precision/Targeted Therapy,TRUE,Ceritinib,,,Ceritinib,466,,NA,,,Ceritinib treatment still ongoing,TRUE
17094,MGH086,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, docetaxel",10,161,Completion of standard course,,,,TRUE
17095,MGH086,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib,710,1074,Progression and relapse,,,,TRUE
17096,MGH086,Chemotherapy,TRUE,Pemetrexed,,,Pemetrexed,1106,1685,Progression and relapse,,,,TRUE
17097,MGH086,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,1786,2415,Progression and relapse,,,,TRUE
17098,MGH086,Precision/Targeted Therapy,TRUE,Brigatinib,,,Brigatinib,2510,3935,Progression and relapse,,,,TRUE
17099,MGH086,Precision/Targeted Therapy,TRUE,Lorlatinib,,,Lorlatinib,3936,,Progression and relapse,,,Treatment stop date unknown (verified by MGH),TRUE
17100,MGH086,Immunotherapy,TRUE,Avelumab,,,Avelumab,3936,4223,Other,,,,TRUE
17101,MGH090,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, paclitaxel",11,73,Completion of standard course,,,,TRUE
17102,MGH090,Biological Therapy,TRUE,Bevacizumab,,,bevacizumab,11,73,Completion of standard course,,,,TRUE
17103,MGH090,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,103,697,Progression and relapse,,,,TRUE
17104,MGH090,Precision/Targeted Therapy,TRUE,Alectinib,,,Alectinib,698,782,Progression and relapse,,,,TRUE
17105,MGH10023,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",17,38,Progression and relapse,,,,TRUE
17106,MGH10023,Immunotherapy,TRUE,Nivolumab,,,nivolumab,58,72,Progression and relapse,,,,TRUE
17107,MGH10023,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, paclitaxel",80,183,Progression and relapse,,,,TRUE
17108,MGH10023,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Gemcitabine,234,338,Progression and relapse,,,,TRUE
17109,MGH10023,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Navelbine,345,387,Progression and relapse,,,,TRUE
17110,MGH508,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,15,333,Progression and relapse,,,,TRUE
17111,MGH508,Precision/Targeted Therapy,TRUE,Lorlatinib,,,Lorlatinib,339,494,Progression and relapse,,,,TRUE
17112,MGH9051,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,33,345,Progression and relapse,,,,TRUE
17113,MGH9051,Precision/Targeted Therapy,TRUE,Lorlatinib,,,Lorlatinib,345,513,Progression and relapse,,,,TRUE
17114,MGH9051,Precision/Targeted Therapy,TRUE,repotrectinib,,,Repotrectinib,663,695,Progression and relapse,,,,TRUE
17115,MGH9051,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",695,800,Completion of standard course,,,,TRUE
17116,MGH952,Chemotherapy,TRUE,Cisplatin,,,"cisplatin, pemetrexed",22,50,Progression and relapse,,,,TRUE
17117,MGH952,Precision/Targeted Therapy,TRUE,Brigatinib,,,Brigatinib,76,966,Progression and relapse,,,,TRUE
17118,MGH952,Precision/Targeted Therapy,TRUE,Lorlatinib,,,Lorlatinib,974,1016,Progression and relapse,,,,TRUE
17119,MGH952,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, gemcitabine",1023,1198,Progression and relapse,,,,TRUE
17120,MGH952,Precision/Targeted Therapy,TRUE,Alectinib,,,Alectinib,1023,1255,Progression and relapse,,,Patient noncompliance on day 1035,TRUE
17121,MGH952,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Navelbine,1199,1255,Progression and relapse,,,,TRUE
17122,MGH952,Precision/Targeted Therapy,TRUE,repotrectinib,,,Repotrectinib,1267,1294,Progression and relapse,,,,TRUE
17123,MGH952,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Navelbine,1305,1317,Progression and relapse,,unk,,TRUE
17125,MGH953,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,13,176,Progression and relapse,,,,TRUE
17126,MGH953,Precision/Targeted Therapy,TRUE,Alectinib,,,Alectinib,179,414,Progression and relapse,,,,TRUE
17127,MGH953,Precision/Targeted Therapy,TRUE,Lorlatinib,,,Lorlatinib,421,634,Progression and relapse,,,,TRUE
17128,MGH962,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,64,239,Progression and relapse,,,,TRUE
17129,MGH962,Precision/Targeted Therapy,TRUE,Alectinib,,,Alectinib,252,333,Toxicity,,,,TRUE
17130,MGH962,Precision/Targeted Therapy,TRUE,Lorlatinib,,,Lorlatinib,397,653,Progression and relapse,,,,TRUE
17131,MGH962,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",655,711,Completion of standard course,,,,TRUE
17132,MGH962,Chemotherapy,TRUE,Pemetrexed,,,Pemetrexed,655,893,Completion of standard course,,,,TRUE
17133,MGH962,Precision/Targeted Therapy,TRUE,Ceritinib,,,Ceritinib,804,925,Other,,,,TRUE
17134,MGH962,Precision/Targeted Therapy,TRUE,repotrectinib,,,Repotrectinib,928,931,Progression and relapse,,,,TRUE
17135,MGH968,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",4,99,Completion of standard course,,,,TRUE
17136,MGH968,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib,4,13,Other,,,,TRUE
17137,MGH968,Biological Therapy,TRUE,Bevacizumab,,,Bevacizumab,25,99,Completion of standard course,,,,TRUE
17138,MGH968,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,100,1827,Progression and relapse,,,,TRUE
17139,MGH968,Precision/Targeted Therapy,TRUE,Taletrectinib,,,Taletrectinib,1842,1884,Toxicity,,,,TRUE
17140,MGH968,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",1899,1962,Progression and relapse,,,,TRUE
17141,MGH968,Biological Therapy,TRUE,Bevacizumab,,,Bevacizumab,1920,1962,Progression and relapse,,,,TRUE
17142,MGH968,Precision/Targeted Therapy,TRUE,Lorlatinib,,,Lorlatinib,1980,1990,Progression and relapse,,,,TRUE
17143,MGH968,Precision/Targeted Therapy,TRUE,Cabozantinib,,,Cabozantinib,1991,2065,Progression and relapse,,,,TRUE
17144,MGH979,Precision/Targeted Therapy,TRUE,Alectinib,,,Alectinib,19,105,Progression and relapse,,,,TRUE
17145,MGH979,Immunotherapy,TRUE,Atezolizumab,,,Atezolizumab,19,105,Progression and relapse,,,,TRUE
17146,MGH979,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",179,291,Progression and relapse,,,,TRUE
17147,MGH979,Biological Therapy,TRUE,Bevacizumab,,,bevacizumab,179,333,Progression and relapse,,,,TRUE
17148,MGH979,Chemotherapy,TRUE,Pemetrexed,,,Pemetrexed,179,333,Progression and relapse,,,,TRUE
17149,MGH979,Chemotherapy,TRUE,Cisplatin,,,"cisplatin, gemcitabine",396,413,Progression and relapse,,,,TRUE
17150,MGH979,Precision/Targeted Therapy,TRUE,Alectinib,,,Alectinib,414,435,Progression and relapse,,,,TRUE
17151,MGH979,Precision/Targeted Therapy,TRUE,Ceritinib,,,Ceritinib,436,441,Progression and relapse,,,,TRUE
17152,MGH987,Precision/Targeted Therapy,TRUE,Ceritinib,,,Ceritinib,494,655,Progression and relapse,,,,TRUE
17153,MGH987,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",656,718,Progression and relapse,,,,TRUE
17154,MGH987,Precision/Targeted Therapy,TRUE,Alectinib,,,Alectinib,332,493,Progression and relapse,,,,TRUE
17155,MGH987,Precision/Targeted Therapy,TRUE,Lorlatinib,,,Lorlatinib,719,810,Progression and relapse,,,,TRUE
17156,MGH987,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,48,331,Progression and relapse,,,,TRUE
17157,MGH987,Precision/Targeted Therapy,TRUE,Entrectinib,,,Entrectinib,840,888,Progression and relapse,,,,TRUE
17158,MGH992,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,237,600,Progression and relapse,,,,TRUE
17159,MGH992,Precision/Targeted Therapy,TRUE,Alectinib,,,Alectinib,601,882,Progression and relapse,,,,TRUE
17160,MGH992,Chemotherapy,TRUE,Carboplatin,,,"carboplatin, pemetrexed",883,933,Progression and relapse,,,,TRUE
17161,MGH992,Precision/Targeted Therapy,TRUE,Alectinib,,,Alectinib,934,949,Progression and relapse,,,,TRUE
17162,MGH992,Precision/Targeted Therapy,TRUE,repotrectinib,,,Repotrectinib,920,,Progression and relapse,,,stop date unknown,TRUE
17163,MGH700,Biological Therapy,TRUE,Bevacizumab,,,2 cycles Carboplatin/Pemetrexed/Avastin,3,34,Completion of standard course,,,,TRUE
17164,MGH700,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib,34,979,Progression and relapse,,,,TRUE
17165,MGH700,Precision/Targeted Therapy,TRUE,Rociletinib,,,11 cycles of Rociletinib (CO-1686),979,1191,Progression and relapse,,,,TRUE
17166,MGH700,Chemotherapy,TRUE,Docetaxel,,,Taxotere + Erlotinib,1191,1434,Progression and relapse,,,,TRUE
17167,MGH700,Immunotherapy,TRUE,Nivolumab,,,Nivolumab,1434,1464,Progression and relapse,,,,TRUE
17168,MGH700,Precision/Targeted Therapy,TRUE,Erlotinib,,,Navelbine + Erlotinib,1495,1583,Progression and relapse,,,,TRUE
17169,RA_T06710,Biological Therapy,TRUE,Bevacizumab,,,"1 cycle carboplatin, alimta, avastin",21,21,Other,,,Patient found to have EGFR mutation whilst on cycle 1,TRUE
17170,RA_T06710,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib,43,477,Progression and relapse,,,,TRUE
17172,RA_T06711,Biological Therapy,TRUE,Bevacizumab,,,"1 cycle Carboplatin, Pemetrexed, Bevacizumab",27,42,Patient noncompliance,,,"Developed hives, Allergy testing comfirmed allergy to Carboplatin",TRUE
17173,RA_T06711,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib,84,539,Progression and relapse,,,,TRUE
17174,RA_T06711,,FALSE,,,,3 Gy in a single fraction,538,538,Progression and relapse,,,,TRUE
17175,RA_1186,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib,26,656,Progression and relapse,,,,TRUE
17176,RA_1186,Chemotherapy,TRUE,Carboplatin,,,"2 cycles Carboplatin, Pemetrexed",672,691,Progression and relapse,,,,TRUE
17177,RA_1186,Precision/Targeted Therapy,TRUE,Rociletinib,,,C0-1686,755,1230,Progression and relapse,,,,TRUE
17178,RA_1186,Chemotherapy,TRUE,Docetaxel,,,2 cycles Taxotere,1230,1258,Toxicity,,,,TRUE
17179,RA_1186,Precision/Targeted Therapy,TRUE,Afatinib Dimaleate,,,Afatinib,1230,1282,Toxicity,,,,TRUE
17180,RA_1192,,FALSE,,,,total dose of 35 Gy in 14 fractions,14,31,Completion of standard course,,,,TRUE
17181,RA_1192,Precision/Targeted Therapy,TRUE,Afatinib Dimaleate,,,Afatinib,32,735,Progression and relapse,,,,TRUE
17182,RA_1192,,FALSE,,,,SRS to R singular met,359,359,Completion of standard course,,,,TRUE
17183,RA_1192,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib,532,699,Progression and relapse,,,,TRUE
17184,RA_1192,Chemotherapy,TRUE,Pemetrexed,,,pemetrexed,700,700,Progression and relapse,,,,TRUE
17185,RA_3999,,FALSE,,,,"Left VATS, left upper lobectomy and mediastinal lymph node dissection",0,0,NA,,,,TRUE
17186,RA_3999,Chemotherapy,TRUE,Cisplatin,,,Cisplatin/pemetrexed,56,119,Toxicity,,,Switched to cisplatin to carboplatin for cycle 3,TRUE
17187,RA_3999,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab,294,569,Progression and relapse,,,,TRUE
17188,RA_3999,,FALSE,,,,RT to mesenteric mass/node 45 Gy,345,380,Completion of standard course,,,,TRUE
17189,RA_3999,,FALSE,,,,Hypofractionated RT to the AP window LN,427,448,Completion of standard course,,,,TRUE
17190,RA_3999,Chemotherapy,TRUE,Docetaxel,,,Docetaxel,605,626,Completion of standard course,,,,TRUE
17191,RA_3493,Chemotherapy,TRUE,Carboplatin,,,Carboplatin,315,379,Completion of standard course,,,,TRUE
17192,RA_3493,Chemotherapy,TRUE,Pemetrexed,,,Pemetrexed/Pembrolizumab,315,595,Completion of standard course,,,,TRUE
17193,RA_3493,Immunotherapy,TRUE,Pembrolizumab,,,Pemetrexed/Pembrolizumab,315,595,Completion of standard course,,,,TRUE
17194,RA_3901,,FALSE,,,,60 Gy RT with no chemo,28,97,Completion of standard course,,,,TRUE
17195,RA_3901,Immunotherapy,TRUE,Pembrolizumab,,,Pembrolizumab,213,213,NA,,,"Death (no additional treatments after 213, but before their death date on 575)",TRUE
17196,RA_2694,Chemotherapy,TRUE,Cisplatin,,,cisplatin/taxotere,85,154,Completion of standard course,,,,TRUE
17197,RA_T06725,Chemotherapy,TRUE,Carboplatin,,,1st cycle with Erlotinib,345,345,Patient noncompliance,,,,TRUE
17198,RA_T06725,Precision/Targeted Therapy,TRUE,Afatinib Dimaleate,,,2nd cycle with Afatinib,369,369,Progression and relapse,,,,TRUE
17199,RA_T06727,Chemotherapy,TRUE,Cisplatin,,,cisplatin/pemetrexed,444,444,Progression and relapse,,,,TRUE
17200,RA_T06725,Chemotherapy,TRUE,Docetaxel,,,Taxotere,515,515,Progression and relapse,,,,TRUE
17202,RA_1141,Chemotherapy,TRUE,Carboplatin,,,Carboplatin+pemetrexed x 4 cycles,766,890,Progression and relapse,,,,TRUE
17203,RA_1141,Chemotherapy,TRUE,Etoposide,,,Etoposide 75 mg/m2 D1-D3 for SCLC transformation,1029,1068,Progression and relapse,,,,TRUE
17204,RA_1348,Chemotherapy,TRUE,Carboplatin,,,chemotherapy,1666,2267,Progression and relapse,,,,TRUE
17205,RA_1348,Chemotherapy,TRUE,Vinorelbine Tartrate,,,chemotherapy + targeted (navelbine/osimertinib),2632,2646,Progression and relapse,,,,TRUE
17206,RA_2694,Precision/Targeted Therapy,TRUE,Erlotinib,,,tarceva on clinical trial 07-259,164,894,Completion of standard course,,,,TRUE
17207,RA_T06726,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib with Hydroxychloroquine,53,316,Progression and relapse,,,,TRUE
17208,RA_T06725,Precision/Targeted Therapy,TRUE,Afatinib Dimaleate,,,Afatinib,34,344,Progression and relapse,,,,TRUE
17209,RA_1141,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib,50,366,Progression and relapse,,,,TRUE
17210,RA_T06725,Precision/Targeted Therapy,TRUE,Rociletinib,,,CO-1686,399,438,Progression and relapse,,,,TRUE
17211,RA_T06727,Precision/Targeted Therapy,TRUE,Afatinib Dimaleate,,,Afatinib,52,444,Progression and relapse,,,,TRUE
17212,RA_T06725,Precision/Targeted Therapy,TRUE,Afatinib Dimaleate,,,Restart Afatinib,442,487,Progression and relapse,,,,TRUE
17213,RA_T06725,Precision/Targeted Therapy,TRUE,osimertinib,,,AZD9291,497,514,Progression and relapse,,,,TRUE
17216,RA_1141,Precision/Targeted Therapy,TRUE,Nazartinib,,,EGF816,366,760,Progression and relapse,,,,TRUE
17217,RA_1141,Chemotherapy,TRUE,Docetaxel,,,"Docetaxel (D1,D8) + Osimertinib 80mg",921,1029,Progression and relapse,,,,TRUE
17218,RA_1348,Precision/Targeted Therapy,TRUE,osimertinib,,,targeted (gemcitabinel/osimertinib),2268,2513,Progression and relapse,,,,TRUE
17219,RA_2694,Precision/Targeted Therapy,TRUE,Erlotinib,,,tarceva on clinical trial 09-097,1622,3001,Progression and relapse,,,,TRUE
17220,RA_2694,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib,3004,3671,Progression and relapse,,,,TRUE
17221,RA_T06727,,FALSE,,,,"radiation to L5 vertebral lesion, 35Gy in 14 fractions",13,31,Completion of standard course,,,,TRUE
17222,RA_T06727,,FALSE,,,,"whole brain radiation for remaining lesions, 35Gy in 14 fractions",20,38,Completion of standard course,,,,TRUE
17223,RA_1141,,FALSE,,,,WBXRT; 3500 cGY in 14 fractions,21,38,Completion of standard course,,,,TRUE
17224,RA_T06726,,FALSE,,,,Radiation to Spine,38,38,Completion of standard course,,,,TRUE
17225,RA_T06727,,FALSE,,,,SRS to residual lesion in brain,169,169,Completion of standard course,,,,TRUE
17226,RA_T06725,,FALSE,,,,Palliative RT to L posterior chest wall/8th rib met,323,323,Completion of standard course,,,,TRUE
17228,RA_1141,,FALSE,,,,"SRS to a growing left parietal calvarial metastasis, treated with 18 Gy",634,634,Completion of standard course,,,,TRUE
17229,RA_1141,,FALSE,,,,Cerebellar reirradiation for multiple small progressive CNS lesions,976,976,Completion of standard course,,,,TRUE
17230,RA_2694,,FALSE,,,,RT to R superior skull met,2686,2709,Completion of standard course,,,,TRUE
17231,RA_2694,,FALSE,,,,SRS to R mandibular met,2871,2871,Completion of standard course,,,,TRUE
17233,MGH175,Precision/Targeted Therapy,TRUE,Erlotinib,,,,26,143,Progression and relapse,,,,TRUE
17234,MGH175,Precision/Targeted Therapy,TRUE,Afatinib Dimaleate,,,,187,234,Progression and relapse,,,,TRUE
17235,MGH175,Precision/Targeted Therapy,TRUE,Rociletinib,,,,243,648,Progression and relapse,,,,TRUE
17236,MGH1118,Immunotherapy,TRUE,Ipilimumab,,,Ipilimumab + nivolumab,26,26,NA,,,,TRUE
17237,MGH983,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,"carboplatin, gemcitabine",38,68,Progression and relapse,,,,TRUE
17238,MGH983,Chemotherapy,TRUE,Paclitaxel,,,"carboplatin, paclitaxel",130,173,Progression and relapse,,,,TRUE
17239,MGH983,Chemotherapy,TRUE,Paclitaxel,,,"carboplatin, paclitaxel",189,219,Progression and relapse,,,,TRUE
17240,MGH997,Chemotherapy,TRUE,Etoposide,,,"etoposide, cisplatin",21,79,Progression and relapse,,,,TRUE
17241,MGH9020,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",61,180,Completion of standard course,,,,TRUE
17242,MGH9020,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",596,637,Progression and relapse,,,,TRUE
17243,RA_2243,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",296,414,Progression and relapse,,,,TRUE
17244,RA_3500,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",214,348,Completion of standard course,,,,TRUE
17245,RA_3870,Chemotherapy,TRUE,Pemetrexed,,,carboplatin/pemetrexed,272,421,Progression and relapse,,,,TRUE
17246,RA_2218,Chemotherapy,TRUE,Pemetrexed,,,chemotherapy,3484,3547,Completion of standard course,,,,TRUE
17247,RA_1348,Precision/Targeted Therapy,TRUE,osimertinib,,,chemotherapy + targeted (docetaxel/osimertinib),2527,2583,Progression and relapse,,,,TRUE
17248,RA_6070,Precision/Targeted Therapy,TRUE,Erlotinib,,,erlotinib + crizotinib,53,374,Progression and relapse,,,,TRUE
17249,RA_6070,ADC,TRUE,Telisotuzumab,,,14-438: erlotinib 75 mg qd w ABBV399 q21days,423,633,Progression and relapse,,,,TRUE
17250,RA_6070,Immunotherapy,TRUE,Pembrolizumab,,,Carboplatin /pemetrexed /pembrolizumab,676,830,Progression and relapse,,,CNS progression,TRUE
17251,RA_6070,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin /pemetrexed /pembrolizumab,676,830,Progression and relapse,,,CNS progression,TRUE
17252,RA_6070,Precision/Targeted Therapy,TRUE,Gefitinib,,,INC280 + gefitinib,843,2005,Progression and relapse,,,,TRUE
17253,RA_2244,Chemotherapy,TRUE,Pemetrexed,,,carbo/pemetrexed,507,619,Progression and relapse,,,Brain MRI: Stable to improved; Chest CT mild progression,TRUE
17254,RA_3624,Chemotherapy,TRUE,Etoposide,,,4 cycles of cisplatin/etoposide,30,121,Completion of standard course,,,,TRUE
17255,RA_3624,Chemotherapy,TRUE,Pemetrexed,,,carboplatin (AUC 5) and pemetrexed 500 mg/m2,553,637,Completion of standard course,,,,TRUE
17256,RA_3624,Chemotherapy,TRUE,Pemetrexed,,,Lorlatinib + Pemetrexed,3017,3030,Progression and relapse,,,,TRUE
17257,RA_3663,Chemotherapy,TRUE,Docetaxel,,,cisplatin/taxotere q 3 wk x 4 cycles,48,110,Completion of standard course,,,Tolerated well,TRUE
17258,RA_3663,Chemotherapy,TRUE,Pemetrexed,,,carbo (AUC 5) and alimta (500mg/m2,2791,2884,Completion of standard course,,,,TRUE
17259,RA_3663,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pemetrexed,5334,5383,Progression and relapse,,,Ongoing chemo with Lorlatinib,TRUE
17260,RA_3663,Precision/Targeted Therapy,TRUE,Lorlatinib,,,lorlatinib/binimetinib,5681,5789,Toxicity,,,D/C binimetinib for grade 2 retinopathy,TRUE
17261,RA_3663,Precision/Targeted Therapy,TRUE,batoprotafib,,,lorlatinib 50 mg qd + TNO155 40 mg qd 2 weeks on/1 week off,5887,5946,Progression and relapse,,,,TRUE
17262,RA_4098,Immunotherapy,TRUE,Pembrolizumab,,,Carboplatin/Pembro/Pemetrexed,24,136,Progression and relapse,,,Mixed response to therapy with slight progression,TRUE
17263,RA_4098,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pembro/Pemetrexed,24,136,Progression and relapse,,,Mixed response to therapy with slight progression,TRUE
17264,RA_1405,Chemotherapy,TRUE,Pemetrexed,,,Cisplatin/Alimta x 4 cycles,14,124,Completion of standard course,,,,TRUE
17265,RA_1405,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pemetrexed + Alectinib,994,1019,Progression and relapse,,,,TRUE
17266,RA_1405,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pemetrexed + Alectinib,994,1019,Progression and relapse,,,,TRUE
17267,RA_1405,Chemotherapy,TRUE,Paclitaxel,,,taxol/bevacizumab,1043,1378,Progression and relapse,,,Progressed primarily in chest,TRUE
17268,RA_1405,Precision/Targeted Therapy,TRUE,Vandetanib,,,Vandetanib 300 mg daily and everolimus 10 mg daily,1392,1504,Patient noncompliance,,,Poor tolerance by patient,TRUE
17269,RA_1405,Precision/Targeted Therapy,TRUE,Selpercatinib,,,LOXO-292 + bevacizumab,2203,2442,Progression and relapse,,,Continued treatment until death,TRUE
17270,RA_5603,Precision/Targeted Therapy,TRUE,savolitinib,,,Osimertinib 80mg + savolitinib (MET inhib) 600mg,601,886,Progression and relapse,,,Progressed after 6 cycles and further progression after 10 cycles,TRUE
17271,RA_5603,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/pemetrexed/osimertinib x 3 cycles,887,949,Progression and relapse,,,,TRUE
17272,RA_5603,Precision/Targeted Therapy,TRUE,osimertinib,,,Carboplatin/pemetrexed/osimertinib x 3 cycles,887,949,Progression and relapse,,,,TRUE
17273,RA_5603,Biological Therapy,TRUE,Ramucirumab,,,Docetaxel/ramucirumab/osi,956,1006,Progression and relapse,,,ramucirumab dropped on 11/13/2019 due to blood clot,TRUE
17274,RA_5603,Precision/Targeted Therapy,TRUE,osimertinib,,,Docetaxel/ramucirumab/osi,956,1006,Progression and relapse,,,ramucirumab dropped on 11/13/2019 due to blood clot,TRUE
17275,RA_1694,Chemotherapy,TRUE,Pemetrexed,,,Cisplatin/Pemetrexed,33,418,Toxicity,,,Took a holiday from therapy in may 2017 for rising Cr and was able to stay of fall therapy with stable disease x 1 year,TRUE
17276,RA_1694,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib + Pemetrexed,1153,1860,Toxicity,,,chronic renal insuff in summer 2021 and decision made to stop pem permanently.,TRUE
17277,RA_1694,Precision/Targeted Therapy,TRUE,osimertinib,,,Docetaxel + Osimertinib,2175,2301,Progression and relapse,,,progression after 4 months. Passed away on 08/20/2022,TRUE
17278,RA_5180,Chemotherapy,TRUE,Paclitaxel,,,Carbo/Taxol/Avastin,42,70,Completion of standard course,,,,TRUE
17279,RA_5180,Precision/Targeted Therapy,TRUE,osimertinib,,,Carbo/Taxol/Avastin,42,70,Completion of standard course,,,,TRUE
17280,RA_5180,Chemotherapy,TRUE,Pemetrexed,,,Carbo/Alimta,2943,3017,Completion of standard course,,,,TRUE
17281,MGH013,Chemotherapy,TRUE,Paclitaxel,,,"carboplatin, paclitaxel",10,73,Progression and relapse,,,,TRUE
17282,MGH020,Chemotherapy,TRUE,Paclitaxel,,,"carboplatin, paclitaxel",10,30,Completion of standard course,,,,TRUE
17283,MGH048,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",963,991,Completion of standard course,,,,TRUE
17284,MGH051,Chemotherapy,TRUE,Pemetrexed,,,"cisplatin, pemetrexed",13,33,Toxicity,,,,TRUE
17285,MGH051,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",34,47,Progression and relapse,,,,TRUE
17286,MGH055,Chemotherapy,TRUE,Pemetrexed,,,"cisplatin, pemetrexed",17,38,Toxicity,,,,TRUE
17287,MGH058,Chemotherapy,TRUE,Paclitaxel,,,"carboplatin, paclitaxel",30,75,Completion of standard course,,,,TRUE
17288,MGH061,Chemotherapy,TRUE,Pemetrexed,,,"cisplatin, pemetrexed",114,177,Completion of standard course,,,,TRUE
17289,MGH062,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",81,110,Progression and relapse,,,,TRUE
17290,MGH062,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",790,910,Progression and relapse,,,,TRUE
17291,MGH068,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",18,213,Progression and relapse,,,,TRUE
17292,MGH068,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",387,450,Progression and relapse,,,,TRUE
17293,MGH085,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",162,324,Completion of standard course,,,,TRUE
17294,MGH086,Chemotherapy,TRUE,Docetaxel,,,"carboplatin, docetaxel",10,161,Completion of standard course,,,,TRUE
17295,MGH090,Chemotherapy,TRUE,Paclitaxel,,,"carboplatin, paclitaxel",11,73,Completion of standard course,,,,TRUE
17296,MGH9051,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",695,800,Completion of standard course,,,,TRUE
17297,MGH952,Chemotherapy,TRUE,Pemetrexed,,,"cisplatin, pemetrexed",22,50,Progression and relapse,,,,TRUE
17298,MGH952,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,"carboplatin, gemcitabine",1023,1198,Progression and relapse,,,,TRUE
17300,MGH968,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",4,99,Completion of standard course,,,,TRUE
17301,MGH968,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",1899,1962,Progression and relapse,,,,TRUE
17303,MGH979,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,"cisplatin, gemcitabine",396,413,Progression and relapse,,,,TRUE
17304,MGH987,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",656,718,Progression and relapse,,,,TRUE
17305,MGH992,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",883,933,Progression and relapse,,,,TRUE
17306,MGH700,Chemotherapy,TRUE,Carboplatin,,,2 cycles Carboplatin/Pemetrexed/Avastin,3,34,Completion of standard course,,,,TRUE
17307,MGH700,Chemotherapy,TRUE,Pemetrexed,,,2 cycles Carboplatin/Pemetrexed/Avastin,3,34,Completion of standard course,,,,TRUE
17308,MGH700,Precision/Targeted Therapy,TRUE,Erlotinib,,,Taxotere + Erlotinib,1191,1434,Progression and relapse,,,,TRUE
17309,MGH700,Chemotherapy,TRUE,Vinorelbine Tartrate,,,Navelbine + Erlotinib,1495,1583,Progression and relapse,,,,TRUE
17310,RA_T06710,Chemotherapy,TRUE,Carboplatin,,,"1 cycle carboplatin, alimta, avastin",21,21,Other,,,Patient found to have EGFR mutation whilst on cycle 1,TRUE
17311,RA_T06710,Chemotherapy,TRUE,Pemetrexed,,,"1 cycle carboplatin, alimta, avastin",21,21,Other,,,Patient found to have EGFR mutation whilst on cycle 1,TRUE
17312,RA_T06710,Chemotherapy,TRUE,Pemetrexed,,,"7 cycles Alimta, Erlotinib",295,477,Progression and relapse,,,,TRUE
17313,RA_T06711,Chemotherapy,TRUE,Carboplatin,,,"1 cycle Carboplatin, Pemetrexed, Bevacizumab",27,42,Patient noncompliance,,,"Developed hives, Allergy testing comfirmed allergy to Carboplatin",TRUE
17314,RA_T06711,Chemotherapy,TRUE,Pemetrexed,,,"1 cycle Carboplatin, Pemetrexed, Bevacizumab",27,42,Patient noncompliance,,,"Developed hives, Allergy testing comfirmed allergy to Carboplatin",TRUE
17315,RA_1186,Chemotherapy,TRUE,Pemetrexed,,,"2 cycles Carboplatin, Pemetrexed",672,691,Progression and relapse,,,,TRUE
17316,RA_3999,Chemotherapy,TRUE,Pemetrexed,,,Cisplatin/pemetrexed,56,119,Toxicity,,,Switched to cisplatin to carboplatin for cycle 3,TRUE
17317,RA_2694,Chemotherapy,TRUE,Docetaxel,,,cisplatin/taxotere,85,154,Completion of standard course,,,,TRUE
17318,RA_T06725,Precision/Targeted Therapy,TRUE,Erlotinib,,,1st cycle with Erlotinib,345,345,Patient noncompliance,,,,TRUE
17319,RA_T06725,Chemotherapy,TRUE,Pemetrexed,,,1st cycle with Erlotinib,345,345,Patient noncompliance,,,,TRUE
17320,RA_T06725,Chemotherapy,TRUE,Carboplatin,,,2nd cycle with Afatinib,369,369,Progression and relapse,,,,TRUE
17321,RA_T06725,Chemotherapy,TRUE,Pemetrexed,,,2nd cycle with Afatinib,369,369,Progression and relapse,,,,TRUE
17322,RA_T06727,Chemotherapy,TRUE,Pemetrexed,,,cisplatin/pemetrexed,444,444,Progression and relapse,,,,TRUE
17323,RA_1141,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin+pemetrexed x 4 cycles,766,890,Progression and relapse,,,,TRUE
17324,RA_1348,Chemotherapy,TRUE,Pemetrexed,,,chemotherapy,1666,2267,Progression and relapse,,,,TRUE
17325,RA_1141,Precision/Targeted Therapy,TRUE,osimertinib,,,"Docetaxel (D1,D8) + Osimertinib 80mg",921,1029,Progression and relapse,,,,TRUE
17326,MGH1118,Immunotherapy,TRUE,Nivolumab,,,Ipilimumab + nivolumab,26,26,NA,,,,TRUE
17327,MGH023,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Docetaxel,30,91,Progression and relapse,,,,TRUE
17328,MGH023,,FALSE,,,,SRS,935,935,Completion of standard course,,,No treatment between day 30 and 935,TRUE
17329,MGH023,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib,945,1036,Other,,,,TRUE
17330,MGH023,Chemotherapy,TRUE,Pemetrexed,,,Pemetrexed,1067,1310,Progression and relapse,,,,TRUE
17331,MGH023,Precision/Targeted Therapy,TRUE,Crizotinib,,,Crizotinib,1542,2039,Progression and relapse,,,,TRUE
17332,MGH023,Chemotherapy,TRUE,Paclitaxel,,,Taxol,1909,1967,Progression and relapse,,,,TRUE
17333,MGH023,Precision/Targeted Therapy,TRUE,Ceritinib,,,Ceritinib,2072,2332,Progression and relapse,,,,TRUE
17334,RA_3690,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pemetrexed/Pembro,9,163,Progression and relapse,,,,TRUE
17335,RA_3690,Immunotherapy,TRUE,Pembrolizumab,,,Carboplatin/Pemetrexed/Pembro,9,163,Progression and relapse,,,,TRUE
17336,RA_3690,,FALSE,,,,"Fractionated proton beam RT to choroidal met, 20 Gy over 2 fractions.",28,29,Completion of standard course,,,,TRUE
17337,RA_3690,Chemotherapy,TRUE,Docetaxel,,,MM-121 + docetaxel,212,317,Progression and relapse,,,,TRUE
17338,RA_3690,,FALSE,,,,SRS to R frontal metastasis 18 GY x 1,357,357,Completion of standard course,,,,TRUE
17339,RA_3690,Chemotherapy,TRUE,Vinorelbine Tartrate,,,,345,394,Progression and relapse,,,Navelbine,TRUE
17340,RA_3690,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,,394,422,Progression and relapse,,,,TRUE
17341,RA_3690,,FALSE,,,,SRS to 9mm right middle frontal gyrus and 6 mm right precentral gyrus. 18 Gy x 1 to each,409,409,Completion of standard course,,,,TRUE
17342,RA_3690,Chemotherapy,TRUE,Irinotecan Hydrochloride,,,,436,443,Progression and relapse,,,,TRUE
17343,MGH903,Chemotherapy,TRUE,Carboplatin,,,,49,123,Completion of standard course,,,,TRUE
17344,MGH903,Chemotherapy,TRUE,Pemetrexed,,,,49,123,Completion of standard course,,,,TRUE
17345,MGH903,Immunotherapy,TRUE,Pembrolizumab,,,,213,321,Progression and relapse,,,,TRUE
17346,MGH903,Chemotherapy,TRUE,Docetaxel,,,,322,426,Progression and relapse,,,,TRUE
17347,MGH903,Chemotherapy,TRUE,Vinorelbine Tartrate,,,,427,472,Progression and relapse,,,,TRUE
17348,MGH903,Precision/Targeted Therapy,TRUE,Entrectinib,,,,480,1239,Progression and relapse,,,,TRUE
17349,MGH903,Precision/Targeted Therapy,TRUE,Trametinib,,,Trametinib + Enterectinib,1090,1239,Other,,,stop because of death on 1248,TRUE
17350,RA_T01119,Chemotherapy,TRUE,Cisplatin,,,Cisplatin/Etoposide,141,184,Toxicity,,,,TRUE
17351,RA_T01119,Chemotherapy,TRUE,Etoposide,,,Cisplatin/Etoposide,141,184,Toxicity,,,,TRUE
17352,RA_T01119,Immunotherapy,TRUE,Durvalumab,,,Durva,214,240,Toxicity,,,,TRUE
17353,RA_6524,,FALSE,,,,nephro ureterectomy,0,0,Completion of standard course,,,,TRUE
17354,RA_6524,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,adjuvant,45,112,Progression and relapse,,,,TRUE
17355,RA_6524,Immunotherapy,TRUE,Pembrolizumab,,,,112,193,Progression and relapse,TMB and PDL1 high,,"4 cycles - mixed response predominantly progressive disease | Old note: patient with mixed reponse but predominanly progressive disease, 2 impressive right renal bed nodes that have shown marked regression during Pembrolizumab therapy.",TRUE
17356,RA_6524,Precision/Targeted Therapy,TRUE,Rezatapopt,,,20-544 - PC14586 for patients with p53 Y220C,249,383,Progression and relapse,,,Transferred to home care after progression,TRUE
17357,RA_3450,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,,23,379,NA,,,dose reduced to 20mg/m2 Cis secondary to neutropenia after C6,TRUE
17358,RA_3450,,TRUE,Futibatinib,,,14-135 TAS 120,379,400,Progression and relapse,,,,TRUE
17359,RA_3450,Chemotherapy,TRUE,"Cisplatin, Gemcitabine Hydrochloride",,,"Gem 750mg/m2, Cis 20mg/m2",414,1009,NA,,,,TRUE
17360,RA_3450,Precision/Targeted Therapy,TRUE,RYL-4008,,,20-577 RYL-4008 50mg daily,1035,1099,Progression and relapse,,,C1D15 held drug due to grade 2 central serous retinopathy Resumed at 30mg po qd C1D25 Dropped to 20mg qd C2D15 C2D16 HELD drug due to OSH admission for grade 3 thromboembolic event (pulmonary embolism) in setting of holding AC for biopsy; scans with stable disease by RECIST v1.1 with mild progression  C2D22 resumed C3D1 stopped drug,TRUE
17361,RA_3450,,TRUE,LOXO,,,"20-487 LOXO, IDH1 inhibitor (400mg qd)",1182,1196,Toxicity,,,"C1D7 admitted for work-up progressive SOB, drug held C1D11 resumed C1D15 stopped drug for ongoing SOB  TIMC/Recist show SD (18% from baseline), however, coming off trial for AE (dyspnea - remains on O2)",TRUE
17362,RA_3450,Chemotherapy,TRUE,"Fluorouracil, Oxaliplatin",,,,1229,1450,Other,,death,,TRUE
17363,MGH023,Chemotherapy,TRUE,Docetaxel,,,Carboplatin/Docetaxel,30,91,Progression and relapse,,,,TRUE
17364,MGH10008,,FALSE,,,,,2177,2177,NA,,,SRS to CNS at 2177 days,TRUE
17365,MGH10023,Chemotherapy,TRUE,Pemetrexed,,,"carboplatin, pemetrexed",17,38,Progression and relapse,,,,TRUE
17366,MGH10023,Chemotherapy,TRUE,Paclitaxel,,,"carboplatin, paclitaxel",80,183,Progression and relapse,,,,TRUE
17367,RA_3690,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pemetrexed/Pembro,9,163,Progression and relapse,,,,TRUE
17368,RA_3690,,TRUE,Seribantumab,,,MM-121 + docetaxel,212,317,Progression and relapse,,,,TRUE
17369,RA_5432,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/pemetrexed,19,39,Other,,,"Day 0: RLL mass biopsy - PDL1 5%, ALK and ROS negative, EGFR negative",TRUE
17370,RA_5432,Chemotherapy,TRUE,Pemetrexed,,,PEMETREXED/CARBOPLATIN/OSIMERTINIB,780,992,Progression and relapse,,Brain MRI with increase in mets,,TRUE
17371,RA_T06726,Other,TRUE,Hydroxychloroquine,,,Erlotinib with Hydroxychloroquine,53,316,Progression and relapse,,,,TRUE
17372,MGH770,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib,2014,,NA,,,Additional treatment is still ongoing,TRUE
17373,MGH714,Precision/Targeted Therapy,TRUE,Rociletinib,,,Rociletinib,812,1312,Progression and relapse,,,,TRUE
17374,MGH714,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib,1331,4287,Progression and relapse,,,,TRUE
17375,MGH714,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pemetrexed + Osimertinib,2667,3028,Progression and relapse,,,,TRUE
17376,MGH714,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pemetrexed + Osimertinib,2667,3028,Progression and relapse,,,,TRUE
17377,MGH714,,FALSE,,,,"RT to the R lung/hilum, 6000 cGy/24 fractions",3067,3099,Completion of standard course,,,,TRUE
17378,MGH714,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pemetrexed/Bevacizumab,3815,3944,Progression and relapse,,,,TRUE
17379,MGH714,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pemetrexed/Bevacizumab,3815,3944,Progression and relapse,,,,TRUE
17380,MGH714,Biological Therapy,TRUE,Bevacizumab,,,Carboplatin/Pemetrexed/Bevacizumab,3815,3944,Progression and relapse,,,,TRUE
17381,MGH714,Chemotherapy,TRUE,Pemetrexed,,,Pemetrexed/Bevacizumab/Atezolizumab,3945,3953,Toxicity,,,,TRUE
17382,MGH714,Biological Therapy,TRUE,Bevacizumab,,,Pemetrexed/Bevacizumab/Atezolizumab,3945,3953,Toxicity,,,,TRUE
17383,MGH714,Immunotherapy,TRUE,Atezolizumab,,,Pemetrexed/Bevacizumab/Atezolizumab,3945,3953,Toxicity,,,,TRUE
17384,MGH714,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,,4073,4287,Progression and relapse,,,,TRUE
17385,MGH130,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib,3468,,NA,,,Osimertinib treatment still ongoing,TRUE
17386,MGH130,,FALSE,,,,"BRT to RLL nodule, 45 Gy in 5 fractions",5208,5212,Completion of standard course,,,,TRUE
17387,MGH130,,FALSE,,,,"SRS to right posterior temporal metastasis, 18 Gy x 1",5841,5841,Completion of standard course,,,,TRUE
17388,MGH130,,FALSE,,,,"BRT to RUL NSCLC, 50 Gy in 5 fx",6279,6283,Completion of standard course,,,,TRUE
17389,MGH086,Chemotherapy,TRUE,Carboplatin,,,Carboplatin + Pemetrexed + Pembrolizumab,4541,4541,Toxicity,,,,TRUE
17390,MGH086,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin + Pemetrexed + Pembrolizumab,4541,4541,Toxicity,,,,TRUE
17391,MGH086,Immunotherapy,TRUE,Pembrolizumab,,,Carboplatin + Pemetrexed + Pembrolizumab,4541,4541,Toxicity,,,,TRUE
17392,MGH020,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pemetrexed,577,891,NA,,,,TRUE
17393,MGH020,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pemetrexed,577,891,NA,,,,TRUE
17394,MGH801,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pemetrexed,62,62,Completion of standard course,,,,TRUE
17395,MGH801,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pemetrexed,62,62,Completion of standard course,,,,TRUE
17396,MGH801,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib,91,1185,Progression and relapse,,,,TRUE
17397,MGH801,Precision/Targeted Therapy,TRUE,Afatinib Dimaleate,,,Afatinib,1186,1320,Progression and relapse,,,,TRUE
17398,MGH806,Precision/Targeted Therapy,TRUE,osimertinib,,,Osimertinib,854,1474,Other,,,Death,TRUE
17399,RA_2243,Immunotherapy,TRUE,Atezolizumab,,,atezolizumab,414,465,Progression and relapse,,,,TRUE
17400,RA_2243,Chemotherapy,TRUE,Docetaxel,,,Docetaxol,483,715,Progression and relapse,,,,TRUE
17401,RA_2243,,FALSE,,,,SRS to left frontal lobe,738,738,Completion of standard course,,,,TRUE
17402,RA_2243,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,gemcitabine,759,806,Progression and relapse,,,,TRUE
17403,RA_2243,,FALSE,,,,Radiation to the cerebellum,848,848,Completion of standard course,,,,TRUE
17404,MGH047,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pemetrexed,19,64,Completion of standard course,,,,TRUE
17405,MGH047,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pemetrexed,19,64,Completion of standard course,,,,TRUE
17406,MGH047,Precision/Targeted Therapy,TRUE,Crizotinib,,,N/A,90,180,Progression and relapse,,,,TRUE
17407,MGH034,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Paclitaxel/Bevacizumab,29,181,Completion of standard course,,,,TRUE
17408,MGH034,Chemotherapy,TRUE,Paclitaxel,,,Carboplatin/Paclitaxel/Bevacizumab,29,181,Completion of standard course,,,,TRUE
17409,MGH034,Biological Therapy,TRUE,Bevacizumab,,,Carboplatin/Paclitaxel/Bevacizumab,29,181,Completion of standard course,,,,TRUE
17410,MGH034,Chemotherapy,TRUE,Pemetrexed,,,Pemetrexed/Bevacizumab,182,485,Completion of standard course,,,,TRUE
17411,MGH034,Biological Therapy,TRUE,Bevacizumab,,,Pemetrexed/Bevacizumab,182,485,Completion of standard course,,,,TRUE
17412,MGH034,Chemotherapy,TRUE,Docetaxel,,,Docetaxel/Bevacizumab,486,911,Progression and relapse,,,,TRUE
17413,MGH034,Biological Therapy,TRUE,Bevacizumab,,,Docetaxel/Bevacizumab,486,911,Progression and relapse,,,,TRUE
17414,MGH034,Precision/Targeted Therapy,TRUE,Erlotinib,,,N/A,912,943,Progression and relapse,,,,TRUE
17415,MGH034,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,N/A,1033,1061,Completion of standard course,,,,TRUE
17416,MGH034,Precision/Targeted Therapy,TRUE,Crizotinib,,,N/A,1119,1372,Progression and relapse,,,,TRUE
17417,MGH034,Precision/Targeted Therapy,TRUE,Ceritinib,,,N/A,1396,1698,Progression and relapse,,,,TRUE
17418,MGH034,Precision/Targeted Therapy,TRUE,Alectinib,,,N/A,1699,,NA,,,Stop date NA,TRUE
17419,MGH021,Chemotherapy,TRUE,Cisplatin,,,Cisplatin/Pemetrexed,40,160,Toxicity,,,,TRUE
17420,MGH021,Chemotherapy,TRUE,Pemetrexed,,,Cisplatin/Pemetrexed,40,160,Toxicity,,,,TRUE
17421,MGH021,Chemotherapy,TRUE,Pemetrexed,,,N/A,186,218,Progression and relapse,,,,TRUE
17422,MGH021,Precision/Targeted Therapy,TRUE,Crizotinib,,,N/A,433,816,Progression and relapse,,,,TRUE
17423,MGH021,Precision/Targeted Therapy,TRUE,Ganetespib,,,STA9090,843,890,Toxicity,,,,TRUE
17424,MGH021,Precision/Targeted Therapy,TRUE,Ceritinib,,,N/A,922,1008,Progression and relapse,,,,TRUE
17425,MGH021,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Gemcitabine,1009,,NA,,,Stop date NA,TRUE
17426,MGH021,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,Carboplatin/Gemcitabine,1009,,NA,,,Stop date NA,TRUE
17427,MGH037,Precision/Targeted Therapy,TRUE,Crizotinib,,,N/A,54,,NA,,,Stop date NA,TRUE
17428,MGH048,Precision/Targeted Therapy,TRUE,Crizotinib,,,N/A,26,362,Progression and relapse,,,,TRUE
17429,MGH048,Precision/Targeted Therapy,TRUE,Alectinib,,,N/A,406,875,Progression and relapse,,,,TRUE
17430,MGH048,Precision/Targeted Therapy,TRUE,Lorlatinib,,,N/A,881,962,Progression and relapse,,,,TRUE
17431,MGH048,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pemetrexed,963,991,Progression and relapse,,,,TRUE
17432,MGH048,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pemetrexed,963,991,Progression and relapse,,,,TRUE
17433,MGH048,Precision/Targeted Therapy,TRUE,Entrectinib,,,N/A,1015,1034,Completion of standard course,,,,TRUE
17434,MGH048,Chemotherapy,TRUE,Docetaxel,,,N/A,1036,1038,Completion of standard course,,,,TRUE
17435,MGH048,Precision/Targeted Therapy,TRUE,Crizotinib,,,N/A,1039,1067,Completion of standard course,,,,TRUE
17436,MGH048,Immunotherapy,TRUE,Pembrolizumab,,,N/A,1047,,NA,,,Stop date NA,TRUE
17437,MGH048,Precision/Targeted Therapy,TRUE,Ceritinib,,,N/A,1068,,NA,,,Stop date NA,TRUE
17438,MGH071,Precision/Targeted Therapy,TRUE,Erlotinib,,,Erlotinib/Bevacizumab,62,671,Progression and relapse,,,,TRUE
17439,MGH071,Biological Therapy,TRUE,Bevacizumab,,,Erlotinib/Bevacizumab,62,201,Completion of standard course,,,,TRUE
17440,MGH071,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Taxol,133,201,Completion of standard course,,,,TRUE
17441,MGH071,Chemotherapy,TRUE,Paclitaxel,,,Carboplatin/Taxol,133,201,Completion of standard course,,,,TRUE
17442,MGH071,Chemotherapy,TRUE,Pemetrexed,,,N/A,229,315,Completion of standard course,,,,TRUE
17443,MGH071,Chemotherapy,TRUE,Gemcitabine Hydrochloride,,,N/A,755,783,Toxicity,,,,TRUE
17444,MGH071,Precision/Targeted Therapy,TRUE,Crizotinib,,,N/A,860,2488,Progression and relapse,,,,TRUE
17445,MGH071,Precision/Targeted Therapy,TRUE,Brigatinib,,,N/A,2492,2518,Progression and relapse,,,,TRUE
17446,MGH071,Precision/Targeted Therapy,TRUE,Lorlatinib,,,N/A,3518,,NA,,,Stop date NA,TRUE
17447,MGH079,Precision/Targeted Therapy,TRUE,Crizotinib,,,N/A,35,166,Progression and relapse,,,,TRUE
17448,MGH079,Precision/Targeted Therapy,TRUE,Alectinib,,,N/A,167,564,Progression and relapse,,,,TRUE
17449,MGH079,Precision/Targeted Therapy,TRUE,Lorlatinib,,,N/A,572,576,Completion of standard course,,,,TRUE
17450,MGH079,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pemetrexed/Bevacizumab,577,822,Toxicity,,,,TRUE
17451,MGH079,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pemetrexed/Bevacizumab,577,1034,Completion of standard course,,,,TRUE
17452,MGH079,Biological Therapy,TRUE,Bevacizumab,,,Carboplatin/Pemetrexed/Bevacizumab,577,914,Toxicity,,,,TRUE
17453,MGH079,Immunotherapy,TRUE,Nivolumab,,,N/A,1222,1230,Progression and relapse,,,,TRUE
17454,MGH079,Precision/Targeted Therapy,TRUE,Ceritinib,,,N/A,1231,,NA,,,Stop date NA,TRUE
17455,MGH085,Precision/Targeted Therapy,TRUE,Crizotinib,,,N/A,24,160,Progression and relapse,,,,TRUE
17456,MGH085,Chemotherapy,TRUE,Carboplatin,,,Carboplatin/Pemetrexed,161,314,Completion of standard course,,,,TRUE
17457,MGH085,Chemotherapy,TRUE,Pemetrexed,,,Carboplatin/Pemetrexed,161,323,Completion of standard course,,,,TRUE
17458,MGH085,Chemotherapy,TRUE,Docetaxel,,,N/A,367,416,Toxicity,,,,TRUE
17459,MGH085,Precision/Targeted Therapy,TRUE,Crizotinib,,,N/A,417,464,Progression and relapse,,,,TRUE
17460,MGH085,Precision/Targeted Therapy,TRUE,Ceritinib,,,N/A,465,,NA,,,Stop date NA,TRUE